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1 Summary 
Lipocalin-2 (LCN2) is a 25-kDa secretory protein with great importance as a sensitive and 
specific screening and diagnostic biomarker for hepatic inflammation, acute hepatic injury, hepatic 
cancer, radiation-induced early phase hepatic damage and lipid abnormalities. However, little is 
known about LCN2's functions in the homeostasis and metabolism of hepatic lipids or in the 
development of steatosis as well as its actual role in the event of inflammation.  
The aim of this study was to prospectively evaluate the LCN2 role in the ‘two-hit’ 
development of Non-alcoholic steatohepatitis (NASH) meaning the steatosis and the injury, 
observed by the appearance of inflammation. NASH is a condition where fatty liver is 
accompanied with inflammation. The objective of this study was to determine in wild type (WT) 
and Lcn2-deficient (Lcn2
−/−
) mice the possible differences in their biological reactions after a 
Methionine and Choline deficient diet (MCD), a nutritional model used to induce the pathological 
condition of NASH.  
The current study compares initially the intrahepatic lipid accumulation, lipid droplet 
formation, mitochondrial content, and expression of the Perilipin proteins known to regulate 
cellular lipid metabolism. Lcn2
−/−
 mice fed with MCD diet accumulated more lipids in the liver 
than WT controls, and that the basal expression of the lipid droplet coat protein Perilipin 5 
(PLIN5) was significantly reduced in these animals. Similarly, the overexpression of LCN2 and 
PLIN5 were also found in animals that were fed with a high fat diet. Furthermore, the loss of 
LCN2 and/or PLIN5 in hepatocytes prevented normal intracellular lipid droplet formation both in 
vitro and in vivo. In in vitro experimentation the restoration of LCN2 in Lcn2
−/−
 primary 
hepatocytes by either transfection or adenoviral vector infection induced PLIN5 expression and 
restored proper lipid droplet formation.  
The other section of this study targeted the role of LCN2 specifically in the inflammation 
process accompanying hepatic injury after administration of the MCD diet. Therefore, the hepatic 
LCN2 and inflammatory cytokines’ interleukin- 6 and interleukin-1β (IL-6, IL-1β), tumor necrosis 
factor α (TNF-α), chemokine (C-C motif) ligand 2 (CCL2), and chemokine (C-C motif) receptor 2 
(CCR2) expression was compared between the two genotypes. The expression of the activated 
forms of the Signal Transducers and Activators of Transcription (STAT1 and STAT3) were tested 
as well. Additionally, histology inflammation score and immunohistochemistry stainings with 
leukocytes and neutrophil granulocyte markers were performed. Both genotypes had inflammation 
sites as a result of the MCD diet, however the WT mice recruited more inflammatory cells than the 
Lcn2
−/−
 accompanied with a strong upregulation of LCN2. Moreover, the WT mice fed with MCD 
diet, presented a remarkably stronger expression of phosphorylated forms of STAT1 and STAT3.  
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In conclusion this study shows that LCN2 is a protein of high significance with multiple 
functions in MCD-induced NASH in mice. The presented findings indicate that first of all, LCN2 
is a key modulator of hepatic lipid homeostasis that controls the formation of intracellular lipid 
droplets by regulating PLIN5 expression while a second significant role in inflammation is that its 
upregulation serves as a ‘HELP-ME’ signal while inflammation appears. The upregulation of the 
LCN2-‘HELP-ME’-factor, enhances the recruitment of neutrophil granulocytes and leukocytes 
towards resolution of the inflammation protecting the liver from progression to further hepatic 
damage agreeing to previous reports of LCN2’s hepato-protective role in liver injury models. 
LCN2 may therefore represent a novel therapeutic drug target for the treatment of liver diseases 
associated with inflammation and elevated fat accumulation. 
In the present dissertation the results that will be discussed have been published already in the 
following research papers:  
 Asimakopoulou A, Borkham-Kamphorst E, Henning M, Yagmur E, Gassler N, Liedtke 
C, Berger T, Mak TW, Weiskirchen R. Lipocalin - 2 [LCN2] regulates PLIN5 expression 
and intracellular lipid droplet formation in the liver. Biochim. Biophys. Acta (2014), 
1841:1513 - 1524. 
 Asimakopoulou A, Borkham-Kamphorst E, Tacke F, Weiskirchen R. Lipocalin-2 
(NGAL/LCN2), a "HELP-ME" signal in organ inflammation. Hepatology (2015), 62, in 
press. 
 Asimakopoulou A, Weiskirchen R. Lipocalin 2 in the pathogenesis of fatty liver disease 
and nonalcoholic statohepatitis. Clin Lipidology (2015), 10:47-67. 
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2 Highlights  
 A lack of LCN2 predisposes mice to develop hepatic steatosis. 
 LCN2 is involved in intracellular lipid droplet formation. 
 LCN2 regulates the expression of the lipid droplet coat protein PLIN5. 
 Transient LCN2 expression can restore proper intracellular lipid droplet formation in 
Lcn2
-/-
hepatocytes. 
 LCN2 represents the ‘HELP-ME’ signal after inflammation develops. 
 The LCN2-‘HELP ME’ signal contributes to the resolution of inflammation by recruiting 
leukocytes and mainly neutrophil granulocytes in the NASH mouse model. 
 LCN2 is involved in the inflammation pathway mediated by STAT3 and STAT1. 
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3 Abbreviations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abbreviation Explanation 
°C degrees Celsius 
µ micro (x10
-6
) 
ADRP or PLIN2 adipocyte differentiation-related protein  
AFLD alcoholic fatty liver disease 
AKI acute kidney injury  
ALT alanine transaminase  
ASH alcoholic steatohepatitis 
AST aspartate transaminase 
BSA bovine serum albumin 
CCL2 chemokine (C-C motif) ligand 2  
CCl4 carbon tetrachloride 
CCR2 chemokine (C-C motif) receptor 2 
CD45 cluster of differentiation 45 
cDNA complementary deoxyribonucleic acid 
CHCl3 chloroform  
Conc. concentration 
Cont. continue 
Da dalton 
DAKO 3.3′-diaminobenzidine substrate  
DAPI 4',6-diamidino-2-phenylindole 
dH2O distilled water 
DNA deoxyribonucleic acid 
DNAse deoxyribonuclease 
dNTP nucleoside triphosphates containing deoxyribose 
DTT dithiothreitol 
E.coli Escherichia coli 
et al. et alii (and others) 
EtOH ethanol 
FABP(s)- fatty acid-binding proteins(s)- 
FCS  fetal calf serum 
FFA free fatty acid  
FLD fatty liver disease  
FLS fatty liver Shionogi 
g gram 
g gravitational force 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
H&E haematoxylin and Eosin  
HCC hepatocellular carcinoma  
HCl hydrogen chloride 
HCV hepatitis C virus 
HFD high fat diet 
HGNC HUGO Gene Nomenclature Committee guidelines 
hr(s) hour(s) 
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Abbreviation Explanation 
IFN-γ interferon gamma  
IgG immunoglobulin  
IL-1β interleukin 1β  
IL-6  interleukin 6 
in vitro in artificial culture 
in vivo  within the living 
k kilo 
L litre 
 LCN(s)- lipocalin(s)- 
Lcn2
−/−
 Lcn2-deficient 
LDC Lieber-DeCarli diet 
LPS lipopolysaccharide  
LSDP5 lipid storage droplet protein 5 
m milli 
M mole per litre 
MCD Methionine and Choline deficient diet  
MES 2-(N-morpholino)ethanesulfonic acid 
MLDP myocardial lipid droplet protein 
mM milli mole per litre 
MOPS  morpholinopropanesulfonic acid 
MPO myeloid peroxidase  
mRNA messenger ribonucleic acid 
n number 
n nano (x10
-9
) 
NAFLD non-alcoholic fatty liver disease  
NASH non-alcoholic steatohepatitis  
NGAL neutrophil gelatinase associated lipocalin 
NL or HNL (Human) Neutrophil Lipocalin  
NP-40 nonyl-phenoxypolyethoxylethanol 
OD600 optical density at 600 nm 
OXPAT oxidative tissue-enriched PAT  
PAGE polyacrilamide gel electrophoresis 
PBS phosphate-buffered saline 
PBST phosphate-buffered saline supplemented with Tween20 
PCR polymerase chain reaction 
PEG polyethylene Glycol 
PFA paraformaldehyde  
PLIN- perilipin- 
PLIN4 or S3-12 perilipin4 
PLIN5 perilipin 5 
PPAR-γ peroxisome proliferator-activated receptor γ, 
qRT-PCR quantitative real-time PCR  
RBP(s)- retinol-binding protein(s)- 
RNA ribonucleic acid 
RNase ribonuclease 
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Abbreviation Explanation 
rpm round per minute 
RT room temperature 
SD standard deviation  
SDS sodium dodecyl sulfate 
sec second 
Sip24 24 kDa super-inducible protein  
STAT1 signal transducers and activators of transcription 1 
STAT3 signal transducers and activators of transcription 3 
TBST tris-buffered saline supplemented with 1% Tween20 
TE tris and EDTA buffer 
TIP47 or PLIN3 tail-interacting protein-47  
TNF-α tumor necrosis factor-α 
v/v volume /volume 
VLDL very low density lipoproteins  
w/v weight /volume 
WT wild type 
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4 Introduction 
4.1 Lipocalins 
The lipocalins form a family of proteins originally classified as a widespread group of 
transport proteins for small hydrophobic molecules. They share a limited homological sequence. 
However, they have a common three dimensional structure architecture. Their common structure is 
comprised of an eight stranded antiparallel β-barrel which encloses an internal hydrophobic 
binding domain. Research of the last decades, has instated the wide family of lipocalins in an 
extended spectrum of biological processes that most often become visible during disease 
formation. Important biological functions of the lipocalins include transport of iron, pheromone, 
retinoids, arachidonic acid, steroids, colouring pigments, histamine and lipids, control of cell 
regulation, and the enzymatic synthesis of prostaglandins [Flower et al., 1996; Cianci et al., 2002; 
Marchese et al., 1998; Beynon et al., 2003; Andersen et al., 1998]. 
 
4.1.1 General structure and function of Lipocalins 
Members of the broad lipocalin protein family are found in several organisms including 
bacteria, plants, insects, and mammals such as human [Ganfornina et al., 2000]. In mid-80's 
Pervaiz and Brew categorised the first proteins of the lipocalin family [Pervaiz and Brew 1985]. 
They, as well gave the name ’lipo-calins’ to these proteins in order to describe their common 
ability to bind lipophilic molecules such as drugs and certain steroids in a way to protect them 
from degrading [Pervaiz and Brew 1985; Pervaiz et al., 1987]. The lipocalin family grew in 
members when methods such as informatics, sequence analysis, crystallography and nuclear 
magnetic resonance spectrometry were applied. Numerous extracellular and intracellular proteins 
with sequence homology, secondary structures and three-dimensional structure, similar to the first 
lipocalins, were identified and classified into the continuously extending Lipocalin superfamily 
[Pervaiz and Brew, 1985; Flower et al., 1991]. All the known members of the Lipocalin family in 
humans are depicted in Figure 4-i.  
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 Although some proteins of the lipocalin family share only an overall small sequence 
homology, all members of this protein family have a highly conserved structure with highly 
conserved folding segments, known as the lipocalin folds. This characteristic lipocalin fold is 
composed of a single eight-stranded continuously anti-parallel β-barrel that forms an integral 
hydrophobic pocket in which the different ligands are embedded. This ligand binding site is the 
special tool that the lipocalins use to function as transport proteins [Flower et al., 1996]. In Figure 
4-ii the characteristic structure of the Lipocalin 2 is depicted. 
 
 
Figure 4-i: Phylogenetic tree for human Lipocalins. The tree 
includes human lipocalins that are deposited in GenBank 
database under accession numbers. CAI14045 (LCN1), 
CAG46889.(LCN2), NP_945184 (LCN6), NP_848564 
(LCN8), NP_001001676 (LCN9), NP_001001712 (LCN10), 
NP_848631 (LCN12), NP_976222 (LCN15), CAG46887 
(FABP1), AAH69617 (FABP2), CAG33148 (FABP3), 
CAG33184 (FABP4), NP_001435 (FABP5), AAB82751 
(FABP6), CAG33338 (FABP7), CAG46802 (RBP1), 
AAH69513 (RBP2), CAH72328 (RBP4), NP_113679 (RBP5), 
CAI14685 (RBP7), N P_001624 (AMBP), CAG46572 
(APOD), NP_000597 (C8G), CAG33298 (CRABP1), 
CAG29353 (CRABP2), CAI14043 (OBP2A), AAQ89340 
(OBP2B), NP_000598 (ORM1), NP_000599 (ORM2), 
NP_002562 (PAEP), CAG46538 (PMP2) and NP_000945 
(PTGDS), respectively. The sequence alignment and 
generation of phylogenetic tree was done at the GenomeNet 
Database Resource that is available at 
http://www.genome.jp/tools/clustalw. (Source: 
Asimakopoulou and Weiskirchen 2015). 
 
Figure 4-ii: Three dimensional structural architecture 
of Lipocalin 2. (A) In the monomeric structure of the 
human Gelatinase-associated Lipocalin (NGAL/LCN2) 
that was determined by Nuclear Magnetic Resonance 
(NMR) Spectroscopy the typical three dimensional 
lipocalin fold is recognizable. It consists of an eight-
stranded antiparallel β-barrel. In the cavity of this barrel 
hydrophobic molecules can be incorporated. More details 
of the solution structure and dynamics of human LCN2 are 
given elsewhere [Coles et al., 1999]. The coordinates of 
the respective protein (1NGL, human NGAL) was taken 
from the RCSB Protein Data Bank repository that can be 
found at http://www.rcsb.org. The image was generated 
using the Ribbons XP software (Version 3.0) [Carson 
1997]. (Source: Asimakopoulou and Weiskirchen 
2015). 
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Additional advantageous characteristics of the lipocalins are their general small size, their 
ability to be secreted from various cells and that they contain ligand binding sites that target the 
multitude of specific substances with high specificity [Godovac-Zimmermann 1988]. These major 
features have involved the lipocalins in many biological processes. Bright examples of lipocalins 
are the retinol-binding protein (RBP) [Cowan et al., 1990], which transports retinol (vitamin A) 
through the blood to target cells [Newcomer et al., 2000] and the different intracellular fatty acid-
binding proteins (FABP) that bind hydrophobic molecules such as fatty acids [Matarese et al., 
1990]. Another group of the lipocalin superfamily known as the ‘immunocalins’ including the α1-
acid glycoprotein and the α1-microglobulin have drug-binding properties which mediate 
immunological and inflammatory processes in a protective way [Logdberg et al., 2000]. In 
humans, the most well-known subgroups of lipocalins are formed by the "classical lipocalin" (i.e. 
LCNs), the FABPs, and the RBPs. Most of the lipocalins are found in literature under multiple 
synonyms indicating the various roles in biological processes. The several lipocalins based on their 
chromosomal localizations, it was suggested that they have evolved by in situ tandem duplication 
forming gene clusters in which each gene has obtained a distinct spatial expression and regulation 
[Suzuki et al., 2004]. 
 
4.1.2 Lipocalins in hepatic disease initiation and progression 
 As outlined above, lipocalins have been studied widely as possible non-invasive, biochemical 
markers for many diseases. In addition, they have already been extensively used as markers for 
clinical cases of inflammatory diseases, lipid abnormalities, cancer, kidney injury, and liver 
functions. Several members of the lipocalin superfamily such as the retinol-binding protein (RBP), 
Complement C8, lipocalin 13 (LCN13), FABP1, LCN2, and others have been associated with 
hepatic injury including acute and chronic inflammation, insulin resistance as well as failures in 
lipogenesis, fatty acid oxidation and nutrient metabolism. 
The human complement C8 is mainly produced in liver cells and has been classified in the 
lipocalin family as an acute-phase protein due to the fact that its production is strongly associated 
with pro-inflammatory cytokines such as IL-1β, IL-6, and Interferon gamma (IFN-γ) in the 
hepatoma cell lines HepG2 [Scheurer et al., 1997]. RBP is another lipocalin that is considered a 
acute phase protein that is elevated soon after the hepatic necrosis. The serum concentrations of 
RBP have been considered as a great diagnostic tool to predict the hepatic recovery and outcome 
of patients after acute necrosis [Horn et al., 1999] while it has also been found to be increased in 
obese children with non-alcoholic fatty liver disease (NAFLD) that correlated with the activity of 
alanine transaminase (ALT) suggesting that this lipocalin is a contributor to the pathogenesis of 
NAFLD suggesting serum RBP as a novel marker to predict the disease [Boyraz et al., 2013]. A 
wide set of experiments has demonstrated that LCN13 reduces hepatic lipid accumulation by both 
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inhibiting hepatic lipogenesis and enhancing β-oxidation and further that LCN13 deficiency is 
likely to contribute to fatty liver disease in obese mice [Cho et al., 2011; Sheng et al., 2011]. 
Therefore, also LCN13 is potentially a novel useful diagnostic marker for formation of fatty liver. 
Another interesting group of lipocalins that are grouped as FABP contains also several members 
that were already associated with hepatic steatosis. Independently of obesity, liver fat was initially 
associated with mRNA expression of the FABP4 and FABP5 [Westerbacka et al., 2007]. 
Additionally FABP1 was finally reported to protect from lipotoxicity of free fatty acids and to 
mediate the trafficking of fatty acids in the liver [Guzman et al., 2013]. LCN2 is one members of 
the lipocalin family with various associations in hepatic conditions regarding injury, inflammation, 
lipid homeostasis and mitochondrial malfunctions described below. 
 
4.2 Lipocalin 2 
The main subject of interest, Lipocalin-2 was discovered by Kjedsen’s group in 1993 as a 
25 kDa protein that was associated with human neutrophil gelatinase [Kjeldsen et al., 1993]. The 
protein was isolated from exocytosed material obtained from phorbol myristate-stimulated human 
neutrophils. Based on the high primary sequence similarity of this new protein with the sequences 
of the deduced rat a2-microglobulin and the mouse lipocalin 24p3, this neutrophil gelatinase 
associated lipocalin (NGAL) was recognized as a novel member of the lipocalin family [Kjeldsen 
et al., 1993]. As many other lipocalins, NGAL has many synonyms depicted in Table 4-i.  
 
Species Synonym Feature References 
Human 
Neutrophil gelatinase associated 
lipocalin (NGAL) 
25-kDa protein purified from exocytosed material from 
phorbol myristate acetate-stimulated human neutrophils 
[Kjeldsen et al., 
1993] 
(Human) Neutrophil Lipocalin (NL 
or HNL) 
Purified from the granules of human neutrophils [Xu et al., 1994] 
25kDa α2-micro globulin – related 
protein 
Homology to an α2-microglobulin-related protein from 
rats 
[Triebel et al., 
1992] 
Siderocalin 
Demonstration that LCN2/NGAL binds bacterial 
catecholate-type ferric siderophores 
[Goetz et al., 
2002] 
Mouse 
Lipocalin 2 
Chromosomal assignment of LCN2 to human 
chromosome 9q34 
[Chan et al., 1994] 
Oncogene 24p3 protein Expression in breast cancer 
[Slamon et al., 
1987] 
Uterocalin Expression of this lipocalin in the uterus [Liu et al., 1997] 
24 kDa super-inducible protein 
(Sip24) 
Fibroblast growth factor inducible protein in BALB/c 3T3 
cells 
[Davis et al., 
1991] 
Rat 
Neu-related lipocalin (NRL) Expressed in neu-initiated breast cancers 
[Stoesz et al., 
1995] 
α2u-globulin, α2-microglobulin-
related protein 
Male rat liver protein under complex hormonal control, 
present in the urine of mature male rats and absent from 
the urine of female rats 
[Roy et al., 1966; 
Kurtz et al., 1977; 
Drickamer et al., 
1981] 
Table 4-i: Synonyms of LCN2/NGAL in: human, mouse and rat (Source: Asimakopoulou and Weiskirchen, 2015). 
  
In accordance with the approved gene symbols of the HUGO Gene Nomenclature Committee 
guidelines (HGNC) (http://www.genenames.org/genefamilies/lipocalin), here the name lipocalin 2 
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(LCN2) will be used when referring to this protein in this dissertation. In 1994, the group of 
Kjeldsen achieved the molecular cloning of the full-length human LCN2 cDNA and in 
recombinant expression of this lipocalin in E. coli [Bundgaard et al., 1994]. 
In the same year, the gene encoding LCN2 was assigned by in situ hybridization to human 
chromosome 9 on the HSA9q34 area, where most of the known human lipocalins are clustered 
[Chan et al., 1994]. Over the last years LCN2 has been reported to be expressed in several tissues 
including liver, kidney, pancreas, and lungs. More analytically sources of LCN2 in humans as 
published are depicted in Table 4-ii. 
      
Source of LCN2 in humans Literature 
Supernatant of activated Neutrophils Kjeldsen et al., 1993 
Bronchus, stomach, adipose tissue,small intestine, 
pancreas, kidney, prostate gland, and thymus. 
Friedl et al., 1999 
Adenocarcinomas of lung, colon and pancreas. Friedl et al., 1999 
Inflamed epithelia in bowel Nielsen et al., 1996 
Mammary adenocarcinomas Stoesz et al., 1998  
Urothelial carcinomas Monier et al., 2000 
Normal liver and Hepato-carcinomas Zhang et al., 2012  
     Table 4-ii: Sources of LCN2 in human tissues 
 
Lipocalin 2 in iron transport - One of LCN2’s main features is the ability to bind iron. That 
was first indicated by Goetz et al [Goetz et al., 2002] proven to be the result of an iron molecule 
bound on the enterochelin, which is E. coli’s siderophore. Yang et al., supported this finding by 
reporting that LCN2 plays a critical role in delivering iron to the cytoplasm in which it regulates 
iron-associated genes mediating many cellular iron-dependent reactions [Yang et al., 2002]. 
Additionally, the Goetz group reported that LCN2 has the ability to bind bacterial ferric 
siderophores, suggesting that LCN2 mediates the antibacterial iron-depletion strategy of the innate 
immune system by sequestering iron giving the synonym name Siderocalin to LCN2 [Goetz et al., 
2002]. Not long after, Flo and coworkers using mice knock out for LCN2 proved their sensitivity 
in bacterial infection compared to WT animals. The absence of secreted LCN2 enhanced bacterial 
growth while LCN2 presence, sequestered the iron bound on siderophore, limiting the bacterial 
growth [Flo et al., 2004]. For more than a decade, numerous studies reporting the elevated 
expression of LCN2 in bacterial infection cases gave the unarguable role of LCN2 in the immune 
system to limit bacterial growth by sequestrating the iron-laden siderophore [Flo et al., 2004; 
Berger et al., 2006].However, several other experimentation classified LCN2 as a factor that is 
upregulated in many other conditions such as infection, intoxication, inflammation and other forms 
of cellular stress. 
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 Lipocalin 2 in cellular stress - Regarding liver conditions, there are many experimental and 
clinical findings in which altered hepatic expression of LCN2 was reported (Table 4-iii). Jiang et 
al., showed that LCN2 was significantly upregulated by anaemia and hypoxia in murine liver and 
serum [Jiang et al., 2008]. LCN2 was also proposed as a possible biomarker of early liver damage 
that occurred during ethanol consumption in mice [Bykov et al., 2007]. At the same period, Sunil 
and coworkers reported that endotoxemia-induced by intraperitoneal injection of 
lipopolysaccharide (LPS) to mice (at 1 mg/kg body weight) or rats (at 5 mg/body weight) resulted 
in an early upregulation of LCN2 that was already evident 4 hrs post infection and persisted for 
24-48 hrs [Sunil et al., 2007]. This report further demonstrated that the injection of LPS was also 
effective in inducing LCN2 expression in the lung, suggested that LCN2 plays a critical role in 
restoring liver and lung tissue homeostasis after endotoxemia [Sunil et al., 2007]. More reports 
showed that different tissues including heart, kidney and mainly liver are capable to upregulate 
expression of LCN2 after an acute and long-term exposure to X-rays [Roudkenar et al., 2007]. 
After these first reports numerous studies about hepatic inflammation and damage were initiated 
aiming to understand the regulation of LCN2 and the underlying molecular pathways. Borkham et 
al., demonstrated a remarkable upregulation of LCN2 in mice after administration of carbon 
tetrachloride (CCl4), LPS, Concanavalin A or after bile duct ligation that are all suitable 
experimental models for acute or chronic liver injury suggesting LCN2 as a reliable indicator for 
liver damage and that LCN2 evolves hepato-protective effects during phases of acute liver injury 
[Borkham-Kamphorst et al., 2013]. Shortly before, Labbus et al. showed the intense upregulation 
of LCN2 in inflammatory responses, indicating the role of LCN2 to restore liver homeostasis after 
appropriate insult [Labbus et al., 2012]. That result was supported by Lai et al who reported 
enhanced expression of LCN2 during liver regeneration using a partial hepatectomy model [Lai et 
al., 2013]. 
 
Lipocalin 2 in AKI and HCC - The strong association of LCN2 in acute kidney injury (AKI) 
became the centre of attention when Mishra and co-workers for the first time suggested that LCN2 
is a promising and sensitive biomarker of ischemic and nephrotoxic renal injury [Mishra et al., 
2003; Mishra et al., 2004; Mishra et al., 2005].Additionally the association of human LCN2 with 
AKI patients post-liver-transplantation was proved [38, Niemann et al., 2009]. Moreover, LCN2 
further plays a significant role in the formation of hepatic cancer, ovarian cancer, lung 
adenocarcinomas, and breast cancer [Bartsch et al., 1995; Furutani et al., 1998; Friedl et al., 1999; 
Liu et al., 1995]. Recently, LCN2 was proved to be a diagnostic marker with high sensitivity and 
specificity for increasing lobular inflammation, ballooning and fibrosis that are the pathogenetic 
changes during formation of hepatocellular carcinoma (HCC) [El Moety et al., 2013].  
During the last years, LCN2 has also been widely studied in obesity and other metabolic 
dysregulation conditions. Several studies have proved the strong correlation of LCN2 to insulin 
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resistance [Yan et al., 2007], obesity, obesity-related metabolic complications and cardiovascular 
diseases [Auquet et al., 2011; Wang et al., 2007] as well as to mitochondrial oxidation and 
adipocyte metabolism [Zhang et al., 2014]. 
 
 
Species Model/Disease Treatment LCN2 Expression Conclusions Refs 
Mouse Anaemia and hypoxia 
Anaemia was induced by 
phlebotomy, iron deprivation, 
or phenylhydrazine treatment 
Upregulation of LCN2 
during anaemia and 
hypoxia 
LCN2 has a physiological role during 
increased iron utilization and 
mobilization from stores 
[Hvidberg et 
al., 2005] 
WT and Lcn2-/- mice Acute liver injury 
Administration of LPS or 
Concanavalin A and bile duct 
ligation. 
Highly elevated hepatic 
LCN2 expression 
LCN2 has an hepato-protective role and 
it’s a reliable biomarker of acute liver 
injury 
[Borkham-
Kamphorst E et 
al., 2013] 
WT and Lcn2-/- mice Inflammatory liver injury LPS stimulation 
Dramatic upregulation 
of LCN2 
LCN2 has essential function in liver 
homeostasis 
[Labbus et al., 
2013] 
Human Patients with chronic liver disease 
Clinical samples: 25 controls, 
25 HCC patients, 25 HCC 
patients with hepatitis C 
LCN2 elevated in HCV 
and in combination of 
combined HCC and 
HCV 
LCN2 associated with increasing liver 
inflammation, ballooning & fibrosis. 
LCN2 - diagnostic marker for progression 
of HCC 
[El Moety et 
al., 2013] 
Rat Acute and chronic liver injury 
Administration CCl4 or bile 
duct ligation 
High expression of 
LCN2 in cultured 
hepatocytes isolated 
from injured rats 
LCN2 expression shows clear correlation 
to liver damage and resulting 
inflammatory responses; Possible 
diagnostic value as an early biomarker of 
liver inflammation 
[Borkham-
Kamphorst E et 
al., 2011] 
Human Severely obese women with NAFLD 
Clinical samples: Liver 
histology of 59 obese women 
and LCN2 serum ELISA 
measurements  
Upregulated expression 
in NAFLD women 
LCN2 is related to NAFLD 
[Auguet et al., 
2013] 
Mouse Fatty liver Shionogi Genetic development of NASH 
Increased LCN2 
expression in NASH 
mice 
LCN2 important for pathogenesis of 
NASH 
[Semba et al., 
2013] 
Human NAFLD Chinese patients Clinical samples: LCN2 serum 
ELISA measurements in 436 
patients with NAFLD and 467 
controls 
Elevated levels of 
circulating and serum 
LCN2 
Contribution of LCN2 in the progression 
of NAFLD 
[Ye et al., 
2014] 
Rat Hepatic steatosis HFD, and liquid LDC 
administration (diet high 
fructose) 
Upregulated LCN2 in 
rats with NAFLD 
Correlation of LCN2 and NAFLD and 
hepato-protective role of LCN2, 
correlation of LCN2 to oxidative stress 
and mitochondrial dysfunction 
[Alwahsh et 
al., 2014] 
 
*Abbreviations used: CCl4, carbon tetrachloride; HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus; HFD, High fat diet; LDC, Lieber-DeCarli diet; LCN2, Lipocalin 2; 
LCN2-/- Lipocalin 2 knock out; LPS, Lipopolysaccharide; ; MCD, Methionine and choline deficient diet; NAFLD, Non-alcoholic fatty liver disease; NASH, Non-alcoholic 
steatohepatitis; PLIN5, Perilipin 5; PPAR-γ, Peroxisome proliferator-activated receptor γ; WT, wild type. 
Table 4-iii: Selected experimental and clinical findings associated with altered hepatic LCN2 expression* (Source: Asimakopoulou and Weiskirchen, 2015) 
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Species Model/Disease Treatment LCN2 Expression Conclusions Refs 
Human NAFLD patients 
Clinical samples: urine from 
65 consecutive patients 
Significant upregulation of urinary 
LCN2 
Correlation of urinary LCN2 with NAFLD-
related hepatic injury, body mass index, insulin 
resistance and lipid profiles 
[Tekkesin et al., 
2012] 
WT and Lcn2-/- 
mice 
Hepatic steatosis HFD feeding 
Highly expressed LCN2 in WT 
mice with NAFLD; lack in LCN2 
resulted in significantly potentiated 
diet-induced obesity, dyslipidemia, 
fatty liver disease and insulin 
resistance 
LCN2 is a key regulator of glucose, lipid 
homeostasis and insulin resistance 
[Guo et al., 2010] 
WT and Lcn2-/- 
mice 
Hepatic steatosis 
HFD and Rosiglitazone 
administration 
LCN2 deficiency cancels 
Rosiglitazone’s activity 
LCN2 regulates PPARγ which regulates hepatic 
lipogenesis 
[Jin et al., 2011] 
WT and Lcn2-/- 
mice 
NAFLD 
MCD diet and LCN2 
transfection/infection in 
primary hepatocytes 
LCN2 upregulation in NAFLD, 
upregulation of PLIN5 after LCN2 
restoration 
LCN2 mediates hepatic lipid droplet formation 
via regulation of PLIN5 
[Asimakopoulou 
et al., 2014] 
Rat 
Hepatic Irradiation 
damage 
Rats received a single 
percutaneous irradiation dose 
(25 Gray) 
LCN2 serum levels increased 
significantly within 6 hrs 
LCN2 is a marker for the early phase of 
radiation-induced liver damage 
[Sultan et al., 
2013] 
Rat Toxic liver injury 
Data taken from the 
toxicogenomics database 
DrugMatrix 
LCN2 is correlated to liver 
fibrogenesis 
LCN2 is a marker of hepatic fibrogenesis in rats 
induced by different toxic treatment 
[AbdulHameed 
et al., 2014] 
Hepatocyte 
specific - and 
global Lcn2-/- 
mice 
Bacterial infection 
and partial 
hepatectomy 
Bacterial infection with 
Klebsiella pneumoniae or 
Escherichia coli or partial 
hepatectomy 
Strong upregulation of hepatic 
LCN2 after bacterial infection and 
partial hepatectomy 
Hepatocytes are the major cell type responsible 
for LCN2 production after bacterial infection or 
partial hepatectomy. Hepatocyte-derived LCN2 
plays an important role in inhibiting bacterial 
infection and promoting liver regeneration 
[Xu et al., 2014] 
Mouse Partial hepatectomy 
Mice were subjected to partial 
hepatectomy 
LCN2 expression is dramatically 
induced in livers and sera of mice 
after partial hepatectomy, whereas 
liver LCN2-receptor expression was 
decreased 
LCN2, although massively induced in mice 
after partial hepatectomy, is not relevant in 
murine hepatic regeneration 
[Kienzl-Wagner 
et al., 2014] 
 
*Abbreviations used: CCl4, carbon tetrachloride; HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus; HFD, High fat diet; LDC, Lieber-DeCarli diet; LCN2, Lipocalin 
2; LCN2-/- Lipocalin 2 knock out; LPS, Lipopolysaccharide; ; MCD, Methionine and choline deficient diet; NAFLD, Non-alcoholic fatty liver disease; NASH, Non-alcoholic 
steatohepatitis; PLIN5, Perilipin 5; PPAR-γ, Peroxisome proliferator-activated receptor γ; WT, wild type. 
Table 4-iv: Selected experimental and clinical findings associated with altered hepatic LCN2 expression* (Source: Asimakopoulou and Weiskirchen, 2015) (cont.) 
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Species Model/Disease Treatment LCN2 Expression Conclusions Refs 
 
Mouse 
 
Acetaminophen 
intoxication, IL-22 
induced endotoxemia 
 
Mice were injected with 
combinations of Acetaminophen 
and IL-22 
 
LCN2 is induced after Acetaminophen-
induced hepatotoxicity and LCN2 
mRNA expression is further increased 
after application of IL-22  
 
LCN2 is a prototypical gene that is up-
regulated by the IL-22/STAT3 axis 
 
[Scheiermann 
et al., 2013] 
Mouse 
Human colon cancer cells 
were injected in nude 
mice 
A human colon cancer cell line 
was genetically manipulated to 
overexpress LCN2 and 
subcutaneously or intrasplenically 
injected into mice 
Cells were genetically modified to 
artificially overexpress LCN2. 
Respective cells substantially inhibited 
liver metastasis compared to 
unmodified colon cancer cells. 
LCN2 is a candidate metastasis suppressor 
[Lee et al., 
2006] 
Mouse 
Implantation of tumors in 
nude mice 
Mice were injected with LCN2-
overexpressing hepatocellular 
carcinoma cells 
Hepatocellular carcinoma cells (Chang 
liver or SK-Hep1 cells were genetically 
modified to artificially overexpress 
LCN2 
LCN2 is a suppressor of proliferation, 
migration, invasion and colony forming 
efficiency in cells expressing LCN2 is 
markedly reduced. Tumor growth is suppressed 
in the presence of LCN2. LCN2 modulates 
MMP-2 protein expression. 
[Lee et al., 
2011] 
Human 
Hepatitis C-induced 
fibrosis/cirrhosis 
18 patients with mild and 24 
patients with severe 
fibrosis/cirrhosis 
Urine LCN2 levels (normalized to 
urine creatinine) were higher in 
patients with severe fibrosis/cirrhosis 
showing a positive correlation with 
urine MMP-9/MMP-2 activity ratios 
Urinary LCN2 is a marker of hepatic fibrosis 
that correlates to urine MMP-9 activity 
[Kim et al., 
2010] 
Human 
Acute-on-chronic liver 
failure, acute liver failure, 
chronic hepatic failure 
Very small cohort of patients with 
acute-on-chronic liver failure, 
acute liver failure (n=8) and 
chronic hepatic failure (n=14) 
Baseline LCN2 serum concentrations 
were significantly increased among 
acute-on-chronic liver failure and acute 
liver failure 
Serum LCN2 may be useful to discern acute 
from chronic hepatic failure and to monitor the 
course as well as the severity of the disease  
[Roth et al., 
2013] 
Rat and 
Mouse 
Turpentine oil- induced 
sterile abscess/acute phase 
response 
Rats and Mice were injected with 
5 mL/kg (rats) or 10 mL/kg 
turpentine oil 
LCN2 was strongly upregulated after 6 
hrs in serum (in ELISA) and 12 hrs in 
liver protein extracts (Western blot) 
Confirming previous reports that LCN2 is an 
acute phase protein 
[Sultan et al., 
2012] 
 
*Abbreviations used: CCl4, carbon tetrachloride; HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus; HFD, High fat diet; LDC, Lieber-DeCarli diet; LCN2, Lipocalin 2; 
LCN2-/- Lipocalin 2 knock out; LPS, Lipopolysaccharide; ; MCD, Methionine and choline deficient diet; NAFLD, Non-alcoholic fatty liver disease; NASH, Non-alcoholic 
steatohepatitis; PLIN5, Perilipin 5; PPAR-γ, Peroxisome proliferator-activated receptor γ, WT, wild type. 
Table 4-v: Selected experimental and clinical findings associated with altered hepatic LCN2 expression* (Source: Asimakopoulou and Weiskirchen, 2015) (cont.) 
 
 
4.2.1 Lipocalin 2 in fatty liver disease 
Fat accumulation in the liver is an abnormal condition that has raised multiple questions from 
the aetiologies to the progression process and the possible restoration mechanisms. Fatty liver 
disease (FLD) describes a reversible situation in which the liver presents either simple fat 
accumulation (steatosis) or fat accumulation accompanied with hepatic inflammation 
(steatohepatitis). LCN2 has concerned the interest of many researchers and clinicians that are 
trying to understand the dynamic process through which fatty liver disorders develop. Despite the 
fact that LCN2 had been widely associated with obesity, insulin resistance and metabolic 
abnormalities, its relation with FLD has also been studied during the last years resulting in some 
interesting findings that suggest that LCN2 is a promising therapeutic target for NAFLD.  
After analysing the liver histology profile of severely obese women with normal histology, 
simple steatosis and non-alcoholic steatohepatitis (NASH), Auquet and colleagues observed that 
hepatic LCN2 gene expression is significantly higher in severely obese women with NAFLD and 
that LCN2 expression is further induced under inflammatory conditions that place the liver in 
danger [Auquet et al., 2013]. An interesting animal model of NASH is the fatty liver Shionogi 
(FLS) mice. This model was used to define the difference in LCN2 expression in NASH mice 
when compared to mice with simple steatosis suggesting a prominent role of LCN2 in the 
pathogenesis of NASH because of the upregulated LCN2 expression under NASH conditions in 
areas surrounding the inflammatory cell infiltrates [Semba et al., 2013]. Ye and co-workers after 
observing higher levels of serum LCN2 in NAFLD Chinese patients suggested that the higher 
circulating serum LCN2 levels possibly contribute to the progression of the investigated disease 
[Ye et al., 2014]. Upregulation of LCN2 was observed in rats-models of hepatic steatosis 
suggested relation with oxidative stress formation and mitochondrial dysfunction [Alwahsh et al., 
2014]. The immunofluorescence staining of those models have shown that LCN2 positivity in the 
liver was restricted to myeloperoxidase-containing cells that are characteristic for neutrophils 
suggesting an hepato-protective role of LCN2 supporting previous results [Borkham-Kamphorst et 
al., 2013; Alwahsh et al., 2014].  
In one more experimental study performed in mice fed on an HFD, the expression of the 
LCN2 gene was analyzed in various tissues. In comparison to normal control mice, Lcn2
-/-
 mice 
showed increased hepatic gluconeogenesis, decreased mitochondrial oxidative capacity, impaired 
lipid metabolism, and increased inflammatory sites under these conditions. Therefore, they 
demonstrated that LCN2 is one of the key regulators of energy metabolism, glucose and lipid 
homeostasis, and formation of insulin resistance [Guo et al., 2010]. The same group investigated 
the role of LCN2 in peroxisome proliferator-activated receptor gamma (PPAR-γ) activation by 
evaluating the insulin sensitization and fatty acid homeostasis of the PPAR-γ–agonist, 
Rosiglitazone, after administration of HFD [Jin et al., 2010]. Deficiency of LCN2 reduced by far 
the effect of Rosiglitazone in increasing body weight, fat deposition, and liver lipid accumulation. 
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The presented data of this study indicated that LCN2 appears to be a strong regulator of the PPAR-
γ which regulates hepatic lipogenesis and suggests that LCN2 is a possible drug target in 
antidiabetic medicine [Jin et al., 2010].  
 
4.2.2 Lipocalin 2 in the diagnosis of hepatic disease 
Many of the reported studies in rodents and humans about LCN2 have shown that this 
lipocalin is of great importance and linked to the pathogenesis of hepatic disease including 
infection, inflammation, organ injury, lipid homeostasis, insulin resistance and gluconeogenesis 
(Figure 4-iii). Several studies have demonstrated the significant positive correlation of enhanced 
LCN2 expression to several sources of inflammation suggesting this protein as a versatile 
biomarker for screening and diagnosis of hepatic injury [Borkham-Kamphorst et al., 2013; Roth et 
al., 2013]. Moreover, the demonstration that the application of a single dose irradiation on liver 
results in an intense increase of LCN2 in serum LCN2 within the first 6 hrs suggests LCN2 as an 
candidate biomarker suitable for detection of early phase hepatic damage induced by radiation 
[Sultan et al., 2013]. The measurement of both LCN2 and its receptor (LCN2R or NGALR) that 
are both overexpressed in human HCC have been suggested to be relevant for the prognostic 
classification [Kim et al., 2010; Zhang et al., 2012]. Additionally the measurement of LCN2 as a 
parameter for liver lipid metabolism and its critical regulator role for PPAR activation is also well 
established [Jin et al., 2011]. 
 In summary, the data of all these studies strongly imply that LCN2 is a sensitive and specific 
biomarker for hepatic inflammation, hepatic cancer, and lipid abnormalities. LCN2 is and will be 
for the upcoming years ‘under the microscope’ as research so far has suggested promising 
therapeutic uses of LCN2 in diagnosis and treatment of disease.  
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Figure 4-iii: Diagnostic measurement of LCN2 in human specimen. Several clinical conditions or liver damage 
induced experimentally are connected with significant expression of LCN2. Many reports based on experimentation on 
rodents led to the outcome that after the induced anaemia, hypoxia, or the application of hepatotoxins (EtOH, LPS, CCl4, 
Concanavalin A), and X-rays that lead to reactive oxygen species formation, remarkably increase expression of hepatic 
LCN2. Moreover experimental induced liver fatty models [induced by feeding of fat rich diets (HFD, LDC) or lack of 
methionine and choline (MCD)] or clinical conditions leading to liver malfunction are associated as well with increased 
expression of hepatic LCN2. Clinical condition The levels of LCN2 in serum, urine or liver protein extracts can be 
measured by quantitative ELISA, Western blot analysis and staining of liver sections with antibodies specific for LCN2. 
In particular, the measurement of LCN2 by ELISA technique is a fast and robust diagnostic option to detect an early 
increase of LCN2 in patients suffering from fatty liver diseases (NAFLD, NASH, and ASH) in which the liver insult 
correlates with LCN2 expression. (Modified after Asimakopoulou and Weiskirchen, 2015) 
4.3 The liver 
The liver is a vital organ and the largest gland in the body of any vertebrate. It has an 
outstanding variety of essential functions in the human body including digestion, metabolism, 
glycogen storage, blood protein synthesis, hormone production, decomposition of red blood cells 
and detoxification. 
 
4.3.1 Functions and anatomy of the liver 
Liver is the ‘chemical factory’ of the body. As the biggest metabolic organ and largest gland 
(secretes bile) in the body it fulfils essential functions in digestion via the metabolism of fats, 
proteins and carbohydrates (fatty acid synthesis, amino acid breakdown, glycogen storage). 
Moreover, liver participates in detoxification of excessive amounts of alcohol and drugs. Other 
important functions of the liver is the embryonic haematopoiesis, the formation of cellular blood 
components (a procedure taken up by the bone marrow before birth) and the production of blood 
clotting factors and proteins (albumin). In the liver, blood passes through spaces called sinusoids 
(low pressure vascular channels) where bacteria, dead or foreign matters are removed by 
phagocytosis (from the Kupffer cells) giving liver a main role in immunology. Additionally, this 
‘chemical factory’ of the body can process certain hormones (thyroid and steroid hormones) while 
Clinical conditions
Experimental liver damage
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it serves as a storage for vitamins (A, D, K, E and B12) and minerals [Löffler et al., 1998; Faller et 
al., 2004]. 
 The liver is found in the upper right-hand portion of the abdominal cavity. It lies beneath the 
diaphragm and on top of the stomach and intestines, towards the right kidney. The liver has a red-
brown colour. This multifunctional organ with roles in metabolism and digestion has an unusual 
dual-blood supply. The two distinct sources of blood are: a) the hepatic artery from where 
oxygenated blood flows in every minute and b) the hepatic portal vein where from, nutrients 
absorbed by the intestine, flow in the liver. The liver consists of four lobes, the right and left lobe 
as the main larger lobes and the smaller caudate and quadrate lobe. Every lobe is made up of 
thousands lobules. Every lobule is connected to small ducts that connect to bigger ones to finally 
form the main hepatic duct which transports the bile produced in the gallbladder and small 
intestine (duodenum) by liver cells. 
The liver in order to carry out all its functions it has different cell types, with different 
responsibilities, as shown in Figure 4-iv. Parenchymal and non-parenchymal cells reside inside or 
outside of the sinusoid, which is the space in liver where the blood flows through, instead of 
capillaries. The hepatocytes are parenchymal cells that constitute 70-80% of the hepatic mass 
[Lӧffler et al., 1998]. Hepatocytes are cuboidal, epithelial cells where most of the metabolic 
procedures storage, digestion, bile production) take place. They are responsible for protein 
synthesis (albumin, lipoprotein, prothrombin,) for fatty acid synthesis and roles in lipid 
metabolism and the inflammation procedure. Other parenchymal cells are the cholangiocytes that 
are responsible for the composition and release of the bile [Tietz et al., 2006]. The non-
parenchymal cells compose 30-40% of the total liver cells. The sinusoidal endothelial cells, 
Kupffer cells, co-live with the hepatocytes in the sinusoid, separated from each other by the space 
of Disse. The Kupffer cells are lined onto the sinusoidal wall and they are an immune response 
tool. They serve as macrophages that are in contact with the blood flow breaking down old, red 
blood cells and foreign molecules [Pocock et al., 2006]. Externally to the sinusoid there are the 
non-parenchymal cells hepatic stellate cells. They are also called perisinusoidal cells as they line in 
the space of Disse (perisinusoidal space) attached to the hepatocytes [Kmieć et al., 2001]. These 
cells store fat and vitamin A and they are the main cells for fibrosis events as responsible for 
synthesis of collagen and extracellular matrix [Benyon et al., 2000; Lӧffler et al., 1998]. 
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Figure 4-iv: The structure of the hepatic lobule. Microscopically, the liver consists of many hepatic plates composed 
of hepatocytes. The plates of each lobule usually are organized around a central venule which is the actual connection to 
the hepatic vein. Each hepatic lobule has oxygenated blood running in through the hepatic artery branches, while 
branches of the hepatic portal vein peripherally bring in nutrients absorbed by the stomach and intestine. Between the 
hepatic plates there are hepatic sinusoids that carry blood from the hepatic artery and portal venule to the central vein. 
(Modified figure taken from Frevert et al., 2005). 
 
4.3.2 Hepatocytes in fatty liver disease 
Hepatocytes are key cells for many procedures such as, regulating energy balances, protein 
synthesis and storage, metabolism of carbohydrates, metabolism of fats with the formation and 
secretion of bile, synthesis of cholesterol and phospholipids and conversion or detoxification of 
exo- and endogenous for the liver substances.  
Moreover hepatocytes has become the last years the aim of attractions for studies based on 
metabolism of fats and hepatic injury models. The liver is the number one organ in general 
metabolism. Endogenous and exogenous compounds are taken up by hepatocytes and modified 
them in other forms maintaining the homeostasis of the liver. The liver is the main organ, where 
carbohydrates and proteins are converted into fatty acids and triglycerides that are later exported 
and stored in adipose tissue. Hepatocytes are responsible for fatty acid uptakes and storage of 
lipids and triglycerides. Another critical function of hepatocytes is to synthesize and secrete 
lipoproteins such as very low density lipoproteins (VLDL) [Bouma et al., 1988]. The participation 
of the hepatocytes in all this paths has set it as useful tool to represent liver behaviour to study 
cases of inflammation and steatosis (lipid accumulation) models such as chronic or acute liver 
damage and fatty liver diseases. In examples of laboratory induced acute and chronic hepatic 
damage hepatocytes has been representative of liver damage and inflammation [Borkham-
Kamphorst et al., 2011; Semba et al., 2013; Zhao et al., 2009]. In models of fatty liver disease such 
as NASH where inflammation follows after steatosis hepatocytes tend to give the most answers in 
the question of fatty acid uptake, inflammatory markers regulation, oxidative stress, lipid 
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metabolism and in general liver homeostasis [Csak et al., 2011; Zhao et al., 2009; Liu et al., 2011]. 
Except all the above significant functions of the hepatocytes, another hint that favoured this study 
is that, experimental liver injury induces rapidly a sustained LCN2 production by injured 
hepatocytes [Borkham-Kamphorst et al., 2011]. 
 
4.4 NAFLD-NASH 
Fat accumulation in the liver is an abnormal condition that has raised multiple questions from 
the aetiologies to the progression process and the possible restoration mechanisms. FLD describes 
a reversible situation in which the liver presents either bland fat accumulation (steatosis) or fat 
accumulation accompanied with hepatic inflammation (steatohepatitis). 
 Two most common phenotypes of FLD are the alcoholic fatty liver disease (AFLD) and 
NAFLD. ALFD is a form of dangerous fat accumulated in the liver that is the result of excessive 
and chronic consumption of alcohol. Epidemiological studies have shown that AFLD appears in a 
frequency that is much lower than NAFLD. NAFLD nowadays is known as one of the most 
common types of chronic liver disease. In the Western countries, it affects up to 30% of the 
population [Baumeister et al., 2007; Bellentani et al., 2010]. NAFLD is mainly characterized by a 
generalized hepatic excessive fat accumulation that reaches more than 5% of the total liver weight 
[Bellentani et al., 2010]. NASH is a progressive form of the NAFLD condition linked to events of 
lobular inflammation, injury or/and fibrosis occur that follow after steatosis [Larter and Yeh 
1998]. The “two-hit” hypothesis proposed by Day et al.,[Day et al., 1998] in relation to the 
pathogenesis of NAFLD/NASH is widely accepted. According to this hypothesis the first hit 
involves lipid accumulation in the hepatocytes [Qureshi et al., 2007; Seki et al., 2002] making the 
liver sensitive to factors (environmental and genetic) which will cause the second hit that will 
cause hepatic injury, inflammation and fibrosis. NASH may progress to advanced stages of hepatic 
fibrosis and cirrhosis, and when liver failure occurs it can cause death.  
 
4.4.1 Diagnosis of NAFLD 
Up to now, despite the high prevalence of NAFLD in the general population, no clear 
common etiology has been suggested. Moreover, so far the only reliable method in diagnosis 
NAFLD with high sensitivity is the histological examination of liver tissue obtained by the 
invasive procedure of a needle biopsy [Fierbinteanu- Braticevici et al., 2010]. Through the last 
years, alternative non-invasive methods in diagnosis that are less risky for the health of and minor 
painful for the patient have been proposed for the diagnosis of FLD. So far the mostly used 
biomarker is ALT which is most often increased in patients suffering from FLD but still not 
globally accepted as a reliable diagnostic marker for this disease [Barr et al., 2010; Mayers 2009]. 
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4.4.2 NASH models and MCD diet 
Nowadays, several NASH animal models have been developed. These appear promising for 
Researchers who investigate the mechanism of the transition from simple steatosis in NAFLD to 
the inflammatory and progressive injury condition of steatohepatitis in NASH. Some genetic 
models such as knock out mice for acyl-CoA oxidase-ACOX (responsible for the 1
st
 step of 
peroxisomal b-oxidation of long chain fatty acids) or null mice for methionine 
adenosyltransferase-MATO (involved in the synthesis of Phosphatidylcholine which is required 
for hepatic triglycerides as VLDL) and mice lacking either leptin or the leptin receptor, develop 
severe steatosis. However, all these models can not represent NASH 100% as they fail in causing 
one or more metabolic abnormalities related with NASH such as inflammation, continuous 
steatosis (they become steatosis resistant), insulin resistance, obesity or hyperglycaemia. Moreover 
there are the nutrition NAFLD/NASH models such as the widely used HFD and MCD. HFD is 
broadly used over-nutritional model for rodents in research. HFD given to mice for more than 
10 weeks caused steatosis however HFD had to be administrated for more than 50 weeks to 
develop histological steatohepatitis [Ito et al., 2007]. The long feeding periods set it as not 
practical for NASH investigation. MCD is a diet better established in rodents for inducing NASH. 
The use of MCD diet induces rapidly steatohepatitis in rodents. As mentioned above for the 
MATO-null mice the luck of methionine and phosphatidylo-choline synthesis leads to impaired 
VLDL secretion and impaired mitochondrial β-oxidation [Yao et al., 1988; Anstee et al., 2006; 
Krahmer et al., 2011] The administration of the MCD diet leads to triglyceride accumulation 
which causes steatosis in rodents in just a few days while three weeks after MCD administration 
steatohepatitis has been established with increased ALT levels [De la Pena et al., 2005; Ip et al., 
2004]. 
 
4.4.3 The mouse as experimental animal in NASH 
 The use of mice in the elucidating of NASH has been valuable. Animal models of 
NAFLD/NASH provide critical information either in investigating the pathogenesis of 
NAFLD/NASH, but also for examining the therapeutic effects of treating agents. The animal 
models developed to research NAFLD/NASH need to reflect both the histopathology and 
pathophysiology of the human NAFLD/NASH. The mice models developed so far have been more 
representing in total more the human conditions than other models. Till now no animal model has 
reflected 100% the human NASH symptoms, however, the mice models of NAFLD have provided 
phenotypically consistent tools to estimate the NAFLD/NASH pathogenesis. 
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4.4.4 Aim of the study 
 The aim of this study was to analyse the role of LCN2 in liver homeostasis after a nutritional 
model of NASH in mice. NASH is widely known to disturb liver homeostasis by inducing fat 
formation and liver damage. Specifically this study focused on the function of LCN2 in the 
metabolism of the lipids that accumulated after the diet administration and the role of LCN2 in the 
inflammation induced by the development of NASH. Mice WT and Lcn2
-/-
 developed NASH after 
4 weeks of a MCD diet. In vitro experimentation to support the in vivo findings was performed on 
hepatocytes, from both WT and Lcn2
-/-
 mice, fed on normal chow diet. In both in vivo and in vitro 
experiments markers of lipid metabolism and inflammation were analysed. 
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5 Experimental Methods  
The composition of all the solutions used in the experimental methods, are mentioned in 
alphabetic order in section 10.2 Solutions and buffers in the Appendix in the end of the 
dissertation. 
5.1 Animal model 
Male mice of C57BL/6 genetic background were housed (4-5 mice per cage) in an animal facility 
maintained at a constant temperature of 20 °C, a relative humidity of 50%, and with a 12-hr 
on/off light cycle. The animals had free access to mouse chow and drinking water, supplemented 
with 1% glucose. WT mice (n= 14) and previously generated Lcn2
-/-
 mice [Berger et al., 2006] 
(n= 12) were fed ad libitum (n= 4-8/group), for 4 weeks on a normal diet of standard mouse 
chow containing methionine and choline, or a MCD diet (MP Biomedicals) to induce non-
alcoholic steatosis. Body weight was monitored weekly. Food intake was assessed twice a week 
by subtracting the amount of chow remaining in a cage from the amount of chow supplied at the 
start of a given period, and dividing that number by the number of mice in the cage. All animals 
used in this study received human care, and all animal protocols were in full compliance with the 
guidelines for animal care approved by the German legislation on protection of animals and 
approved by the government of the state North Rhine-Westphalia.  
5.2 High Fat Diet animal model 
As an alternative induction of steatosis, C57BL/6 WT mice at the age of 8 weeks were treated in 
the same as above animal facilities with unlimited access to drinking water and they were fed a 
HFD for 16 weeks (Research Diet Services BV) as published before [de Wit et al., 2008]. As 
control, mice were fed standard chow diet (SSNIFF). 
5.3 Blood sampling, serum analysis 
Blood sampling, for baseline hematological analyses and liver function tests, was carried out 
under isoflurane anesthesia before the animals were sacrificed. Blood samples (400-800 μl) were 
obtained from the Caudal Vena Cava using 27x3/4 G needles and standard 1 mL plastic syringes 
(Beckman Dickinson) washed with EDTA (100 mM pH 8.0) to avoid immediate blood clotting 
in syringe. The blood was placed in Microvette CB 100/200 capillary blood collection tubes for 
serum test (Starstedt). The blood samples were let undisturbed at room temperature (RT) for the 
blood to clot at 4
o
C overnight. After clotting the clot was removed by centrifuging at 3,000 g for 
10 min in a refrigerated centrifuge. The serum (supernatant) was transferred in new sterile 
Eppendorf tubes and the serum was then analyzed for aspartate transaminase (AST), ALT, total 
protein, total bilirubin, glucose, triglycerides, and total cholesterol using standard biochemical 
assays. 
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5.4 Liver steatosis and inflammation scoring 
Mice were sacrificed under isoflurane (Forene®) anaesthesia (Abbott), and whole livers were 
resected. A part of the liver was fixed in 4% buffered paraformaldehyde (PFA) or Methacarn for 
24 hrs and afterwards embedded in paraffin while a second part was snap frozen in liquid 
nitrogen after it was covered with Tissue TEK OCT solution (Sakura) and kept at -80 
o
C. The 
embedded in paraffin and also snap frozen tissues were sliced into 5 μm standard sections. To 
evaluate steatosis in liver, frozen cryosections were stained with the lipophilic stain Oil Red O 
[Koopman et al., 2001] following standard procedures (see section: Oil Red O staining of neutral 
lipids on liver sections). For steatosis and further histological evaluation paraffin embedded 
standard liver sections were stained with either Haematoxylin and Eosin (H&E) or Sirius Red 
solution (Sigma-Aldrich) using standard procedures. H&E is one of the principal stains in 
histology. Hematoxylin is a dark blue stain that binds negatively charged substances such as 
DNA/RNA. On the other hand Eosin is a red or pink stain that binds to positively charged 
substances such as amino acids-proteins and intracellular membranes. Moreover, Sirius red 
collagen stain is a method used for collagen determination with collagen stained red in a pale 
yellow background. Based on the Oil red O and H&E-stained sections, histological scoring of 
steatosis and inflammation was performed according to guidelines used in the scoring of 
nonalcoholic fatty liver disease in humans [Kleiner et al., 2005]. In this system, steatosis is 
gradually scored as follows: grade 0 = steatosis <5%, grade 1 = steatosis 5%-33%, 
grade 2 = steatosis >33%-66%, and grade 3 = steatosis >66%. According to the same 
guidelines, for lobular inflammation: grade 0 = no foci, grade 1 = < 2 foci per 200x field, 
grade 2 = 2-4 foci per 200x field, and grade 3= > 4 foci per 200x field. Moreover Sirius Red-
stained sections were analyzed to determine collagen levels as a measure of fibrosis. Stained 
tissues were examined using a mono and color light microscope [Nikon Eclipse E80i (Nikon)] 
equipped with 10x, 20x and 40x objective lenses.  
5.5 Isolation of primary hepatocytes and cell culture 
Hepatocytes were isolated from livers of 8-14 week old WT and Lcn2
-/- 
male mice using the 
collagenase method of Seglen [Seglen et al., 1976]. Hepatocytes as non-adherent cells were 
cultured on collagen-coated 6 well dishes in HepatoZYME-SFM medium (Gibco) supplemented 
with 1% L-glutamine, 1% penicillin/streptomycin (Lonza) and 200 μg/mL bovine serum albumin 
(BSA) and incubated at 37 
o
C in incubator conditions of 5% CO2 and 100% humidity. The dishes 
were coated with 1 mL of 0.05 mg/mL collagen in 0.1% Acetic acid the day before for 1 hr, 
washed 3x with phosphate-buffered saline (PBS) and kept in RT covered with parafilm 
membrane. For staining the wells included microscopy glasses previously washed overnight with 
25% hydrogen chloride (HCl), washed with sterile dH2O and stored in 70% ethanol (EtOH) at 
4 
o
C. Before use, the PBS was discarded and dishes were let to dry under the cell culture hood 
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for 10-15 min. After treatment (e.g. fatty acid or Rosiglitazone stimulation, infection or 
transfection; see below), hepatocytes were subjected to RNA or protein extraction as described 
below. Cells seeded on cover slips were washed 3x with PBS (pH 7.4), fixed with 4% PFA in 
PBS for 20 min, and kept in 1 mL PBS at 4°C until used in experiments.  
5.6 Stimulation with fatty acids or Rosiglitazone 
Hepatocytes cultured for 24 hrs on collagenase-coated 6 wells dishes with and without cover 
slips, as described above, were stimulated by the addition of unsaturated oleic acid or saturated 
palmitic acid (both from Sigma Aldrich) to final concentrations of 0.5 mM and 1 mM. When 
both fatty acids were used simultaneously for a combination treatment, the final total 
concentrations of unsaturated oleic acid and saturated palmitic acid together were 1 mM and 
2 mM. Control hepatocyte cultures were incubated in standard medium or in medium containing 
the vehicle in which the fatty acids were emulsed. As an agonist of PPAR-γ, Rosiglitazone was 
chosen. For stimulation, the hepatocytes were incubated for 24 hrs with 10 µM Rosiglitazone 
(Abcam) and the control ones with vehicle (0.1% DMSO). 
5.7 Adenoviral vector preparation  
For construction of the adenoviral vector expressing murine LCN2, pCMV-SPORT6-mLCN2 
was digested with SalI and HindIII and the resulting ~0.8-kbp fragment was cloned into the 
adenoviral shuttle vector pShuttleCMV (Stratagene). The integrity of the resulting vector, 
pShuttle-CMV-mLCN2, was confirmed by restriction digestion and sequence analysis. The 
pShuttle-CMV-mLCN2 was linearized with PmeI, dephosphorylated, and transferred into the 
adenoviral backbone vector pAdEasy-1 (Stratagene) following the manufacturer’s procedures. 
One recombinant clone, designated AdEasy-CMV-mLCN2, was validated by restriction 
digestion and sequence analysis. For generation of infectious adenoviral particles, AdEasy-
CMV-mLCN2 was linearized with PacI and transfected into 293A cells following the 
manufacturer’s procedures. The resulting adenoviral particles, designated Ad-CMV-mLCN2, 
were isolated using the Adeno-X-Maxi purification kit (Clontech) following the manufacturer’s 
protocol. Viral particles were amplified by repeated infection of 293A cells, purified by CsCl 
gradient centrifugation, and desalted on Centri•Pure P50 gel filtration columns (Emp Biotech.). 
Final viral particle titers were determined by photometric analysis. The luciferase-based vector 
AdEasy-CMV-Luc was employed as a control [Borkham-Kamphorst et al., 2014]. 
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5.8 Infection of primary hepatocytes 
For adenoviral infections, hepatocytes (4 x 10
5
 cells/well) were seeded on collagenase-coated 
cover slips in 6-well plates in HepatoZYME SFM medium supplemented with 2 mM L-
glutamine, 1% penicillin/streptomycin, 50 µg/mL gentamycin, and 1 mg/mL BSA. The next day, 
cells were infected by incubation for 4.5 hrs with 1 x 10
10
 viral particles (Ad-CMV-mLCN2 or 
Ad-CMV-Luc). After the addition of fresh medium, infected cells were incubated for another 
48 hrs prior to use in experiments. Normal uninfected hepatocyte cultures were always 
examined in parallel with infected hepatocytes as a control. If adenoviral infections were 
performed for the purpose of protein extract preparation, 1.2 x 10
6
 hepatocytes / well were plated 
in 6-well plates and infected in 2 mL medium including 2 x 10
9
 viral particles / mL. 
 
5.9 Plasmid DNA preparation (small prep)  
The expression constructs pCMV-SPORT6-mLCN2 (encoding full-length murine LCN2; 
IMAGp998L208764Q) and pCMV-SPORT6-mPLIN5 (encoding full-length murine PLIN5; 
IRAVp968B0772D) used in transfection experiments (see below) were both obtained from 
ImaGenes GmbH (Source BioScience LifeSciences). A small scale plasmid DNA preparation 
was applied to prove the identity of the cloned DNA. In the tube containing the clones with the 
ordered construct 200 μl of LB medium was added, mixed and then transferred in a new sterile 
tube (clone stock kept at 4 
o
C). Then dilutions were made in Eppedorf tubes with LB medium of 
1:10
3
, 1:10
5
, 1:10
7
 and 1:10
9
 ratio and vortexed well. Afterwards 20 μl of each dilution was 
applied to separate petri dishes containing LB-agar and ampicillin. With a sterile glass pen 
passed above a Bunsen burner, the cells were applied evenly in the petri dishes. The dishes were 
thereafter placed in incubator at 37 
o
C overnight. The next day, from the petri dish area that 
single colonies were easier observed, a single bacterial colony was inoculated into 3 mL LB 
medium containing the appropriate antibiotic in a 15-mL tube and incubated overnight at 37°C 
under vigorous agitation. Then 1.5 mL of bacterial culture was transferred into a microfuge tube 
and centrifuged at 12000 g for 30 sec. The medium was removed by aspiration and the bacterial 
pellet was resuspended in 100 μl of ice cold Solution I under vigorous vortexing, and straight 
after 200 μl of Solution II (freshly prepared) were added, mixed, incubated for 2 min on ice and 
neutralized with 150 μl of ice cold Solution III, vortex and centrifugation followed at 12000 g for 
5 min. The supernatant was transferred to a new 1.5 mL tube and 500 μl of phenol and 
chloroform (CHCl3) (1:1) was added, then vortexed vigorously for 2 min to remove the 
contaminating proteins, and centrifuged for 5 min. Then the supernatant was transferred to a new 
tube and the DNA was precipitated with 1 mL of absolute EtOH for 2 min at RT, followed by 
centrifugation for 10 min. The pellet was washed with cold 70% ethanol and spinned down. The 
supernatant was removed and air dried. The pellet was dissolved in 20 μl TE. For restriction 
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analysis with restriction enzymes (HindIII and EcorI), 3 μl of 1 μg DNA was added to 7 μl of 
restriction mix (1 μl restriction buffer, 1 μl RNAse, 3 Units restriction enzyme, and TE until final 
total volume 7 μl). After 1 hr of incubation at 37 °C the samples were subjected to 
electrophoresis in an agarose gel to prove the presence of expected sizes from the known sites of 
the vectors including the plasmid plus the purity of the product. After the first plasmid 
preparation and purification the plasmids were sent for sequencing to prove the presence of the 
plasmid of interest before further experimentation. The sequencing was performed by Eurofin 
MWG Genomics with 300 ng/μl sample.  
 
5.10 Plasmid preparation (large prep) 
On the first day, the plasmid amplification was performed with placing a single colony from the 
overnight agar dish culture into a 250 mL of LB medium containing the appropriate antibiotic 
250 μl ampicillin (final conc. 100 mg/mL) in a loosely capped 1L flask. The flask culture was 
incubated overnight at 37 °C (12 - 16hr) with vigorous shaking, 200 - 250 rpm. The day after, the 
amplified cells were harvested. 200 - 250 mL of the culture were poured into a GSA bottle. 
Centrifugation followed for 15 min at 3000 rpm in a JA13-Rotor at 4 °C. The upper phase was 
discarded and the pellet was dried with inversing the bottle. Then, the pellet was resuspended 
with 100 mL STE buffer and re-centrifuged again for 15 min at 3000 rpm in a JA13-Rotor at 
4°C. In the next steps the alkaline lysis was performed. The supernatant was discarded and 
10 mL Solution I were added to resuspend well the precipitate. Then 1mL of Lysozyme – 
Solution (final conc. 10 mg/mL) was added and let on ice for 10 min incubation. 20 mL Solution 
II were added, mixed and let at RT for 10 more min. Next 15 mL Solution III were added and 
shaked vigorously till there were no longer two distinguishable liquid phases. The bottle was 
incubated on ice for 10 min. A white precipitate was formed. Centrifugation for 15 min at 4 °C 
and 6000 rpm followed. The supernatant was filtered through bandages while transferred in a 
new 250 mL GSA bottle. 
In the new bottle 25 mL Isopropanol were added, mixed well and let for 10min in RT 
(isopropanol precipitation). The nucleic acids were recovered by centrifugation at 5000 rpm for 
15 min at RT in a Sorval GS3 or equivalent rotor. The supernatant was discarded and the bottle 
was inverted to let the Isopropanol to evaporate for a few seconds. The pellet and walls were 
washed with 70% EtOH at RT (3-5mL).The EtOH was drained off by centrifugation for 5 min 
10000 rpm. The supernatant was removed extensively with a pipette, and the tube was then dried 
by inverting it for a few min in RT. Then 2 mL TE (pH 8.0) were added and mixed well with a 
pipette to dissolve the pellet. Afterwards the purification of the Plasmid DNA with Polyethylene 
Glycol (PEG) followed with transferring the dissolved, in TE pellet, in a new polypropylene, 
14 mL tubes and adding 2 mL of 5 M LiCl. It was mixed well and centrifuged for 10 min, at 
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4 °C and 10000 rpm. The supernatant was poured in a new 14 mL tube containing 6 mL of 
isopropanol and then mixed well (isopropanol precipitation). After 10 min of incubation at RT 
the solution was centrifuged at 10000 rpm for 10 min at 4 °C. The supernatant was discarded and 
the pellet was washed RT 70% EtOH (3 – 5 mL). Centrifugation for 5 min 10.000 rpm to drain 
of the EtOH followed. The supernatant was discarded and the tube was inverted till the EtOH 
was evaporated. Finally the pellet was solved in 500 µl TE (intense pipetting) and transferred 
into a 1.5 mL sterile tube. RNAse-A solution 10 mg/mL was prepared and 20 μl were added in 
the tube. The tube was let at 37 °C for 30 - 40 min. Afterwards 520 µl of 1.6M NaCl/13% PEG 
solution were added, short vortex and centrifugation for 10min at 4°C and 15000 rpm followed. 
The supernatant was removed carefully with a pipette and 400 μl of TE pH 8.0 were added. The 
tube was let at 37 °C for 30 min to 1 hr until the pellet was dissolved. As soon as the pellet was 
dissolved 400 µl Phenol were added and vortexed vigorously for 1 minute for the two phases to 
mix well. Then centrifugation for 5 min at 15.000 rpm followed. The upper phase was collected 
and transferred in a new 1.5 mL tube with 200 µl of phenol and 200 µl of CHCl3 and vortexed 
vigorously for 1 min. Another centrifugation in RT for 5 min and 15.000 rpm followed. The 
upper phase was collected and transferred in a new tube containing 400 µl of CHCl3 and 
vortexed for 1 min. Centrifuged at RT for 5 min and 15.000 rpm followed and the upper phase 
was transferred in a tube again with 100 µl of 10 M ammonium acetate and 1 mL of absolute 
ethanol. After incubation for 10 min at RT, centrifugation at 4 °C for 5 min in 15000 rpm 
followed. The supernatant was carefully removed with a pipette and the pellet was then washed 
with 200 µl cold 70% EtOH and centrifuged at 4 °C for 5 min and 15000 rpm. The ethanol was 
discarded and 500 µl TE, pH 8.0 were added. The plasmid was let at 37 °C on a thermomixer 
until the pellet was dissolved (30 min – 1 hr). Meanwhile during this time vortex and pipetting 
helped the dissolving procedure. Finally when the pellet was completely dissolved with a 
Photometer and a clean glass cuvette the DNA was quantified. For the DNA quantification 2 μl 
sample were diluted in 998 μl dH2O (1:500 dilution) and added it in the glass cuvette to be 
measured, with water as control, in CARY 50 Scan UV Visible Spectrophotometer (Varian). The 
plasmid was then stored at -20 °C. 
5.11 Rubidium competent cells 
An overnight 5 mL (LB medium with no antibiotics) culture of the desired strain XL1-Blue 
bacteria was prepared. The next day 1 mL of the overnight culture was added to a flask with 
100 mL YT medium and let grow with shaking at 225 rpm at 37 °C till they reach OD600 = 0.5 
(grow duration 2 - 4 hrs). Every hr the optical density (OD) of 1 mL of the culture was measured 
in the spectrophotometer. After reaching the desired OD, the culture was transferred into two 
50 mL conical falcons and chill on ice for 20 min being careful not to contaminate the caps, and 
after spinning down the cells at 4°C at 3000 rpm for 10 min. From then on, every step was 
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performed on ice so that the pores that would be created on the bacteria would not close. The 
supernatant was discarded and each pellet was resuspended in 25 mL of TFB I (50 mL/100 mL 
culture) gently by hand and incubated on a shaker on ice for 10-20 min. Afterwards the cells 
were spinned again at 4 °C, 3000 rpm for 10 min and the supernatant was discarded. Each pellet 
was gently resuspended in 2 mL of TFB II (4 mL/100 mL culture) and incubated on ice for 
30 min (incubation on ice could be skipped if the aliquots were made quickly to be placed in -
80 °C). Aliquots of 200 µl competent bacteria were made and frozen at -80 °C in autoclaved 
labelled cryotubes.  
5.12 Transformation of competent cells 
A vial of competent cells (XL1-Blue) was thawed on ice. After addition of 100 ng plasmid DNA 
and tapped smoothly .The vial was then incubated for 30 min on ice. Straight after, the tube was 
heated at 42°C for 2 min (Heat shock). Then immediately the tube was transferred on ice for 
5 min. LB medium, 600 μl to 1 mL (without antibiotic) was added and briefly mixed. The 
samples were incubated at 37 
o
C and 225 rpm for 1 hr. Afterwards dilutions of 1:1, 1:10, 1:100 
and 1:1000 were made and 20 – 100 µl were added in agar plates containing Ampicillin 
(50 mg/mL). The cells were spread with a sterile glass stick to an even surface. Finally the 
inverted dishes were incubated overnight at 37 °C incubator. 
5.13 Transfection of primary hepatocytes 
For transfections, hepatocytes (4 x 10
5
 cells/well) were seeded on collagenase-coated 6-well 
plates in 2 mL HepatoZYME SFM (Life technologies) supplemented with 2 mM L-glutamine 
and 1% penicillin/streptomycin. One day prior to transfection, cells were transferred to medium 
without antibiotics and allowed to reach 70-80% confluence. Cells were transfected by the 
addition of 2 µg DNA plus 4 µl Lipofectamine® 2000 transfection reagent (Life technologies) in 
OptiMEM medium (Life technologies). At 6 - 8 hrs post-transfection, the medium was 
exchanged for standard HepatoZYME medium containing antibiotic and the cells were incubated 
overnight at 37 °C before harvesting.  
5.14 RNA isolation of primary hepatocytes 
For isolation and purification of total RNA from hepatocytes the PureLink RNA Mini kit system 
(Life Technologies) was used, according to the manufacturer’s instructions. In summary, the 
cells were washed 3x with ice cold PBS and 150 µl of buffer containing 1% (v/v) β-
Mercaptoethanol were added in each well. Cells were scraped off using RNase free tissue cell 
rubber scrapers. Cells were then homogenized using 27x3/4 G needles and standard 1-mL plastic 
syringes (Becton Dickinson). Then the manufacturer’s instructions of the Purelink RNA Mini kit 
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system were followed. The RNA was finally eluted in 30 mL RNase free dH2O. The 
concentration of the total RNA was measured and the RNA was stored at -80 °C. 
5.15 RNA isolation from liver sections 
The liver tissue as soon as it was extracted was placed in 1.5 mL tube with 1 mL of QiaZol Lysis 
Reagent (Qiazen) and stored in -80 
o
C. For the RNA extraction the sample was thawed on ice. 
The thawed sample was emptied in a sterile Polystyrene tube 13 mL (Sarstedt) where it was 
homogenized for 30 sec with Dispersing drive Ultra Turrax T 25 basic, and then poured back in 
the initial 1.5 mL tube. The sample was then incubated in RT for 5 min and then 200 μl of 
Chloroform were added in the sample. Slight-shake followed for 15 sec (inversions of tubes). 
After 3 min incubation in RT the sample was centrifuged for 15 min at 4
o
C and 12000 g. Without 
disturbing the middle white phase the upper phase was transferred in a new sterile 1.5 tube. Then 
isopropanol of the same volume with the upper phase (1:1) was added and after vortex and 
10 min incubation in RT, centrifugation at 4 
o
C and 12000 g for 10 min followed. The 
supernatant was carefully discarded without disturbing the pellet. Then 1 mL 75% EtOH was 
added and after vortexing the sample was centrifuged at 4
o
C and 7000 g for 5 min. After the 
centrifugation the supernatant was carefully discarded and the pellet was let to dry under the 
hood for 30 min to 1 hr. When the pellet was dried 100 - 200 μl of RNase free water from the 
PureLink RNA mini kit (Life Technologies) was added and incubated at RT for 30 min or on ice 
at 4 
o
C for the pellet to dissolve. 
After the RNA quantification followed and 100 μg of the sample was transferred in new sterile 
1.5 mL tubes (the rest sample was placed in -80
o
C for later use). In the tube containing the 
sample and RNase free water (total volume 87.5 μl) 12.5 μl MIX 1 (1.25 μl 10 X DNAse buffer, 
2.5 μl DNAase and 8.75 μl RNase free water) were added, mixed and incubated for 10 min at 
RT. Then 357 μl MIX 2 (350 μl lysis buffer and 7 μl DTT 2M) were added and the solution was 
shaked well. Pure EtOH, 100%, 250 μl was added in the tube and mixed. Then 700 μl of the 
probe were transferred to the RNA extraction tubes from PureLink RNA mini kit and the tube 
was then spinned for 30 sec in 12000 g at RT. After spin the membranes were transferred in new 
caps and 500 μl of Wash buffer II were added and spinned for 30 sec in 12000 g at RT. The 
resulting flow-through was discarded and 500 μl of Wash buffer II were re-added and 
centrifuged for 5 min in 12000 g at RT to dry the membrane. The excess liquid was discarded 
and the membrane was centrifuged under same conditions for 1 min. Then the membranes were 
transferred in new sterile recovery tubes and 50-100 μl of RNase free water was added in the 
middle of the membrane and incubated at RT for 1 min. Finally the membranes were centrifuged 
for 1 min in 12000 g at RT and the RNA was then quantified and stored in -20 
o
C. 
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5.16 Complementary DNA (cDNA) synthesis 
Purified RNA was quantified and 1 μg samples were reverse –transcribed in a final volume of 25 
μl using Superscript II reverse transcriptase and random hexamer primers (all from Life 
Technologies). The procedure for the cDNA synthesis included adding 1 μg of the RNA sample 
in a 500 µl reaction tube. Then 16 µl of the first Mix containing 1 µl random primers (250 ng), 
1 µl dNTP mix (10 mM each) and sterile dH2O (14 - VolumeRNA µl) were added. The mixture 
then was heated in the Polymerase chain reaction (PCR) device at 65 
o
C for 5 min and then 
quickly chilled on ice. After a short spin the second mix containing 4 µl of First strand buffer and 
2 µl of Dithiothreitol (DTT) 0.1 M. The samples were incubated in the PCR device at 25 
o
C for 
2 min. Finally 1 µl of SuperScript II reverse transcriptase was added and placed back to the PCR 
device where it was incubated at 42 
o
C for 50 min. Afterwards, the reaction was inactivated at 
70
o
C for 15 min. Thereafter the samples were stored at 4 
o
C for short period or at -20 
o
C for long 
term.  
5.17 PCR for cDNA synthesis check up 
For the verification of successful cDNA synthesis a standard PCR for the house gene 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed. For a 25 µl reaction 
volume 1 µl cDNA sample (produced by 1 µg RNA) was placed in a 500 µl reaction tube. 24 µl 
master mix containing, 1 µl forward primer (10 nmol), 1 µl reverse primer (10 nmol), 0.5 µl 
dNTP mix (10 mM each), 2.5 µl Buffer 10x (without Mg
+
), 2 µl Mg
+
, 0.25 µl TaqMan 
polymerase and 16.75 µl sterile dH2O, were added in the same reaction tube and incubated in the 
PCR device under a standard PCR program including the initial denaturation at 94°C for 5 min in 
the first cycle and 30 seconds for every other cycle (30 cycles) which included annealing at 
57 °C for 30 sec, and elongation at 72 
o
C for 1 min in all cycles (10 min for the last cycle). After 
the 30 cycles the temperature reached the preservation temperature of 4 
o
C. In the end the PCR 
products samples were subjected to electrophoresis in an agarose gel to prove the presence of the 
amplified product. 
5.18 Quantitative real time PCR (qRT-PCR) 
For the preparation of the samples for the qRT-PCR 5 µl of cDNA (preserved as 5x diluted) were 
placed in a 98 well PCR-plate and add 20 µl of the Master mix containing: 6.5 µl sterile dH2O 
and 12.5 µl SYBR GreenTM qPCR SuperMix (Life Technologies). The primer pairs for specific 
mouse mRNAs amplification were designed using the Universal Probe Library tool (Roche) and 
are listed in Supplementary table 10-i. For amplification of target gene sequences, samples were 
incubated with all necessary reagents at 50 °C for 2 sec, denatured at 95 °C for 10 min, and 
amplified in 40 cycles of 95 °C for 15 sec followed by 60 °C for 1 min. All samples were placed 
and analyzed in double. Relative levels of target mRNA were calculated using the comparative 
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CT method [Schmittgen et al., 2008] and normalized to the mRNA expression of the 
housekeeping gene, GAPDH. The final mRNA quantities were expressed as the normalized 
quantity of target mRNA relative to the normalized quantity of the housekeeping gene mRNA. 
5.19 Protein extraction  
Total protein, from cultured hepatocytes, or from samples of freshly extracted total liver tissue 
that had been snap-frozen in liquid nitrogen, was prepared using RipaC buffer containing 20 mM 
Tris–HCl (pH 7.2), 150 mM NaCl, 2% (v/v) NP-40, 0.1% (w/v) SDS, 0.5% (w/v) sodium 
deoxycholate and the Complete™-mixture of proteinase inhibitors (Roche). The cell samples 
were passes 10 x through a 27x3/4 G needle and standard 1-mL plastic syringe (Becton 
Dickinson). For liver tissue homogenisation with a tissue grind pestle (Kimble & Chase) was 
initially used. For protein extraction both cells and tissue were sonicated in an UltraSonic 
processor (Hielscher) 3x for 1 min each time on ice at 100% amplitude. The samples (cells and 
tissue) homogenised in RipaC were incubated on ice for 30 min and then centrifuged in 
10000rpm and at 4 oC for 10 min. The protein extract (supernatant) was transferred in new 
1.5mL tubes and stored at -80 oC.  
5.20 Protein quantification (DC assay) 
For the protein quantification of cell lysates or extracted tissue the DC protein Assay kit from 
BIO RAD was used. Protein quantification standards for the standard curve were prepared of 
final concentrations 0 μg/μl, 0.6 μg/μl, 0.9 μg/μl, 1.2 μg/μl, 1.5 μg/μl, 1.8 μg/μl, 2.1 μg/μl and 
2.4μg/μl with BSA and RipaC buffer. In a 96-well micro-titer plate 5 μl of the sample were 
added twice in a 96-well plate. Then 25 μl of Reagent A* (20 μl Reagent S and 1 mL Reagent A) 
were added in every sample and standard and in the end 200 μl of Reagent B from the kit were 
added on top. Incubation was performed in a dark room for 15 min in a smooth shaker and then 
the absorbance was measured in Victor X3 - Multimode Plate Reader at 690 nm. 
5.21 SDS-PAGE and Western blot analysis 
Equal amounts of total protein (20 µg/lane for hepatocyte lysates and 100 µg/lane for whole liver 
tissue extracts) were mixed with Nu-PAGE™ LDS electrophoresis sample buffer containing 
DTT 1M, as a reducing agent. Samples were heated at 87 °C for 10 min before fractionation on 4 
- 12% Bis-Tris gels in MES (2-(N-morpholino) ethanesulfonic acid) or MOPS 
(morpholinopropanesulfonic acid) running buffer (both by Roth). Proteins were electroblotted 
onto a Protran membrane (GE Healthcare), and equal protein loading was confirmed by Ponceau 
S (Sigma Aldrich) staining. 
For Western blotting, membranes were first blocked by incubation in Tris-buffered saline 
supplemented with 1% Tween20 (TBST) containing 5% (w/v) non-fat milk powder (Roth). 
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Primary antibodies were diluted in 2.5% (w/v) non-fat milk powder in TBST prior to application 
to the membrane. Primary antibodies were visualized with anti-mouse-, anti-rabbit anti-rat IgG 
or anti-goat IgG secondary antibodies (all from Santa Cruz) and the SuperSignal 
chemiluminescent substrate (Thermo Scientific) under the Lumi imager
TM 
(Roche). All 
antibodies used in this study are listed in the Supplementary table 10-ii. 
5.22 Immunohistochemistry  
Liver tissue sections were deparaffinised and rehydrated with xylene and decreasing graded 
ethanol, whereas antigen retrieval was engendered by heating the sections in 10 mM sodium 
citrate buffer (pH 6.0) in a microwave for 20 min. Slides were blocked for non-specific binding 
with 5% FCS (fetal calf serum) made in 1% BSA/PBST (BSA/Phosphate-Buffered Saline 
supplemented with Tween 20) at RT for 1 hr. Primary antibodies polyclonal rabbit anti-PLIN5 
(Novus Biologicals) polyclonal rabbit anti-MPO (Hycult Biotech), and monoclonal rat anti-
CD45 (Beckman Dickinson) were applied on the tissues in dilution 1:50 in blocking solution and 
incubated at 4 °C overnight for the detection of PLIN5, and CD45. An immunoglobulin (IgG) 
was used as a negative control. The day after, the sections were incubated with biotinylated 
secondary antibodies (Vector Laboratories), followed by avidin-conjugated peroxidase (Vector 
Laboratories) and 3.3′-diaminobenzidine substrate (DAKO). The sections were counterstained 
with haematoxylin and microscopy images were taken at a magnification of 200x and 400x using 
the Nikon Eclipse 80i microscope (Nikon) equipped with the NIS Elements Vis software 
(version 3.22.01). 
5.23 Immunofluoresence-histochemistry  
Liver tissue cryosections were let to thaw and air-dried for 1 hr at RT. The tissues then were 
fixed by dipping the slides in 4% PFA for 25 min. Then the sections were washed and rehydrated 
with dipping the slides in PBS 3x 5 min each time. The slides were blocked for non-specific 
binding with 10% donkey serum in PBS supplemented with 0.3% Triton X at RT for 1 hr. For 
the detection of Myeloidperoxidase (MPO) in liver tissues of mice fed on MCD diet, primary, 
polyclonal antibody, rabbit anti-MPO (Hycult Biotech), was applied in dilution 1:100 in antibody 
dillution solution (1% BSA/PBST) and incubated at 4 °C overnight for the detection of MPO. A 
tissue section of tonsilitis (a severe case of neutrophil infitration) was used as a positive control, 
treated as above whereas an IgG was used as a negative control. The primary antibody, 
polyclonal rabbit anti-Plin5 (Novus Biologicals), was used in dilution 1:50 to detect PLIN5 
expression in liver tissue of mice fed on HFD. The day after, the slides were washed 3x with 
PBS and incubated at RT for 1 hr with Alexa 555-donkey anti-rabbit secondary antibody that had 
been conjugated to ALEXA Fluor (Life Technologies) and diluted to 1:200 in antibody dilution 
buffer. The stained slides were washed 3x with PBS and counterstained with 100 ng/mL 4', 6-
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diamidino-2-phenylindole (DAPI) (Life Technologies) in PBS, for 10 min at RT to visualize 
nuclei. Slides were washed twice with PBS and a 3
rd
 wash with dH2O water. Afterwards they 
were mounted with PermaFluor aqueous mounting medium (Thermo Scientific) and analyzed 
under a Nikon Eclipse E80i fluorescence microscope. 
5.24 Immunofluorescence in primary hepatocytes 
Hepatocytes cultured on collagenase-coated cover slips as described above were fixed for 20 min 
in 4% PFA. The fixed cells were washed 3x with PBS, permeabilized on ice by the addition of 
0.5 mL/well of pre-cooled 0.1% Na-citrate/0.1%TritonX solution, and incubation of 2 min. 
Permeabilized cells were washed 3x with PBS and blocked by incubation with 0.5 mL 50% 
FCS/0.5% BSA in PBS for 1 hr at 37 
o
C on a shaker. Blocked cells were washed 3x with PBS 
and incubated with primary antibodies overnight at 4 
o
C in a moist dark chamber. Goat anti-
human LCN2 or rabbit anti-mouse PLIN5 primary antibodies were diluted 1:50 and 1:100, 
respectively, in 1% BSA in PBS. Non-specific goat IgG and rabbit IgG were used as negative 
controls. The next day, slides were washed 3x with PBS and incubated at RT for 1 hr with the 
appropriate secondary antibodies that had been conjugated to ALEXA Fluor (Life Technologies) 
and diluted to 1:500 in 1% BSA in PBS. The stained slides were washed 3x with PBS and 
counterstained with 100 ng/mL DAPI (Life Technologies) in PBS, for 10 min at RT to visualize 
nuclei. Slides were washed with PBS, mounted with PermaFluor aqueous mounting medium 
(Thermo Scientific) and examined using a Nikon Eclipse E80i fluorescence microscope. 
5.25 Cell quantification 
After the immune fluorescence staining of MPO in liver tissue the images were transformed in 8-
bit grayscale data. Then the MPO positive cells were quantified with the help of the Image J, a 
Java-based image processing program developed at the National Institutes of Health [Version 
1.49p 28 Feb. 2015]. 
5.26 Oil Red O staining of neutral lipids on liver sections  
Frozen tissue sections were let in RT to thaw and dry for 1 hr. The tissues then were fixed by 
dipping the slides in 4% PFA for 25 min. Then the sections were washed and rehydrated with 
dipping the slides in dH2O water 3x 5 min each time. Then the slides were incubated in working 
Oil Red O staining solution [Neyzen et al., 2006] at RT for 30 min. Stained slides were 
repeatedly washed in dH2O water followed by counterstaining of nuclei (blue colour) with 
dipping the slides in undiluted DAKO REAL haematoxylin solution (DAKO). Slides were 
mounted using PermaFluor aqueous mounting medium (Thermo Scientific). Stained slides were 
examined using a Nikon Eclipse E80i microscope equipped with 10x, 20x and 40x objective 
lenses. 
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5.27 Oil Red O staining of neutral lipids on hepatocytes 
Cultured hepatocytes were fixed on collagenase-coated slides in 4% PFA for 20 min and the 
slides were incubated in working Oil Red O staining solution [Neyzen et al., 2006] at RT for 30 
min. Stained slides were repeatedly washed in dH2O water followed by counterstaining of nuclei 
(blue colour) with 2 mL undiluted DAKO REAL haematoxylin solution (DAKO). Slides were 
mounted using PermaFluor aqueous mounting medium (Thermo Scientific). Stained slides 
examined using a Nikon Eclipse E80i microscope 
5.28 Nile red staining on primary hepatocytes 
An alternative neutral lipid staining method, ultra-pure Nile Red reagent (ENZO Life Sciences) 
was applied to collagenase-coated slides with fixed hepatocytes using a previously published 
protocol [Listenberger et al., 2007]. Briefly, Nile red working solution was applied on slides for 
10 min at RT in the dark. The slides were afterwards washed with PBS and counterstained for 1 
min with DAPI working solution 100 ng/mL in PBS for 10 min. Coverslips were mounted on the 
glass slides as mentioned before and the cells were examined using a Nikon Eclipse E80i 
microscope in the green fluorescent channel. The green channel was chosen instead of the red to 
increase contrast. 
5.29 Triglyceride assay 
Liver tissue samples were homogenized in 5% (v/v) nonyl phenoxypolyethoxylethanol (NP-40) 
in water. The homogenized tissue was afterwards heated at 100 
o
C and cooled down for 5 min to 
solubilize all triglycerides (the heating – cool down procedure was repeated twice). The 
triglycerides were quantified with the use of the Triglyceride Quantification kit, by Abcam 
according to the manufacturer’s instructions and the colorimetric absorbance measurements were 
taken on the Victor X3 - Multimode Plate Reader at 490 nm. 
5.30 Free fatty acid assay 
Liver tissue samples were homogenised in 1% Triton X in pure CHCl3 and vacuumed for 3-4 hrs 
at 50 
o
C for the CHCl3 to be removed and the lipids to dry. The free fatty acids were later 
quantified with the use of the Free Fatty acid Quantification kit, by Abcam according to the 
manufacturer’s instructions and the colorimetric absorbance measurements were taken on the 
Victor X3 - Multimode Plate Reader at 490 nm. 
5.31 Myeloperoxidase (MPO) activity quantification assay 
Liver tissue samples were homogenized in 4 volumes of 0.1% (v/v) NP-40 in PBS. The 
homogenized tissue was afterwards centrifuged at 13000 g for 10 min and the supernatant was 
collected. The MPO activity was quantified with the use of the MPO activity quantification kit, 
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by Abcam, according to the manufacturer’s instructions and the colorimetric absorbance 
measurements were taken on the Victor X3 - Multimode Plate Reader at 450 nm. 
5.32 RNA and DNA quantification  
The concentration and purity of RNA was determined by measuring the absorbance at 260 nm 
using a spectrophotometer. For single stranded RNA, CRNA in mg/mL = OD260 x dilution factor x 
40. The ratio of pure RNA for OD260nm and OD280nm was between 1.8 and 2.2. The 
concentration and purity of DNA was determined by measuring the absorbance at 260 nm using 
a spectrophotometer. The concentration of double stranded DNA CDNA in mg/mL = OD260 x 
dilution factor x 50. The ratio of OD260nm and OD280nm was accepted when between 1.8 and 2.0 
[Barbas et al., 2007]. 
5.33 Statistical analysis 
Statistical analyses were performed using the Student’s t-test for comparison of individual 
groups. Results are expressed as the mean ± standard deviation (SD). For in vitro experiments, 
results are the mean ± SD of 3 independent trials each performed in triplicate. For in vivo 
experiments, results are the mean ± SD involving at least 4 animals per group. Probability values 
of < 0.05 were considered statistically significant. All statistical analyses were performed using 
Excel Analysis 2010 and Windows XP software. 
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6 Lipocalin 2 regulates PLIN5 expression and intracellular lipid 
formation in the liver 
The initial aim of this study was to unravel how LCN2 participates in the lipid homeostasis in 
the liver. To this end it was known that in the liver, LCN2 triggers protective effects following 
acute or chronic injury, and that its expression is a reliable indicator of liver damage. Additionally, 
there was the interesting observation from a previous report, that Lcn2
-/- 
hepatocytes accumulated 
lipid droplets after induced liver injury while the WT didn’t. However, little is known about 
LCN2’s functions in the homeostasis and metabolism of hepatic lipids or in the development of 
steatosis.  
 
6.1 Introduction 
Lipocalin 2 is a protein mainly associated, with injury and inflammation sites. However, there 
are studies suggesting that LCN2 has important roles in intracellular lipid metabolism and the 
maintenance of liver homeostasis [Guo et al., 2010; Borkham-Kamphorst et al., 2011]. Guo et al., 
showed that LCN2 protein is highly abundant in normal adipose tissues [Guo et al., 2013] and 
more recently, it was demonstrated that IFN-γ and TNF-α can induce LCN2 secretion by cells 
within white adipose tissue depots, and that STAT1 and NF-κB can bind directly to the human 
LCN2 gene promoter in human fat cells [Zhao et al., 2014]. Experimenation with primary 
hepatocytes of Lcn2
-/-
 mice has revealed abnormal lipid droplet accumulation and increased 
apoptosis [Borkham-Kamphorst et al., 2013]. These observations imply that LCN2 has essential 
functions in the control of hepatic lipid homeostasis. 
A family of proteins associated with lipid droplet formation and triacylglycerol storage 
[Brasaemle 2007] is the Perilipins. They constitute a highly conserved family of five proteins 
(PLIN1-PLIN5). Perilipins are also known as PATs, an acronym derived from the first three 
family members identified: perilipin 1 (PLIN1), adipocyte differentiation-related protein (ADRP 
or PLIN2), and tail-interacting protein-47 (TIP47or PLIN3) [Greenberg et al., 1991; Heid et al., 
1996 and Diaz et al., 1998]. PLIN4 is also known as S3-12, while PLIN5 was originally called 
oxidative tissue-enriched PAT (OXPAT), or alternatively LSDP5 (lipid storage droplet protein 5) 
or MLDP (myocardial lipid droplet protein) [Nagase at al., 2001; Wollins et al., 2003; Wollins et 
al., 2006; Dalen et al., 2007]. Several studies have focused on the essential regulation of the 
Perilipins in lipid metabolism. In humans and mice, PLIN2 is strongly upregulated during the 
development of fatty liver and steatosis [Motomura et al., 2006]. In vitro, overexpression of PLIN2 
promotes the uptake and incorporation of lipids into lipid droplets [Gao et al., 1999; Londos et al., 
2005]. Mice fed with a high fat diet (HFD) so that they develop fatty liver show increased PLIN2 
expression that depends on activation of PPAR-γ [Motomura et al., 2006]. Conversely, mice 
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lacking PLIN2 are protected against diet-induced obesity, adipose tissue inflammation, and fatty 
liver disease [McManaman et al., 2013]. Likewise, expression levels of PLIN3 and PLIN5 are 
increased in hepatocytes exposed in vitro to free fatty acids, suggesting that these two perilipins 
are also important for hepatic lipid accumulation [Grasseli et al., 2010]. In mouse and human 
adipocytes, levels of PLIN1 and PLIN4 are tightly correlated to the expression and activation of 
PPAR-γ, and the promoters of these genes contain PPAR-γ response elements which are well 
conserved [Dalen et al., 2004]. Taking it all together, the Perilipins appeared to have functions in 
hepatic lipid accumulation, steatosis and inflammation that could associate with possible functions 
of LCN2. 
To investigate whether LCN2 and the Perilipins cooperate to regulate hepatic lipid 
accumulation, WT and Lcn2
-/-
 mice were fed with a MCD diet as a nutritional model of non-
alcoholic steatohepatitis and comparison of the intrahepatic lipid accumulation lipid droplet 
formation, mitochondrial content, and expression of the perilipin proteins followed. As mentioned 
above MCD diet is known to induce strong hepatic steatosis in rodents by impaired VLDL 
secretion due to lack of phosphatidyl-choline synthesis, impaired mitochondrial β-oxidation [Yao 
et al., 1988, Anstee et al., 2006; Krahmer et al., 2011]. In addition, expression of LCN2 and PLIN5 
was analyzed in WT animals that received a high fat diet as an alternative model for hepatic 
steatosis.  
We found that MCD diet accumulated more lipids in the liver of Lcn2
-/-
 mice than WT 
controls, and that the basal expression of the lipid droplet coat protein PLIN-5 was significantly 
reduced in these animals. Moreover, it’s proved in this study that PLIN5 expression is directly 
linked to the presence of LCN2. As restoration of LCN2 activity in Lcn2
-/-
 primary hepatocytes 
induces strong PLIN5 expression and rescues lipid droplet formation. The presented data indicate 
that LCN2 is a key regulator of hepatic lipid homeostasis that operates, at least in part, by inducing 
PLIN5. LCN2 may therefore represent a novel therapeutic drug target for the treatment of liver 
diseases associated with elevated fat accumulation and steatosis. 
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6.2 Results  
Does LCN2 participate in lipid metabolism in fatty liver disease? Initially in order to test 
whether LCN2 is involved in disease-associated fat accumulation in the liver and whether it has 
essential functions in the control of hepatic inflammation and lipid metabolism, WT and Lcn2
-/-
 
mice were subjected to a MCD diet. The MCD diet contains high sucrose and fat but lacks 
methionine and choline, an amino-acid and a nutrient critical for hepatic β-oxidation, VLDL 
production, and the stimulation of hepatic lipogenesis. Prolonged feeding of WT mice on the MCD 
diet, results in severe hepatic lipid accumulation within a short timeframe [Anstee et al., 2006; 
Pickens et al., 2010; Pickens et al., 2009]. These conditions lead to, oxidative stress and altered 
cytokine and adipo-cytokine secretion profiles development that contribute to liver injury 
characterized by increased ALT levels, hepatic steatosis, lobular inflammation, ballooning 
degeneration of hepatocytes, and increased PPAR-γ expression [Larter et al., 2008]. 
Macroscopic appearance of the liver after 4 weeks of MCD or control diet showed a pale color 
to the whole liver as a result of the MCD diet (Figure 6-iA). MCD has been characterized with 
sharply decreased caloric intake [Kirsch et al., 2003] so as expected the feeding of WT and Lcn2
-/-
 
mice on an MCD diet for 4 weeks led to a drastic decrease in body weight in both groups (Figure 
6-iB). The mean decrease in body weight did not really differ between MCD-fed WT and MCD-
fed Lcn2
-/-
 mice.  
However the total liver weight and the liver-to-body weight ratio were higher in MCD-Lcn2
-/-
 
mice than in MCD-WT controls (Figure 6-iC) suggesting a more enlarged fatty liver for the MCD-
Lcn2
-/-
 mice. It’s been shown before in other experimental animals, that MCD administration 
causes enlargement and a more yellowish color to the liver [Ye et al., 2013].  
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Afterwards histological examination of liver sections in WT and Lcn2
-/-
 mice and blood 
biochemical analysis were performed. It was found that, even on a normal diet, Lcn2
-/-
 mice 
exhibited spontaneous mild steatosis (Figure 6-iiA, 6-iiB), decreased total bilirubin, and higher 
serum concentrations of GPT/ALT and GOT/AST than control animals (Figure 6-iii). After 
administration of MCD diet, both WT and Lcn2
-/-
 mice developed prominent steatosis that was 
characterized by apparent elevated levels of intrahepatic fat and increased formation of lipid 
droplets (Figure 6-iiA, 6-iiB). 
Figure 6-i: MCD diet leads to sharp alterations of the body weight. (A) Macroscopic appearance representative 
livers from WT and Lcn2-/- mice (scale bars: 10mm) after 4 weeks of control and MCD diet. In the lower panel higher 
magnification of the livers above which denotes a rougher surface and paler color for the MCD treated mice. The 
bottom line shows the weight in grams of the respective livers on top. (B) Weekly measurements of the changes to 
the body weight of WT or Lcn2-/- mice (n=4-8/group) fed on control or MCD diet for 4 weeks. Results are the mean 
body weight change in grams (g) relative to the starting body weight. (C) Quantitation of the liver-to-body weight 
ratios of the mice in (A) Data are the ratio of the mean total liver weight to mean total body weight expressed as a 
percentage. Although no statistically significant differences between groups were obtained, the data suggest that, 
unlike control animals, MCD-Lcn2-/- mice maintain a constant liver-to-body weight ratio. (Source: Asimakopoulou 
et al., 2014). 
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Figure 6-ii: Effects of the MCD diet on livers of WT and Lcn2-/- mice. (A) H&E staining (top panels), Oil Red O 
staining (middle panels), and Sirius Red staining (lower panels) of specimens of the livers in 3.1A. Scale bars: top 
panels, 100 µm; middle panels, 50 µm; bottom panels, 100 µm. All stainings show the drastic lipid droplet accumulation 
after the MCD diet. Livers from Lcn2-/- mice appear to have slight steatosis even on control diet. Results are 
representative images taken from individual animals in each group. (B) Scoring of steatosis in liver sections from the 
mice after 4 weeks of diet. The histological scoring system was adapted from guidelines used in scoring non-alcoholic 
fatty liver disease in humans [Kleiner et al., 2005]. Results shown are the mean ± SD of WT or Lcn2-/- mice (n=4-
8/group). (Source: Asimakopoulou et al., 2014). 
 
Hepatic fibrosis observed by Sirius red staining was similar in MCD-WT and MCD-Lcn2
-/-
 mice 
(Figure6-iiA). However the MCD-Lcn2
-/-
 animals showed greater hepatic damage than controls 
based on the higher elevations of GPT/ALT and GOT/AST (Figure 6-iii). Enhanced liver 
malfunction in MCD-Lcn2
-/-
 in comparison to the MCD-WT mice was reflected also by the 
reduced total liver protein and cholesterol (Figure 6-iii). Blood glucose was decreased to a similar 
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extent in MCD-Lcn2
-/-
 and MCD-WT mice, and serum triglycerides were significantly higher in 
MCD-Lcn2
-/-
 mice than in MCD-WT animals (Figure 6-iii). 
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Free fatty acid (FFA) and triglyceride assays were also applied on liver tissue extracts 
(colorimetric quantification kits, both by Abcam). The results indicate a clear increase of the 
hepatic FFA levels 2-3 fold after the MCD diet application, as well as total triglyceride levels 
which were increased 1,5-2 folds in MCD conditions as observed in previous report of induced 
steatohepatitis [Larter et al., 2008]. Interestingly the Lcn2
-/- 
mice, tended to higher levels of FFA 
and triglycerides than the WT mice not only in MCD diet but also in control diet (Figure 6-iv) 
suggesting the increased susceptibility of lipid formation in absence of LCN2. 
Figure 6-iii: Serum analysis. WT or Lcn2-/- mice (n=4-8/group) were fed normal chow or an MCD diet for 4 weeks. 
Concentrations or activities of the indicated parameters were measured in the serum of sacrificed animals using 
standard procedures. Results are the mean ± SD. *p  0.05; **p  0.01; ***p  0.001. (Source: Modified and taken 
from Asimakopoulou et al., 2014). 
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In total the above data revealed the first confirmation that the MCD diet inflicts greater liver 
damage in the absence of LCN2. 
 
Does LCN2 correlate with the Perilipins upon MCD diet? After the first hints of LCN2 
participation in the liver homeostasis during MCD diet clarification was needed on how LCN2 is 
correlated to the steatosis development upon MCD diet. As mentioned above the PAT protein 
family is a group of proteins closely associated with lipid droplet formation, fact that gives a hint 
of a possible co-operation with the LCN2 within the event of steatosis development during 
experimental NASH induction. Analysis of the perilipin proteins in total liver extracts revealed a 
remarkable decrease in the expression of PLIN5 in the absence of LCN2, whether or not the 
animals had been fed with the MCD diet (Figure 6-vA). In contrast, PLIN2 protein was already 
increased in livers of Lcn2
-/-
 mice on the normal chow diet compared to WT mice. On the MCD 
diet, WT mice showed by far, greater increase in PLIN2 protein than the Lcn2
-/-
 mice did, while 
PLIN3 protein was strongly expressed in both MCD-WT and MCD-Lcn2
-/-
 mice. Most strikingly, 
MCD-WT mice showed dramatically higher levels of LCN2 than WT mice fed normal chow, 
consistent with results from other experimental models of liver injury models reflecting a strong 
inflammatory response similar to that documented [Borkham-Kamphorst et al., 2011]. The 
observed changes of liver protein expression in MCD-Lcn2
-/-
 mice were most likely the result of 
regulation at the transcriptional level since qRT-PCR analysis revealed parallel differences in 
mRNA levels of all these genes except PLIN3 (Figure 6-vB-E ). qRT-PCR analysis of PPAR-γ 
expression showed that livers of Lcn2
-/-
 mice had slightly lower mRNA levels of this nuclear 
receptor than WT controls when fed either normal or MCD chow (Figure 6-vA F).  
Figure 6-iv: Free fatty acid and triglyceride quantitation. Liver tissue from WT and Lcn2-/- mice, after being 
fed with control or MCD diet for 4 weeks, were homogenised and the Free fatty acid and Triglycerides were 
quantified. Results are the Results are the mean ± SD, (n=4-8 per group) each analyzed in duplicate.  
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Although these differences were not statistically significant, it is tempting to speculate that a 
decrease in PPAR-γ expression in the absence of LCN2 might trigger the observed hepatic 
steatosis and elevated total triglycerides. Additionally, immunohistochemical staining of liver 
sections of both genotypes after control or MCD diet was performed, to conclude that PLIN5 was 
located in the peripheral rings around the lipid droplets in a significant difference of increased 
PLIN5 around the lipid droplets of the WT mice (Figure 6-vi), suggesting that the PLIN5 
regulation is stronger based on LCN2 expression than the MCD diet-induced lipogenesis itself. 
Figure 6-v: Effects of a MCD diet on the protein expression and mRNA level of genes correlated to lipid 
metabolism. (A) Western blot analysis to detect PLIN5, PLIN2, PLIN3 and LCN2 protein in liver extracts from WT 
or Lcn2-/- mice that were fed normal chow or an MCD diet for 4 weeks (n=4-8 mice/group). GAPDH served as a 
loading control. (B-F) qRT-PCR analysis of mRNA expression of Plin5 (B), Plin2 (C), Plin3 (D), Lcn2 (E) and Ppar-
γ (F) in liver extracts from WT or Lcn2-/- mice that were fed normal chow or an MCD diet for 4 weeks (n=4-8 
mice/group). Results are the mean ± SD of qRT-PCR data for n=4-8 mice/group, each analyzed in duplicate. *p  
0.05; **p  0.01; ***p  0.001. (Source: Asimakopoulou et al., 2014). 
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Figure 6-vi: Immunohistochemisty for PLIN5 in the liver tissue. WT and Lcn2-/- mice 4 weeks after the 
administration of control or MCD diet were stained for PLIN5. PLIN5 was found to be located peripherally of the lipid 
droplets that were formed after the MCD diet. The livers from WT mice revealed a higher expression of PLIN5 (darker 
brown color around the droplets) than the Lcn2-/- mice. Bar scales: 100μm. Results are representative images taken from 
individual animals in each group. 
 
Can overexpression of LCN2 upregulate PLIN5 expression? The presented findings indicate 
that the absence of LCN2 is associated with decreased PLIN5 expression in liver extracts 
triggering next to test if transient overexpression of LCN2 in hepatocytes could enhance PLIN5 
expression. To do so, primary hepatocytes from WT and Lcn2
-/-
 mice (submitted to just normal 
chow diet) were isolated and transfected with the empty control vector pCMV-SPORT6 or a 
construct that drove the expression of the full-length murine Lcn2 cDNA (CMV-mLcn2). One day 
post-transfection, with qRT-PCR the expression levels of PLIN5 mRNA were tested and it was 
found that transient LCN2 expression indeed significantly increased PLIN5 mRNA in both, WT 
and Lcn2
-/-
, hepatocytes (Figure 6-viiA). This alteration in PLIN5 transcription resulted in a 
corresponding elevation in PLIN5 protein (Figure 6-viiB), establishing a regulatory link between 
LCN2 and PLIN5 expression. The same stimulatory effect on PLIN5 protein was detected when 
WT and Lcn2
-/-
 hepatocytes were infected with an adenoviral expression vector mediating LCN2 
expression (Ad-CMV-mLcn2), but not when cells were mock-infected or infected with a control 
adenoviral vector expressing luciferase (Ad-CMV-Luc) (Figure 6-viiC). These data support the 
hypothesis that LCN2 is a modulator of the Perilipins involved in hepatic lipid accumulation. 
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Figure 6-vii: Induction of PLIN5 by LCN2 overexpression in cultured hepatocytes. A) qRT-PCR analysis of 
PLIN5 mRNA expression in primary hepatocytes that were isolated from WT or Lcn2-/- mice ,fed with normal chow, 
and transfected with empty vector (control) or a construct expressing LCN2 (CMV-mLcn2). RNA was extracted 24 hrs 
post-transfection. Results are the mean ± SD of triplicates and are representative of 3 independent trials. *p  0.05; **p 
 0.01; ***p  0.001. (B) Western blot analysis to detect LCN2 and PLIN5 proteins in the cells in (A). Proetin extracts 
were prepared 48 hrs post-transfection. The transfection results are representative of 3 independent experiments, while 
the infection was only done once. (C) Western blot analysis to detect LCN2 and PLIN5 proteins in WT and Lcn2-/- 
primary hepatocytes that were left uninfected (mock), infected with control adenoviral vector (Ad-CMV-Luc), or 
infected with adenoviral vector expressing LCN2 (Ad-CMV-mLcn2). Extracts were prepared 48 hrs post-infection. 
Results are representative of 3 independent experiments. (Source: Asimakopoulou et al., 2014). 
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Is LCN2 overexpression induced PLIN5 upregulation capable of affecting lipid formation? PLIN5 
is critical for the storage of fat in primary hepatocytes [Grasselli et al., 2010]. Since LCN2, as 
shown above, regulates the expression of PLIN5, next it was tested if the elevated quantities of 
PLIN5 that are induced by LCN2 overexpression could influence lipid droplet formation or fat 
deposition in hepatocytes. To this question transfection of WT and Lcn2
-/-
 primary hepatocytes 
was performed with LCN2 expression constructs. These cells were later stained (after cultivation 
in basal conditions) with the widely known lipophilic stainings Nile Red (Figure 6-viiiA) and Oil 
Red O (Figure6-viiiB) to detect lipid droplets. Easy to observe, both staining methods revealed 
that LCN2 overexpression led to increased lipid droplet formation, in both WT and Lcn2
-/-
 
hepatocytes. Moreover, the size of these droplets appeared to be enlarged in the presence of 
overexpressed LCN2, suggesting that LCN2 participates in the synthesis or recruitment of lipid 
droplet membranes. 
 
To test if these alterations required LCN2 itself or were solely the consequence of an increase 
in PLIN5, transfection of WT and Lcn2
-/-
 hepatocytes with a construct expressing full-length 
murine PLIN5 (CMV-mPLIN5) was performed. Interestingly, PLIN5 overexpression alone was 
sufficient to enhance lipid droplet formation, irrespective of LCN2’s presence (Figure 6-ix) Under 
condition in which the medium was further supplemented with oleic acid after transfection with 
LCN2 in hepatocytes isolated from Lcn2
-/-
mice, it was demonstrated that LCN2 alone is already 
sufficient for increasing lipid droplet formation as well (not shown). 
Figure 6-viii: Effect of LCN2 overexpression in hepatic lipid droplets. Overexpression of LCN2 in primary 
hepatocytes increased the formation of Lipid droplets. (A) Nile Red staining of lipid droplets in WT or Lcn2-/- primary 
hepatocytes that were transfected with empty vector (mock) or vector expressing LCN2 (CMV-mLCN2). Staining was 
performed 48 hrs post-transfection. To increase contrast, microscope settings were chosen such that Nile Red was 
displayed in green. Nuclei were visualized using DAPI (blue). Scale bars, 50 µm. (B) Oil Red O staining of lipid droplets 
in the primary hepatocytes in (A) examined at 48 hrs post-transfection. Scale bars, 50 µm. For (A) and (B), results are 
representative of 3 cultures/group. (Source: Asimakopoulou et al., 2014) 
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 As a control for a successful stimulation with oleic acid the elevated expression of Adipose 
triglyceride lipase (Atgl) was proved (not shown). 
 
 
So far the results show that LCN2’s key role in this context is to stimulate PLIN5 expression. 
To confirm this hypothesis, immunocytochemistry was applied to analyze PLIN5 protein 
expression in WT and Lcn2
-/-
 hepatocytes subjected to transfection or adenoviral infection with 
LCN2 expression constructs. Again, the data indicated a strict correlation between the presence of 
LCN2 and vigorous PLIN5 production (Figure 6-x). Intriguingly, it was found that transient 
transfection of LCN2, at a transfection rate of ~30% of cells, resulted in similarly strong level of 
PLIN5 expression as adenoviral infection of LCN2, with an infection rate of ~100% of cells. This 
result demonstrates that LCN2 is indeed a key inducer of PLIN5.  
Figure 6-ix: Increase in lipid droplets in primary hepatocytes overexpressing PLIN5. Oil Red O staining of lipid 
droplets in WT or Lcn2-/- primary hepatocytes that were transfected with empty vector (control) or vector expressing 
PLIN5 (CMV-mPLIN5). Staining was performed 48 hrs post-transfection. Scale bars, 50 µm. Results are representative 
of 3 cultures/group examined in 3 independent trials. (Source: Asimakopoulou et al., 2014). 
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Figure 6-x: Immunocytochemical analysis of PLIN5 induction by LCN2 overexpression in primary hepatocytes. 
Top panels: Control immune-staining of WT hepatocytes to confirm the specificity of the antibodies used in this 
analysis. Transfection panels: WT and Lcn2-/- primary hepatocytes were mock-transfected (mock) or transfected with 
vector overexpressing LCN2 (CMV-mLCN2). Cells were fixed at 48 hrs post-transfection and immunostained with 
anti-LCN2 (green) and anti-PLIN5 (red) antibodies. Nuclei were counterstained with DAPI (blue). Infection panels: WT 
and Lcn2-/- primary hepatocytes were not infected (mock) or infected with adenoviral vector overexpressing LCN2 (Ad-
CMV-mLCN2). Cells were fixed at 48 hrs post-infection and immunostained as for transfections. Scale bars, 50 µm. 
Results are representative of 3 cultures/group examined in 3 independent trials. (Source: Asimakopoulou et al., 2014). 
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 Fatty acid rich environment. Can it affect the PLIN5-LCN2 correlation? Till now, it’s clearly  
proven that LCN2 strongly regulates PLIN5 in basal conditions. But in order to investigate if this 
LCN2-PLIN5 regulation can be disturbed from sudden fatty acid accumulation, WT and Lcn2
-/-
 
hepatocytes were stimulated in vitro with oleic acid (unsaturated) and stained with Oil Red O to 
evaluate intracellular lipid accumulation. Loss of LCN2 did not prevent lipid droplet formation in 
oleic acid-treated cells (Figure 6-xi).  
 
However, the lipolytic activity in livers of Lcn2
-/-
 mice was significantly suppressed in MCD 
diet as evident by lower expression of lipolysis associated genes including hormone sensitive 
lipase (HSL), ATGL, monoglyceride lipase (MGL), and hepatic triglyceride lipase (HTGL), 
respectively (Figure 6-xii).  
Figure 6-xi: Stimulation of primary hepatocytes with oleic acid. WT or Lcn2-/- primary hepatocytes were stimulated in 
culture with vehicle (control) or 0.1 mM oleic acid for 16 hrs and lipid droplets were visualized by Oil Red O staining. 
Scale bar, 100 µm. Results are representative of 3 cultures/group. (Source: Asimakopoulou et al., 2014). 
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When levels of PLIN5 and LCN2 proteins were examined in WT and Lcn2
-/-
 hepatocytes 
treated with oleic acid (unsaturated) and/or palmitic acid (saturated) these fatty acids failed to 
significantly increase PLIN5 or LCN2 protein in WT hepatocytes, or PLIN5 protein in Lcn2
-/-
 
hepatocytes (Figure 6-xiiiA and Figure 6-xivA). Similarly, oleic acid treatment of WT hepatocytes 
did not stimulate their expression of Lcn2 mRNA (Figure 6-xiiiB). Interestingly, there was a 
tendency that the levels of PLIN5 mRNA in cultured Lcn2
-/-
 hepatocytes were lower than those in 
WT hepatocytes in the presence or absence of free fatty acids (Figure 6-xivB). Under the chosen 
conditions, no indication for apoptosis or lipotoxic effects was found (Figure 6-xivC). All these 
results suggest that, at least in vitro, LCN2 overexpression can mimic the effects of free fatty acids 
on lipid droplet formation by stimulating high expression of PLIN5, but that free fatty acids cannot 
induce PLIN5 in the absence of LCN2.  
 
Figure 6-xii: Quantitative analysis of lipolytic markers. Mice were fed with a control or MCD diet for four weeks. 
Animals were sacrificed, livers extracted and analyzed for expression of HSL, ATGL, MGL, and HTGL by qRT-PCR.. 
Results are the mean ± SD of qRT-PCR data for n=4-8 mice/group, each analyzed in duplicate. *p  0.05; **p  0.01; 
***p  0.001 (Source: Asimakopoulou et al., 2014). 
 
Figure 6-xiii: Induction of PLN5 expression in hepatocytes 
by stimulation with fatty acids. (A) Western blot analysis to 
detect PLIN5 and LCN2 proteins in extracts of WT or Lcn2-/- 
primary hepatocytes that were left untreated (0) or stimulated 
with 0.1 mM oleic acid for 16 hrs. GAPDH, loading control. 
(B) qRT-PCR analysis of LCN2 mRNA expression in extracts 
of WT or Lcn2-/- primary hepatocytes that were left untreated 
(control) or stimulated with 0.1 mM oleic acid for 16 hrs. 
Results are representative of 3 cultures / group. *p  0.05; **p 
 0.01; ***p  0.001. (Source: Asimakopoulou et al., 2014). 
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Figure 6-xiv: Induction of PLIN5 expression in hepatocytes by stimulation with fatty acids. (A) Western 
blot analysis to detect PLIN5 and LCN2 proteins in extracts of WT or Lcn2-/- primary hepatocytes that were 
stimulated for 24 hrs with the indicated concentrations of palmitic acid, oleic acid, or both. β-actin, loading 
control. Results are representative of 3 cultures/group. (B) qRT-PCR analysis of PLIN5 mRNA in extracts of WT 
or Lcn2-/- primary hepatocytes that were treated with indicated stimuli for 24 hrs. Results are representative of 3 
independent experiments. ),*p  0.05; **p  0.01; ***p  0.001. (C) For test of potential lipotoxicity of the 
conditions used, the expression of several genes associated with apoptosis (BAX, BCL-2, cleaved Caspase-3) 
was analyzed. (Source: Asimakopoulou et al., 2014). 
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Is the observed LCN2-PLIN5 correlation potent? Krahmer et al had already shown that 
phosphatidylcholine is required to prevent lipid droplet coalescence, which results in lipolysis 
resistant lipid droplets [Krahmer et al., 2011] suggesting that the formation of lipid droplets upon 
MCD is due to lipid droplet coalescence and that these droplets are lipolysis resistant in this 
model. In line with these findings trying to clarify if the LCN2-PLIN5 correlation is potent another 
nutritional model was used, a HFD diet, widely used for steatosis development. Briefly it is 
demonstrated that hepatic expression of Lcn2, PLIN5 and PLIN2 is increased in animals that 
received a HFD (Figure 6-xvB) supporting the initial result. Also immunofluorescence-
histochemistry in liver sections for PLIN5 of these animals revealed the upregulation of PLIN5 
after the HFD administration similarly to the MCD diet effect (Figure 6-xvC). Oil red staining was 
applied to prove the HFD induced lipid accumulation in the mouse livers (Figure 6-xvA). 
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Figure 6-xv: High fat diet. WT animals were subjected to a control or a high fat diet (HFD) for 16 weeks. (A) Compared 
to control mice that were fed on a standard chow, HFD animals were characterized by hepatic fat accumulation as 
determined in Oil Red O stain. Space bars represent 50 µm. (B) Expression of Lcn2, PLIN5, PLIN2, and PLIN3 were 
analyzed in respective animals by qRT-PCR). Results are the mean ± SD of qRT-PCR data for n=3-6 mice/group, each 
analyzed in duplicate, *p  0.05; **p  0.01; ***p  0.001. (C) Expression of PLIN5 was determined by 
immunohistochemistry. Nuclei were counterstained with DAPI. Space bars represent 100 µm. (Source: Asimakopoulou 
et al., 2014). 
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Can a PPRA-γ agonist affect the expression of LCN2 and PLIN5? Rosiglitazone is PPR-γ 
agonist reported to downregulate LCN2 [Zhang et al., 2008] and to increase PLIN5 gene 
expression [Wolins et al., 2006]. To investigate how such an agonist will affect the LCN2-PLIN5 
relation, hepatocytes were stimulated with Rosiglitazone. This PPAR-γ agonist failed to suppress 
significantly LCN2 or upregulate PLIN5 expression, while the expression of ATGL representing a 
PPAR-sensitive gene [Shi et al., 2013] is strongly inhibited (Figure 6-xvi) suggesting that the 
LCN2-dependent regulation of PLIN5 is PPAR independent in murine hepatocytes. 
Is LCN2’s expression associated with the mitochondria content? In previous reports, it has 
been suggested that PLIN5 may also be associated with mitochondria (next to the lipid droplet-
associated pool). In a last set of experiments, the hepatic content of mitochondria was tested for 
possible alterations in animals that lack LCN2 and were fed with MCD by quantitative expression 
analysis of mitochondrial marker genes that were previously proved to be downregulated [Guo et 
al., 2010] in brown adipose tissue. This analysis revealed that in complete agreement with this 
previous study, the expression of Tfam, Nrf1, CTP1-β, CoxIV, ATP5-β and CPT1 were 
significantly suppressed in Lcn2
-/- 
mice that received MCD diet compared to WT controls, while 
there was a tendency that respective animals had already lower numbers of mitochondria under 
normal feeding conditions (Figure 6-xvii). which might point (not firmly at the moment) to not 
Figure 6-xvi: Effect of Rosiglitazone on LCN2 and PLIN5 expression. WT or Lcn2-/- hepatocytes were stimulated with 
Rosiglitazone or vehicle (DMSO). 24 hrs later, the cells were harvested and the expression of PLIN5 and LCN2 analysed 
by Western Blot and qRT-PCR. Results are the mean ± SD of triplicates and are representative of 3 independent trials. *p 
 0.05; **p  0.01; ***p  0.001. In addition, the expression of ATGL was measured by qRT-PCR. (Source: 
Asimakopoulou et al., 2014). 
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only a LCN2 association with oxidative metabolism as reported before [Zhang et al., 2014] but 
also a link of PLIN5 and mitochondrial function as suggested before where PLIN5 was proved to 
protect mitochondria from excessive FA influx [Wang et al., 2011].  
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6.3 Figure 6-xvii: Expression of mitochondrial marker genes. The hepatic expression of Tfam, Nrf1, CTP1-β, CoxIV, 
ATP5-β and CPT1 was tested by qRT-PCR in livers of animals that received control chow or MCD with the Lcn2-/- 
presenting significantly reduced expression in the majority of the mitochondrial markers. ). Results are the mean ± SD of 
qRT-PCR data for n=4-8 mice/group, each analyzed in duplicate, *p  0.05; **p  0.01; ***p  0.001 (Source: 
Asimakopoulou et al., 2014) 
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Discussion 
In this study, the functions of LCN2 in hepatic fat homeostasis were explored using two 
nutritional models of non-alcoholic steatohepatitis. WT and Lcn2
-/-
 mice were subjected to an 
MCD diet and compared intrahepatic lipid accumulation, lipid droplet formation, and expression 
of perilipins. Basal expression of PLIN5 was significantly reduced in Lcn2
-/-
 hepatocytes. In a 
second model of steatosis, WT mice were fed with a HFD.  
Lipids accumulated more in Lcn2
-/-
 liver and the expression of LCN2 and PLIN5 increased 
during hepatic steatosis induced by MCD or HFD. These findings fit to a previous report that has 
demonstrated that Lcn2
-/-
 mice develop more severe fatty liver under regular chow diet and high fat 
diet [Guo et al., 2010]. Moreover this previous report suggested that LCN2 has a fundamental role 
in adaptive thermoregulation, diet-induced insulin resistance, and lipid metabolism [Guo et al., 
2010]. Loss of LCN2 and consequently PLIN5 activities prevented normal intracellular lipid 
droplet formation both in vitro and in vivo. Restoration of LCN2 expression in Lcn2
-/-
 primary 
hepatocytes by either transfection or adenoviral vector infection induced PLIN5 expression and 
restored proper lipid droplet formation. Thus, these data indicate that LCN2 is a key modulator of 
hepatic lipid homeostasis that controls the formation of intracellular lipid droplets by regulating 
PLIN5 expression. 
Although the lack in LCN2 results in more severe fatty liver, the cultured hepatocytes had 
more intracellular lipid droplets when transfected or infected with expression vectors for LCN2. 
This paradoxical might be explained by the fact that presently the biochemical consistency of the 
lipid droplets observed in this study is unknown and that there is no discrimination between free 
fatty cytosolic fatty acids and fatty acids that are incorporated in lipid droplets. 
It was previously shown that an increase in LCN2 expression correlates with an inflammatory 
response and has protective effects in models of experimental liver insult [Borkham-Kamphorst et 
al., 2013]. Elevated LCN2 is reliable marker of liver damage, as evidenced by its marked 
upregulation in livers of mice subjected to treatment with toxic agents such as carbon tetrachloride, 
lipopolysaccharide, or Concanavalin A, or that have undergone bile duct ligation surgery 
[Borkham-Kamphorst et al., 2013]. Other laboratories have demonstrated that LCN2 is a critical 
selective modulator of PPAR-γ activation and contribute to the metabolic syndrome in 
nonalcoholic fatty liver disease [Jin et al., 2011 and Milner et al., 2009]. LCN2 thereby functions 
in lipid homeostasis and energy expenditure, and contributes to the metabolic syndrome in non-
alcoholic fatty liver disease in which excess fat accumulates in the liver. 
The present work has revealed a new role for LCN2 in the regulation of at least one of the 
perilipin proteins involved in lipid homeostasis. Each of the perilipins PLIN2, PLIN3 and PLIN5 
is expressed in its own distinct time course after exposure to free fatty acids. It’s demonstrated 
here that the control of PLIN5 expression rests on factors in addition to the presence of free fatty 
acids, and that one of those factors, is LCN2. PLIN3 and PLIN5 are initially upregulated in 
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response to lipid overload, with PLIN3 having a major function in inducing lipid droplet 
formation, initializing droplet structure, and directing droplet coating during rapid fat storage 
[Wolins et al., 2006]. PLIN2 resides on the surface of lipid droplets [Grasselli et al., 2010] and is 
upregulated after PLIN3 and PLIN5 to promote hepatic fat storage [Chang et al., 2006]. It is 
shown that WT mice fed the MCD diet exhibited elevated levels of PLIN3 mRNA that correlated 
with the observed lipid droplet accumulation, and that this increase in PLIN3 expression was 
compromised in the absence of LCN2. Moreover, an increase in PLIN2 mRNA and protein in 
livers of MCD-WT mice was observed, reflecting a correlation between PLIN2 expression and 
lipid loading in hepatocytes that is consistent with that reported for other cell populations 
[Buechler et al., 2001]. Once again, this elevation in PLIN2 mRNA was impaired in the absence of 
LCN2. However, a lack of LCN2 had no significant effect on protein levels of PLIN3 and PLIN2. 
In contrast, an absence of LCN2 compromised both mRNA and protein expression of PLIN5 in 
whole liver and hepatocytes, and consequently led to enhanced lipid accumulation. Thus, LCN2 is 
an important new regulator of perilipin-mediated lipid storage in the liver. 
The mechanism by which LCN2 modulates PLIN5 expression remains a mystery. It might be 
possible that the lack of LCN2 modulates the expression of some lipolytic markers including HSL, 
ATGL, MGL and HTGL (Figure 6-xii) but these results also indicate that LCN2 directly affects 
genes (PLIN5) that are involved in proper lipid droplet formation (Figure 6-vii). These two 
findings might explain why the size of the lipid droplets that was observed in the Lcn2
-/-
 mice is 
increased when compared to WT controls. 
On the other side, it is possible that LCN2 influences hepatocyte uptake of lipids and fatty 
acids by enhancing the passive diffusion of these hydrophobic substances through the membrane 
bilayer. Alternatively, LCN2 may participate in a till now unidentified receptor system. It is 
generally accepted that any uptake of fatty acids in excess of metabolic requirements will lead to 
the storage of these fatty acids as triglycerides, resulting in hepatic steatosis, lipid peroxidation, 
and inflammation progressing to steatohepatitis [Bradbury et al., 2006].  
Based on these experiments, a model was proposed in which LCN2 is a central mediator in 
hepatic lipid metabolism that can influence glucose homeostasis and adipogenesis (Figure 6-xviii). 
A similar role has been proposed for LCN13, which is markedly reduced in mice exhibiting 
obesity and type-2 diabetes [Cho et al., 2011]. Similarly as for LCN2 overexpression in WT mice, 
short-term overexpression of LCN13 via adenovirus-mediated gene transfer attenuated hepatic 
steatosis in mice with either dietary or genetic obesity [Sheng et al., 2011]. Conversely, 
neutralization of endogenous LCN13 increased lipogenesis and suppressed fatty acid β-oxidation 
in primary hepatocytes [Sheng et al., 2011]. The presented data in this dissertation reinforced the 
conclusion that lipocalins have roles far beyond the transport of lipophilic substances, and can act 
as major regulators of lipid metabolism. 
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Figure 6-xviii: Model of LCN2 function in the regulation of PLIN5 expression and control of lipid homeostasis. 
LCN2 is a small protein known to bind to hydrophobic substances such as lipids. It is proposed that LCN2 may import 
lipids into hepatocytes either via an unknown endocytosis pathway or through unidentified LCN2 receptors. Within the 
hepatocyte cytoplasm, the LCN2-lipid complex may be compartmentalized into endosomes whose slightly acidified 
microenvironment may eventually cause LCN2 to dissociate from the lipids. The lipids may be discharged from the 
endosome into the cytoplasm, where they may be bound to the lipid droplet protein PLIN5 to protect them from 
degradation. LCN2 may be returned to the cell’s exterior by endosome recycling. Hepatocyte PLIN5 production may be 
upregulated by PPAR-γ, which itself is upregulated by the higher cytoplasmic fat content that results when LCN2 
facilitates lipid import. Together, this regulatory network of LCN2, PPAR-γ, and PLIN5 affects lipid metabolism, glucose 
homeostasis, adipogenesis, and mitochondrial content. In the presence of LCN2, intracellular concentrations of reactive 
lipid species may be reduced and inflammatory responses suppressed. However, in the absence of LCN2, or when PLIN5 
expression is modulated by PPAR-γ, the formation of triglycerides may be increased and eventually lead to steatosis. 
(Source: Asimakopoulou et al., 2014). 
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In total the results shown in this study give some hints as to how LCN2 can help to protect the 
liver against acute injury. PLIN5 regulates oxidative lipid droplet hydrolysis, and is involved in the 
control of fatty acid flux to protect mitochondria against excessive exposure to fatty acids during 
stress conditions [Wang et al., 2011]. Specifically, PLIN5 stabilizes lipid droplets by inhibiting 
their hydrolysis and channels fatty acids to triglyceride stores at the expense of fatty acid oxidation 
by the mitochondria [Wang et al., 2011].  
The proposed scenario resulting from this study wants LCN2 elevation in response to stress to 
increase concentrations of intracellular PLIN5. This PLIN5 may attempt to maintain cellular 
integrity by storing fatty acids transiently in the lipid droplet compartment, preventing them from 
triggering pro-inflammatory cytokine and chemokine production and the activation of ROS-
associated pathways [Boden et al., 2008]. For example, hepatocytes are induced to produce large 
quantities of IL-8 by exposure to pathophysiologic concentrations of palmitic acid. This palmitic 
acid stimulates an excessive influx of fatty acids into hepatocytes through mechanisms involving 
NF-κB activation [Joshi-Barve et al., 2007] 
It has been previously shown that LCN2 expression correlates with an inflammatory response 
in the liver, and is controlled by the NF-κB pathway in hepatocytes [Borkham-Kamphorst et al., 
2011]. A speculation rises, that an increase in intracellular fatty acid concentration in hepatocytes 
may first trigger the expression of cytokines and chemokines that subsequently activate the NF-κB 
pathway. LCN2 is then expressed and subsequently stimulates PLIN5 expression in concert with 
other factors. In primary cardiomyocytes, PPAR-γ agonist treatment for example has been shown 
to induce PLIN5 mRNA expression [Wolins et al., 2006], and LCN2 modulates PPAR-γ activation 
associated with control of lipid homeostasis and energy expenditure [Shi et al., 2013]. Conversely, 
a deficit in PPAR-γ activity induces steatosis and reduces serum triglycerides [Rogue et al., 2014 
and Seber et al., 2006]. Although there was no statistically significant difference observed in 
PPAR-γ levels in the Lcn2-/- hepatocytes, a suggestion that a decrease in PPAR-γ expression 
associated with loss of LCN2 function might trigger the observed hepatic steatosis and elevated 
serum triglycerides in the MCD-Lcn2
-/-
 mice can be made. 
The lipid droplet formation is a complex process in which many factors are essential and the 
MCD model does not necessarily mimic all the biochemical requirements that control lipid droplet 
formation and coalescence that was in detail reported elsewhere [Krahmer et al., 2011]. Although 
the content of phosphatidylcholine was not analyzed in this study, the finding that Lcn2
-/-
 mice 
have already more lipid droplets than WT mice when fed with a regular chow suggest that 
phosphatidylcholine alone is not responsible for the observed alterations during hepatic steatosis in 
the knock out animals. Moreover, the demonstration that some lipolytic and mitochondrial markers 
are suppressed in Lcn2
-/-
 mice requires additional future experimentation in order to understand the 
pathophysiological role that is induced by lack of LCN2. 
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In conclusion, it’s here shown that LCN2 is a critical regulator of lipid uptake that influences 
the expression of the key perilipin PLIN5 in a PPAR independent manner as well as the formation 
of lipid droplets in primary hepatocytes. These findings support recent proposals that lipid droplets 
can be considered a potential therapeutic target in diseases associated with fatty livers [Anderson 
et al., 2008; Goh et al., 2013]. A deeper understanding of the roles of LCN2 and PLIN5 in the 
pathogenesis of steatosis and hepatic inflammation could yield important fundamental data on 
mechanisms leading to hepatic fat accumulation. Consequently, this knowledge could lead to new 
avenues of therapy and prevention of human diseases, such as NASH and NAFLD that are 
associated with increased hepatic lipid uptake. 
There are recent advances in understanding the role of PLIN proteins in lipid droplet 
formation and the pathogenesis of liver diseases [Okumura et al., 2011 and Li et al., 2012]. PLIN1 
has the ability to bind lipid droplet, PLIN2 coats lipid storage droplets, while PLIN3 failed to be 
associated with amount of lipid droplets in liver and the function of PLIN4 is still unknown 
[Okumura et al., 2011]. It is here shown that PLIN5 is upregulated during hepatic steatosis. In 
addition, other laboratories have shown that the expression of this perilipin family member is 
modulated by PPARα in the liver, heart and skeletal muscle and by PPARγ in epididymal adipose 
tissue [Dalen et al., 2007; Yamaguchi et al., 200; Wolins et al., 2006]. In this study it’s suggested 
that PLIN5 is maybe the most important perilipin that in conjunction with LCN2 controls lipid 
droplet homeostasis and potentially impacts lipolysis and mitochondrial balance. 
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7 Lipocalin-2 (NGAL/LCN2), a "HELP-ME" Signal in hepatic 
inflammation 
 
In this second part of the study, investigation of the role of LCN2 in inflammation induced by 
MCD diet (nutritional model of NASH), fed to WT and Lcn2
−/−
 mice was carried out. The hepatic 
LCN2 and inflammatory cytokines and chemokines (IL-6, IL-1β, TNF-α, CCL2 and CCR2) as 
well as the transcription factors STAT1 and STAT3 expression were compared between the two 
genotypes. Additionally, histology inflammation score and immunohistochemistry stainings with 
leukocytes and neutrophil granulocyte markers were performed. It was found that while both, WT 
and Lcn2
-/- 
, developed inflammation after 4 weeks of MCD diet, the WT presented enhanced 
leukocyte and neutrophil recruitment than the Lcn2
-/- 
mice. Moreover, the WT mice fed with MCD 
diet, presented a remarkably stronger expression of phosphorylated forms of STAT1 and STAT3. 
These results indicate that the biological activity of LCN2 in experimentally-induced liver injury 
acts in a protective way (‘HELP-ME’ signal) to liver homeostasis as it enhances the recruitment of 
the first cells responsible for the immune defence against injury. 
 
7.1 Introduction 
LCN2 has been proved to protect against bacterial growth by sequestering siderophores 
making iron inaccessible to the bacteria [Goetz et al., 2002 and Flo et al., 2004], a characteristic 
which was confirmed when Lcn2
-/-
 mice were reported to favour bacterial infections [Berger et al., 
2006]. The rodent homologue of LCN2 (24p3) was initially localised in mouse urine after viral 
infection (Simian virus 40) in the kidney [Hraba-Renevey et al., 1989], while the human 
homologue, NGAL was purified from stimulated neutrophils [Kjedsen et al., 1993]. LCN2 has 
been attributed several functions, as mentioned before in Chapter 3, however the cellular 
mechanisms still need to be defined.  
Hints have been given of LCN2 correlation in inflammation pathways [Sunil et al., 2007]. 
Injured hepatocytes have been proved to be the main source of hepatic LCN2 [Borkham-
Kamphorst et al., 2011]. More specifically, hepatic LCN2 expression is drastically upregulated 
during inflammation and in response to cellular stress and evolves protective effects during acute 
and chronic injury models. It had been recently reported that LCN2 is induced during experimental 
liver injury showing that the pro-inflammatory cytokine IL-1β induces the LCN2 expression in 
hepatocytes in those models [Borkham-Kamphorst et al., 2011]. Moreover, after administration of 
the hepatoxin CCl4 increased liver damage was found in Lcn2
−/−
 mice in comparison with WT. The 
Lcn2
−/−
 animals presented increased expression of inflammatory cytokines and chemokines such as 
IL-1β, IL-6, TNF-α and MCP-1/CCL2, leading to continuous activation of STAT1 and STAT3 
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pathway suggesting a protective role for LCN2 in liver damage [Borkham-Kamphorst et al., 2013]. 
Several recent studies suggested that LCN2, functions as a recruiter of inflammatory cells in cases 
of inflammation in astrocytes, hind paws and injured spinal cord [Lee et al., 2011; Jha et al., 2014 ; 
Rathore et al., 2011]. However, there are also studies indicating the role of LCN2 in the 
progression of kidney disease in both mice and human [Rinella et al., 2004]. Trying to clarify 
further the role of LCN2 in inflammation WT and Lcn2 
−/−
 mice were fed with a MCD diet-used 
widely to induce NASH . Next the expression of inflammation markers in both genotypes was 
analysed. In the present study it’s shown, that the WT animals showed extreme LCN2 
upregulation after the MCD diet and that they recruited significantly more neutrophils and 
leukocytes than the Lcn2
-/-
 mice. The WT mice appeared to have wider leukocytes and neutrophil 
infiltrates while the active forms of STAT1 and STAT3 expression were significantly higher in the 
WT mice. Moreover, conduction of inflammation score based on liver tissue, agreed with the 
above experimentation. The present study provides solid information that LCN2 serves as a 
‘HELP-ME’ signal inducing recruitment of the first-line immune defence cells (neutrophil 
granulocytes) preventing the liver of further damage development in a MCD model of NASH.  
 
7.2 Results 
MCD is a nutritional model of fatty liver disease for rodents resulting in liver injury similar to 
human NASH, including steatosis, inflammation and fibrosis [Brunt et al., 1999; Pickens et al., 
2010; Pickens et al., 2009; Larter et al., 2008]. Livers of WT and Lcn2
-/-
 mice fed on normal chow 
diet for 4 weeks appeared normal while WT and Lcn2
-/-
 mice on MCD diet showed extensive 
steatosis with the formation of clear lipid droplets and infiltrating inflammatory cells (Figure 7-
iA). However, the WT mice presented more focal and clear lobular inflammatory infiltration than 
the Lcn2
-/-
 with more and wider areas of neutrophil and leukocyte accumulation. Moreover, 
inflammation score by a blinded pathologist, based on the H&E stained tissue sections, showed 
enhanced inflammatory response after the MCD diet for 4 weeks was higher in the WT mice 
(0.430.53 vs. 0.130.35) compared to the Lcn2-/- Figure 7-iB). 
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To study further and in more detail the inflammatory effect after the MCD diet, liver sections 
were immune-stained with CD45 (cluster of differentiation 45) antibody as the leukocyte-common 
antigen After the MCD diet, it’s clear that in the WT animals more leukocytes recruited than the 
Lcn2
-/-
 mice (Figure 7-iiA).The protein level of CD45 was also tested with the WT mice showing 
increased expression of CD45 in control and MCD diet (Figure 7-iiB). Additionally the mRNA 
expression levels of the common-leukocyte marker agreed with the already results (Figure 7-iiC). 
Figure 7-i: Inflammation effect after four weeks of MCD diet administration. (A) Representative Oil Red O staining 
(top panels) and H&E staining (lower panels) of hepatic specimens of both, WT and Lcn2-/- mice, after MCD or normal-
control diet. (Bar scales: 100 μm). Lipid accumulation is observed as well as the formation of inflammation infiltrates 
(indicated with black arrows) as results of the MCD diet mechanism. The WT representative individual samples show 
significantly more and bigger areas of accumulation of inflammatory cells. Results are representative images from 
individual animals from each group. In (B), for all the WT and Lcn2-/- animals fed on chow or MCD diet for 4 weeks, an 
histological inflammation score based on H&E stained tissue sections was performed, enhancing the outcome of the 
stainings in (A). Results shown are the mean ± SD of WT or Lcn2-/- mice (n=4-8/group). (Source: Asimakopoulou et 
al., 2015). 
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Moreover, immunostaining of liver tissues from animals of both genotypes with MPO 
antibody that is mostly abundantly expressed in neutrophil granulocytes was performed. 
Interestingly, the WT animals fed on MCD diet, presented much higher infiltrated neutrophils than 
the Lcn2
-/-
 mice (Figure 7-iiiA). The staining followed by quantification of the MPO expressing 
cells clearly show that MCD diet induces inflammation with WT animals recruiting remarkably up 
to 5-fold more inflammatory cells than the Lcn2
-/-
 suggesting that the expression of LCN2 affects 
expression of proteins related to inflammation (Figure 7-iiiB). Another method used to prove the 
levels of neutrophil infiltration was the MPO activity assay by a colorimetric kit from Abcam. The 
quantification revealed that the MPO activity is significantly increased in the WT mice after MCD 
diet in comparison with the Lcn2
-/-
 mice (Figure 7-iiiC), which supports the previous 
experimentation. 
Figure 7-ii: MCD diet induces the formation of inflammatory infiltrations. With immunohistochemical staining (A) 
Leukocytes were detected on 5 µm liver tissues with CD45 (cluster of differentiation 45) antibody in both WT and Lcn2-
/- after 4 weeks of normal chow diet or MCD, indicating a burst out of leukocytes infiltration in the WT mice after the 
MCD diet in comparison to the Lcn2-/- mice. Scale bars: 100μm. Results are representative images from individual 
animals from each group. (B) Western blot on liver lysates of the same mice revealed significantly enhanced expression 
of CD45 not only in MCD conditions but also when fed a normal-control diet. (C) The expression of the leukocyte 
marker was tested with qRT-PCR. Results shown are the mean ± SD of WT or Lcn2-/- mice (n=4-8/group). (Source: 
Asimakopoulou et al., 2015).  
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Western blot analysis of animals subjected to the MCD diet showed an interesting 
upregulation of the transcription factors, STAT1 and STAT3 protein levels for the WT animals 
compared to the Lcn2
-/-
 ones. The same difference was observed when the activated-
phosphorylated forms of those proteins pSTAT1 and pSTAT3 were tested (Figure 7-ivA). The 
activation of the STATs in tissue damage agrees with previous studies [Lang et al., 2005; Ernst et 
al., 2008 and Wang et al., 2011]. The pro-inflammatory cytokine IL-1β also presented an 
upregulated protein expression in WT animals (Figure 7-ivA). STAT proteins are known to be 
induced by several cytokines [Wang et al., 2011]. The mRNA expression of cytokines, 
chemokines and transcription factors was tested with qRT-PCR The analysis revealed that the 
MCD diet leads to intense upregulation of the mRNA of CCL2, CCR2, IL-6, IL-1β, TNF-α, 
STAT3 and STAT1 with the WT animals marking higher levels of mRNA expression in 
Figure 7-iii: MCD diet enhances the recruitment of neutrophils granulocytes. (A) Immunohistochemical staining 
with MPO antibody, neutrophils were detected in liver tissues of WT and Lcn2-/- after 4 weeks on normal or MCD 
diet. (Top panel) visualisation of MPO expression. (Lower panel) Merged pictures of MPO staining with 
counterstained nuclei with DAPI. Results are representative images from individual animals from each group. Scale 
bars: 100μm. (B) Five different areas of MPO stained tissue of each sample of 40x magnification were used for 
quantification of the neutrophil granulocytes. Results shown are the mean ± SD. (C) The MPO activity was measured 
by a colorimetric assay, enhancing the previous results for MPO significantly greater accumulation in the WT animas 
after MCD diet for 4 weeks. Results shown are the mean ± SD (n=4-5 per group). *p  0.05; **p  0.01; ***p  
0.001. (Source: Asimakopoulou et al., 2015) 
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comparison with the Lcn2
-/-
 (Figure 7-ivB). Although the differences between WT and Lcn2
-/-
 were 
not statistically significant, it enhances the previous significant results from protein analysis, H&E 
staining and immunohistochemistry that LCN2 enhances inflammatory response.  
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Based on the finding that LCN2 expression correlates with STAT1 and STAT3 expression in 
hepatic tissue extracts overexpression (not shown) of the pro-inflammatory agent LCN2 in primary 
hepatocytes was performed to check if the expression of STAT3 and STAT1 will be enhanced. 
Primary hepatocytes were isolated from WT and Lcn2
-/-
 mice and after 24 hrs were, transfected 
with empty control vector or a CMV-mLcn2 construct or infected with adenoviral vector (Ad-
CMV-mLcn2) Primary hepatocytes that served as controls were left untreated or infected with 
control adenoviral vector (Ad-CMV-Luc) (not shown ). Both transfection constructs CMV-mLcn2 
Figure 7-iv: MCD diet affects protein and mRNA expression of genes involved in the inflammation process. 
(A) Western blot analysis to detect STAT3, STAT1, and their activated / phosphorylated forms pSTAT1, pSTAT3, 
the proinflammatory cytokine IL-1β, and LCN2 protein in liver extracts from WT and Lcn2−/− mice after 4 weeks of 
normal chow or MCD diet. GAPDH was used as the loading control. All inflammation markers show a significantly 
higher expression in the WT animals with great enhancement of the STAT1, STAT3 and their activated / 
phosphorylated form pSTAT1 and pSTAT3. (B) qRT-PCR analysis of mRNA expression of the inflammation-
correlated markers CCL2, CCR2, IL-6,  IL-1β, TNF-α, STAT3, STAT1 and LCN2 was performed in liver extracts 
from the WT and Lcn2−/− mice. Results are the mean ± SD of qRT-PCR data for n= (4–8 mice/group), each analysed 
in duplicate. Values of significance are *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.  
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and adenoviral vector (Ad-CMV-mLcn2) led to the expression of the full-length murine Lcn2 
cDNA. Forty eight hrs post transfection the protein levels of STAT1, STAT3, pSTAT1, pSTAT3 
and LCN2 were checked to conclude that overexpression of LCN2 itself is not enough to induce 
the STAT proteins expression (not shown). An overall conclusion of all these results was set on a 
scheme suggesting that LCN2 co-serves with STATs and cytokine induction to informing with a  
‘HELP-ME’ signal the liver to recruit neutrophils and other leukocytes to resolve inflammation 
and protect it develop further injury (Figure 7-v).  
 
Figure 7-v: Proposed scheme of LCN2 role in hepatic inflammation. Based on the results from the experimentation 
shown in this chapter LCN2 seems to maintain the liver from further damage if damage has already occurred. In this 
MCD model steatosis is the first hit to the liver. Secondary factors (unknown) act to development of Inflammation and 
NASH. At this point the organ reacts with induction of expression of chemokines and proinflammatory cytokines such 
as, IL-6,  IL-1β, TNF-α which further upregulate LCN2 via a STAT-dependent pathway. LCN2 seems to be the 
‘HELP-ME’ alarm that induces the recruitment of leukocytes and mainly neutrophil granumocytes to the liver 
preventing further injury to the organ and to inflammation resolution. 
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.  
7.3 Discussion 
This study focused on clarifying the correlation of LCN2 in the inflammation process in Non-
alcoholic fatty liver disease. An MCD nutritional model was used on WT and Lcn2
-/-
 male mice 
for four weeks to induce NASH. The formation of NASH was proven with the steatosis (formation 
of lipid droplets) and the recruitment of inflammatory cells. LCN2 has recently been reported 
multiple times to correlate with inflammation [Borkham-Kamphorst et al., 2011; Valapala et al., 
2014; Lindberg et al., 2014; Lee et al., 2011; Jha et al., 2014; Rathore et al., 2011].  
Inflammation is a reaction of the immune system caused by tissue damage or injury. One of 
the early stages of the inflammatory procedure is the transmigration of leukocytes through the 
endothelium and their recruitment at the area of injury [Kubes et al., 1996; Langer et al., 2009]. 
Additionally, neutrophil granulocytes are large phagocytes that react primarily in case of injury 
[Swirski et al., 2013]. They are an essential part of the immune system that in case of injury they 
are the first-responders cells to migrate towards the inflammation-site. The WT animals of this 
MCD model showed a significant accumulation of inflammatory cells, when compared with the 
liver tissues of the Lcn2
-/-
 mice, a process essential for the resolution of inflammatory processes. 
One of the first studies linking LCN2 to inflammatory recruitment was the work of Lee et al., 
who proved LCN2 to be chemokine inducer in the central nerve system that accelerates cell 
migration upon inflammation [Lee et al., 2011]. LCN2 has also been reported in mouse models of 
systemic lupus erythematosus, collagen induced - arthritis and serum-transfer arthritis that Lcn2
-/-
 
mice presented up to a 50% reduction in inflammation, suggesting that LCN2 regulates immune 
cell recruitment to the site of inflammation [Shashidharamurthy et al., 2013]. Recently Jha et al., 
demonstrated that inflammatory cell-derived LCN2 at the sites of inflammation plays important 
roles in central sensitization and the subsequent nociceptive behaviour in the complete Freund's 
adjuvant-induced chronic inflammatory pain mouse model [Jha et al., 2014]. Moreover, using flow 
cytometry Rathore et al., observed reduced influx of neutrophils in Lcn2
-/- 
injured spinal cords 
accompanied by decreased expression of several pro-inflammatory chemokines and cytokines 
while compared to WT animals, suggesting that LCN2 regulates inflammation in the spinal cord 
injury [Rathore et al., 2011]. Another report of Liu et al., proved that Lcn2
-/-
 mice are characterized 
by impaired neutrophil function that makes them more sensitive to bacterial infections. They 
showed that Lcn2
-/-
 mice presented low functional competence of neutrophils including migration 
and function in response upon inflammatory trigger [Liu et al., 2013]. 
 All the above studies show that in various injury models in many tissues, LCN2, when 
inflammation is about to occur, it clamours a ‘HELP-ME’ signal which is strong enough to 
regulate the direct inflammatory cells recruitment to the inflammation site to process with 
resolution and help the organ from excess damage.  
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Elevation of LCN2 in hepatic injury has been reported before from several research groups 
[Borkham-Kamphorst et al., 2011; Borkham-Kamphorst et al., 2013; Valapala et al., 2014; 
Lindberg et al., 2014]. In this study the elevation of LCN2 is confirmed such in protein level as in 
mRNA after the administration of the MCD diet. It has been previously demonstrated [Borkham-
Kamphorst et al., 2013] via qRT-PCR analysis the elevation of pro-inflammatory markers in 
hepatic injury models. Similarly the mRNA of cytokines including IL-6, TNF-α, IL-1β, TFN-α, 
CCL2, CCR2 in this study clearly indicates the initiation of inflammation processes in the liver 
caused by the MCD diet. 
TNF-α and IL-1β are reported before as inducers of LCN2 [Borkham-Kamphorst et al., 2011; 
Borkham-Kamphorst et al., 2013; Zhao et al., 2014] and are mainly produced from Kupffer cells 
during injury. Its upregulated expression after the MCD diet participated in the elevation of LCN2 
expression as a first signal of liver damage. Furthermore, IL-6 is a cytokine secreted from 
macrophages during tissue damage that leads to inflammation. Its expression was increased in 
mRNA and protein level after MCD diet with the Lcn2
-/-
 presenting reduced expression in 
comparison to the WT. IL-6 has been demonstrated before to enhance neutrophil infiltration and to 
improve bacterial clearance. These roles of IL-6 were assigned to its ability to activate the 
transcription of STAT1 and STAT3 transcription factors [Jones et al., 2006]. Moreover, the 
inflammatory CCL2 and its receptor CCR2 presented a tendency of higher mRNA levels in the 
WT mice after the MCD diet. CCL2 is also referred to as monocyte chemotactic protein 1. As the 
name reveals CCL2 participates in monocytes recruitment, and other immunity cells such as 
dendritic cells to the sites of inflammation [Carr et al., 1994; Mehrabian et al., 1991]. CCL2 and its 
receptor CCR2 have been given by Lança et al., the role of protectors during inflammation in 
cancer conditions as they are responsible for the recruitment of type 1 cytotoxic γδ T lymphocytes 
(another type of white blood cells) [Lança et al., 2013]. 
The protein elevation of the STAT1 and STAT3 in the WT samples for normal chow diet and 
MCD as well as their sustained activation-phosphorylation after the MCD treatment is as well of 
high significance in these results. STAT1 is an agent reported before contributing to inflammation, 
injury and tumours [Przanowski et al., 2014]. STAT1 and STAT3 have also been proved to 
regulate inflammatory cells [Yoshimura et al., 2006]. Activation of STAT3 is induced by 
cytokines like IL-6 [Guobin et al., 2011]. A very interesting study from Xu and colleagues 
demonstrates that the hepatocyte-derived-LCN2 plays an important role in inhibiting bacterial 
infection and promoting liver regeneration via the activation of STAT3 signalling pathway by IL-6 
[Xu et al., 2015]. Another report associates the STAT1 and STAT3 transcription activators to 
enhance neutrophil recruitment in inflammation sites after their phosphorylation/activation for IL-
6 enhancing the control of inflammation resolution [Jones et al., 2006]. STAT1 has been several 
times addressed the role of inducer of neutrophils for the clearance of pathogens in the spleen [Pan 
et al., 2013], and in chronic liver diseases via the IFN-γ/STAT1 pathway [Jaruga et al., 2004]. The 
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sustained activation STAT1 and STAT3 relatively indicate the more intense inflammatory cell 
recruitment in the liver of WT mice in this model.  
After proving with LCN2 overexpression that LCN2 can’t itself induce STAT1 or STAT3 
expression (not shown), LCN2 seems to act synergistically with the STATs to induce and 
accelerate the neutrophil and leukocytes recruitment to the sites of injury for the inflammation to 
be resolved before further damage occurs to the organ.  
In conclusion, LCN2 has been reported before in models of hepatic damage, acute and chronic 
and also models of bacterial infections in several organs to have a protective role against 
inflammation. LCN2 strongly seems to be the ‘HELP-ME’ signal that notifies the immune system 
that inflammation is occurring so the recruitment and release of leukocytes and mainly neutrophils 
overrun the inflammation site to rescue the organ from further future injury. In the presented 
model MCD diet induced the inflammatory cell recruitment in the livers of the WT mice in a grade 
bigger than the Lcn2
-/-
 mice did. Moreover, the upregulation of many proinflammatory cytokines, 
chemokines and the activation of the STAT proteins in the respective mice increases the 
speculation that LCN2 acts cooperatively to clamour for ‘HELP’ for inflammation resolution. The 
performed experimentation with all the previous reports mentioned above assign LCN2 as a 
reliable biomarker for hepatic inflammation and as a novel drug target for infestations associated 
with excess inflammatory reactions in liver and other organs. 
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8 General conclusion and future aspects 
Based on the new evidence demonstrated here and from the already existing reported research 
on LCN2, it’s un-doubtful that LCN2 is a multifunctional protein linked to the pathogenesis of 
several hepatic disorders such as NAFLD, abnormal lipid profile and inflammation. Numerous 
studies including the present one, propose LCN2 as a reliable biomarker and as a novel drug 
target. 
The deep correlation of LCN2 and cases of lipid metabolism disorders and FLD including 
NASH, can suggest that this lipocalin can be developed to an early and robust marker that will 
improve differential diagnosis and prognosis of respective diseases. 
In this study the finding that LCN2 modulates expression of PLIN5 that is an important 
protective factor against hepatic lipotoxicity might be of particular interest. The LCN2/PLIN5 axis 
will potentially allow identifying novel important drug targets that are helpful in specific treatment 
of FLD and NASH.  
Moreover, the LCN2s function as a neutrophil chemoattractant in the liver in cases of 
inflammation brings LCN2 closer to be used a drug against harmful stimuli and to prevent patients 
from risking further their hepatic health. 
LCN2 in this MCD nutritional model gave enough information that make more attractive the 
continuous research on this protein. As a continuation of this project liver tissues from WT and 
Lcn2
-/- 
fed with control or MCD diet for 4 weeks, are being assessed under a full Proteomics 
analysis that will give a bigger spectrum of protein alterations between the two genotypes and also 
the same samples are going under Lipidomics analysis which will reveal the real lipid profile of 
the livers. These two big experimentations, will widen the spectrum of possible correlation of 
several proteins with LCN2 and functions that probably will clarify the role of LCN2 in lipid 
metabolism and not only. 
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Gene Acc. No. Primer (5’→ 3’) 
ATGL NM_001163689.1 for: 5'-gaccatctgccttccaga-3' 
rev: 5'- tgtaggtggcgcaagaca-3' 
ATP5-β NM_016774 for: 5'-gcaaggcagggacagcaga-3' 
rev: 5'-cccaaggtctcaggaccaaca-3' 
CCL2 NM_011333 for: 5'-gtgttggctcagccagatgc-3' 
rev: 5'- gacacctgctgctggtgatcc-3' 
CCR2 NM_009915.2 for: 5'-tcgctgtaggaatgagaa-3' 
rev: 5'-caaggattcctggaaggtggtcaa-3' 
CD45 NM_001111316.1 for: 5'- cttcagagaccacatatcatcca-3' 
rev: 5'- gtctgcgagtcaggctgtg - 3' 
Cox IV NM_009941 for: 5'-atgtcacgatgctgtctgcc-3' 
rev: 5'-gtgcccctgttcatctcggc-3' 
CPT1 NM_153679 for: 5'-agagaagcctgccagtttgtgaga-3'  
rev: 5'-tgtacagtgcaaagaggtgacggt-3' 
CTP1-β NM_009948 for: 5'-tctaggcaatgccgttcac-3' 
rev: 5'-gagcacatgggcaccatac-3' 
GAPDH XM_001473623 for: 5’-actgccacccagaagactg-3’ 
rev: 5’-caccaccctgttgctgtag-3’ 
HSL NM_010719.5 for: 5'- agcgctggaggagtgtttt-3' 
rev: 5'- ccgctctccagttgaacc-3' 
HTGL AY228765.1] for: 5'- gacaaggcgtgggaacag-3' 
rev: 5'- tttaatggcttgctagcttcagt-3' 
IL-1β NM_008361 for: 5'- tgtaatgaaagacggcacacc -3' 
rev: 5'- tcttcttgggtattgcttgg-3' 
IL-6 NM_031168 for: 5’-gctaccaaactggatataatcagga-3’ 
rev: 5’-ccaggtagctatggtactccagaa-3’  
LCN2 NM_008491.1 for: 5’-ccatctatgagctacaagagaacaat-3’ 
rev: 5’-tctgatccagtagcgacagc-3’ 
MGL NM_010719.5  for: 5'- tcggaacaagtcggaggt-3' 
rev: 5'- tcagcagctgtatgccaaag-3' 
Nrf1 NM_010938 for: 5'-tggtccagagagtgcttgtgaag-3' 
rev: 5'-ggaggctgaggaacgatttcttg-3' 
PLIN2 M93275.1 for: 5’-ctccactccactgtccacct-3’ 
rev: 5’-gcttatcctgagcaccctga-3’ 
PLIN3 NM_025836.3 for: 5’-ccacaggatgctgaaaagg-3’ 
rev: 5’-tgatgtccctgaacatgctg-3’ 
PLIN5 NM_025874.3 for: 5’-gtcggagaagctggtggac-3’ 
rev: 5’-tcagctgccaggactgcta-3’ 
PPAR-γ NM_011146.3 for: 5’-tgctgttatgggtgaaactctg-3’ 
rev: 5’-ctgtgtcaaccatggtaatttctt-3’ 
STAT1 U06924.1 for: 5'- aaatgtgaaggatcaagtcatgtg-3' 
rev: 5'- catcttgtaattcttctagggtcttga - 3' 
STAT3 NM_213659.2 for: 5'- ggaaataacggtgaaggtgct -3' 
rev: 5'- catgtcaaacgtgagcgact -3' 
Tfam NC_000076 for: 5' -cactgggaaaccacagcatacag-3' 
rev: 5'-ggacatctgaggaaaagccttgc-3' 
TNF-α NM_013693 for: 5'- accacgctcttctgtctactga-3' 
rev: 5'- tccacttggtggtttgctacg-3' 
Table 10-i: Oligonucleotides-Primers used for PCR and q-RT-PCR 
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Antibody Cat. No. Clonality* Supplier Species* Dilution* 
Primary antibodies 
BAX 2772S poly, rabbit Cell signaling h, m, r, mk 1:1,000 
BCL-2 2870S  mono, rabbit Cell signaling h, m, r 1:1,000 
CD45 553076 mono, rat BD biosciences m 1:1,000 (WB), 1:50 
(IHC) 
cl. CASP-3 9664L  mono, rabbit Cell signaling h, m, r, mk 1:1,000 
GAPDH sc-32233 mono, mouse Santa Cruz h, m, r 1:10,000  
IL-1β AF401NA poly, goat R&D Systems m 1:1000  
LCN2 AF3508 poly, goat R&D Systems m, r 1:1,000 (WB), 1:50 
(IFC) 
MPO HP9048 poly, rabbit Hycult Biotech h, m, r 1:100 (IFH) 
PLIN2 NB-110-40877 poly, rabbit Novus Biologicals h, m 1:1,000 
PLIN3 NB-110-40765 poly, rabbit Novus Biologicals h, m 1:1,000 
PLIN5 NB-110-60509 poly, rabbit Novus Biologicals h, m 1:1,000 (WB), 1:50 
(IHC, IFC) 
pSTAT1 9167L mono, rabbit Cell signaling h, m 1:1,000  
pSTAT3 9131S poly, rabbit Cell signaling h, m, r, c, d 1:1,000  
STAT1 sc346 poly, rabbit Santa Cruz  m, r, h, x 1:1,000  
STAT3 sc7179 poly, rabbit Santa Cruz m, r, h, z, x 1:1,000  
β-ACTIN A5441 mono, mouse Sigma-Aldrich h, m, r  1:10,000 
Secondary antibodies 
Alexa Fluor 488 - IgG A11055 N/A Life technologies g 1:200 (IFC) 
Alexa Fluor 488 - IgG A21206  N/A Life technologies rb 1:200 (IFH) 
Alexa Fluor 555 -IgG  A31572 N/A Life technologies rb 1:200 (IFH), 1:500 
(IFC) 
IgG-Biotinylated E0353 N/A DAKO rb 1:300 (IHC) 
IgG-Biotinylated BA-9400 N/A Vector Lab. r 1:300 (IHC) 
IgG-HRP sc-2004 N/A Santa Cruz rb 1:5,000 
IgG-HRP sc-2005 N/A Santa Cruz m 1:5,000 
IgG-HRP sc-2056 N/A Santa Cruz g 1:5,000 
IgG-HRP sc-2032 N/A Santa Cruz r 1:5,000 
Negative control antibodies 
Normal IgG sc-2027 rabbit Santa Cruz rb 1:100 (IFC, IFHC) 
Normal IgG sc-2028 goat Santa Cruz g 1:100 (IFC) 
Normal IgG sc-2026 rat Santa Cruz r 1:100 (IHC) 
* Abbreviations used are: mono, monoclonal antibody; poly, polyclonal antibody; N/A, not applicable; h = human, m = mouse, r = rat, rb= 
rabbit, g = goat, z = zebrafish, x = xenopus, c = cow, d = dog, IHC = immunohistochemistry , IFH = Immunofluorosence-histochemistry, 
IFC= Immunofluoresence -cytochemistry, WB = Western blot 
Table 10-ii: Antibodies used in his study 
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Plasticware - Glassware Catalogue no. Company 
Cell Culture 6 well Plate with Lid 353046 
Becton Dickinson,Labware Franklin 
Lakes, USA 
Cell culture dish 60 mm x 15 mm 628-160 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell culture dish,10 cm 83.1802 Sarstedt, Nümbrecht, Germany 
Cell scraper 240 mm 99002 
TPP, Techno Plastic Products, 
Trasadingen, Switzerland  
Centri•Pure P50 Gel Filtration Columns N/A Emp Biotech GmbH, Berlin, Germany 
Costar® Stripette® serological pipettes, 10 mL CLS4488  Sigma Aldrich, Steinheim, Germany 
Disposable single sealed Cuvettes 50 - 2000 μl 952010051 Eppendorf AG, Hamburg, Germany 
Feather disposable scalpel No.11 297511 Feather Safety Razor CO., Osaka, Japan 
Folded filters 185 mm 311647 
Schleicher & Schuell GmbH, Dassel, 
Germany 
Glass coverslips 24 mm x 24 mm H875.2 Carl Roth, Karlsruhe, Germany 
Glass coverslips 24 mm x 50 mm 1871.2 Carl Roth, Karlsruhe, Germany 
Glass Cuvette - QS 10 mm (Precision cells) 108-QS 
Hellma Analytics, Mülheim, 
Germany 
GSA centrigugation bottle N/A Beckmann, Munich, Germany 
Low temeperature Freezer vials- Cryotubes, 2 
mL 479-0287 VWR International, Langenfeld, Germany 
Microlance Hypodermic Needle 27G x 3/4", 0.4 
mm x 19 mm 302200 
Becton Dickinson,Labware Franklin 
Lakes, USA 
Microscope glass (76 mm x 26 mm ) 03-0004  
R. Langenbrinck, Emmendingen, 
Germany 
Microtubes 0.5 mL 72.699 Sarstedt, Nümbrecht, Germany 
Microtubes 1.5 mL 72.690.001 Sarstedt Nümbrecht, Germany 
Microvette CB 100/200 capillary blood 
collection tubes N/A  Sarstedt, Nümbrecht, Germany 
MicroAmp® Optical Adhesive Film 4360954 Life technologies, Carlsbad, USA 
Original perfusor Syringe 50 mL, Luer Lock, 
sterile 8728810F B. Braun, Melsungen, Germany 
Parafilm M Laboratory Sealing Film, (100 mm 
x 75 mm) 7016 06 
American National Can, Menasha 
Wisconsin, USA 
Table 10-iii: Material and equipment used in this study 
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Plasticware - Glassware Catalogue no. Company 
Petri dish 92 mm x 16 mm with cams 82.1473 Sarstedt, Nümbrecht, Germany 
Pipettes Pasteur , glass , Length 150 mm 747715 Brand Wertheim, Germany 
Pipettes Pasteur , glass , Length 230 mm 747720 Brand Wertheim, Germany 
Pippete tips 10 µl 740011 
Biozym Diagnostik, Oldendorf, 
Germany 
Pippete tips 1000 µl 1130401 
Heinz Herenz Medizinalbedarf, 
Hamburg, Germany 
Pippete tips 1000 µl with filter 692079 
Biozym Diagnostik, Oldendorf, 
Germany 
Pippete tips 200 µl 70.760.02 Starsdedt, Numbrecht, Germany 
Pippete tips 200 µl with filter 07.652.7300 Nerbeplus, Winsen, Germany 
PS-microplates 96 well, Flat bottom 655101 
Greiner Bio-One GmbH, 
Frickenhausen, Germany 
Sterile Syringe Filter 0.20 μm 431219 Corning Inc., NY, USA 
Syringe 1mL, Sterile, Concentric Luer 
Slip 300013 
Becton Dickinson, Labware Franklin 
Lakes, USA 
Test Tube 14mL Round BottomPP, with 
Snap Cap, Sterile, Individually Wrapped 2006 
Becton Dickinson, Labware Franklin 
Lakes, USA 
TipOne Filter Pipette Tip, 200μl, sterile, 
colour: Natural S1120-8810 Starlab, Merenschwand, Switzerland  
Tissue Grind Pestle 21 886001-0021 
Kimble & Chase, Gerresheimer, 
USA 
Tissue Grind Tube, size: 21 885752-0021 
Kimble & Chase, Gerresheimer, 
USA 
Tissue Tek - Disposable Vinyl Specimen 
Molds (25 mm x 20 mm x 5 mm) 4557 Sakura Finetek, Tokyo, Japan 
Tube 13 mL, 95 mm x 16.8 mm 55.468.001 Sarstedt, Nümbrecht, Germany 
Tubes 15 mL 188 280 
Greiner Bio-One GmbH, 
Frickenhausen, Germany 
Tubes 50 mL 227 261 
Greiner Bio-One GmbH, 
Frickenhausen, Germany 
Vaccum line protector,Vent Filter Unit, 
Autoclavable SLFA05010 Millipore, Massachusetts, USA 
Whatman Protan BA 83 Nitricellulose 
Tranfer Membrane 10401396 GE Healthcare, Freiburg, Germany 
Whatman Protan BA 85 Nitricellulose 
Tranfer Membrane 10600002 GE Healthcare, Freiburg, Germany 
Table 10-iv: Material and equipment used in this study (cont.) 
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Chemicals Catalogue No. Company 
Acetic Acid 99-100% 6052 
J.T. Baker, Deventer, The 
Netherlands 
Agarose LE 11685678001 
Roche Diagnostics, Mannheim, 
Germany 
Albumin A-2153  
Sigma- Aldrich, Steinheim, 
Germany 
Albumin (cell culture) A0850,0050 
Applichem GmbH, Dramstadt, 
Germany 
Bacto Agar 214010 
Becton Dickinson, Labware Franklin 
Lakes, USA 
Bacto Tryptone 211705 
Becton Dickinson,Labware Franklin 
Lakes, USA 
Bicine 9162.3 
Carl Roth GmbH, Karlsruhe, 
Germany 
Bis-Tris 9140.3 
Carl Roth GmbH, Karlsruhe, 
Germany 
Boric acid 1.00165.1000 Merck, Darmstadt, Germany 
Bromophenol Blue sodium salt 32768 
Sigma- Aldrich, Steinheim, 
Germany 
Chloroform 1.02445.1000 Merck, Darmstadt, Germany 
Collagen G from Bovine calf skin, aprox: 
4mg/mLl L 7213 Biochrom AG, Berlin, Germany 
DAKO REAL Hematoxylin S2020 
DAKO Deutschland GmbH, 
Hamburg, Germany 
Deoxycholic Acid (DOC), Na - Salt pure,  18330 
Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Deoxynucleoside Triphosphate Set 
(dNTPs), PCR grade 11969064001 
Roche Diagnostics, Mannheim, 
Germany 
Dithiothreitol 1.4 (DTT) 6908.2 Carl Roth, Karlsruhe, Germany 
DMSO-Dimethyl sulfoxide 41641 Sigma Aldrich, Steinheim, Germany 
Dulbeco's Modified Eagle's Medium 
(DMEM) 500 mL D6171 Sigma Aldrich, Steinheim, Germany 
Ethannol 70% v/v  64-17-5 Otto Fischer, Saarbrücken, Germany 
Ethanol Absolut  27698 Otto Fischer, Saarbrücken, Germany 
Ethidium Bromide solution 10 mg/mL 161-0443 Bio-Rad, Munich, Germany 
Fetal Bovine Serum 500 mL F7524 Sigma-Aldrich, Steinheim, Germany 
Fluorosence Mounting Medium S3023 
DAKO Deutschland GmbH, 
Hamburg, Germany 
Table 10-v: Material and equipment used in this study (cont.) 
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Chemicals Catalogue No. Company 
FORENE Narcotic solution  N01AB06 Abbot, Wiesbaden, Germany 
Gentamycin 15710-049 Life technologies, Carlsbad, USA 
Glycerol 3783.1 Carl Roth, Karlsruhe, Germany 
Glycine Molecular Biology grade A-1067 
Applichem GmbH, Dramstadt, 
Germany 
HepatoZYME SFM (1X) Serum free 
Medium 500 mL 17705-021 Life technologies, Carlsbad, USA 
High fat diet N/A 
Research Diet Services BV, Wijk bij 
Duurstede, The Netherlands 
Hydrochloric acid 100316.1011 Merck, Darmstadt, Germany 
Hydrogen Peroxide 30%, H2O 1.07210.1000 Merck, Darmstadt, Germany 
IsoPropanol 6752.4 Carl Roth, Karlsruhe, Germany 
Kanamycin sulfate 10106801001 
Roche Diagnostics, Mannheim, 
Germany 
L- Glutamine 200mM G7513 Sigma Aldrich, Steinheim, Germany 
Lipofectamin 2000 Reagent 1 mg/mL 11668-019 Life technologies, Carlsbad, USA 
Lithium Chloride 1056790250 Merck , Darmstadt, Germany 
Magnesium Chloride Hexahydrate 1.05833.1000 Merck , Darmstadt, Germany 
Magnesium Sulphate Heptahydrate 1.05886.1000 Merck, Darmstadt, Germany 
MES  4256.4 Carl Roth, Karlscruhe, Germany 
Methanol 20847.295 
VWR Chemicals, Fontenay-sous-
Bois, France 
Methionine/ Choline deficient diet, pellets 960439 MP Biomedicals, Illkirch, France 
MgCl2 Stock solution 14534600 
Roche Diagnostics, Mannheim, 
Germany 
MOPS 6979.3 Carl Roth, Karlsruhe, Germany 
NEEA (Non Essential Amino Acids) 100X, 
100 mL BE13-114E Lonza, Verviers, Belgium 
Nile Red - Ultra Pure 25 mg ENZ-52551 
Enzo - Life Sciences, Lörrach 
Germany 
Nonidet P40 11754599001 
Roche Diagnostics, Mannheim, 
Germany 
NuPAGE® LDS Sample Buffer (4X) NP0008 Life technologies, Carlsbad, USA 
Oil Red O  O-0625 Sigma Aldrich, Steinheim, Germany 
Oleic Acid-Albumin O3008-5ML Sigma Aldrich, Steinheim, Germany 
Table 10-vi: Material and equipment used in this study (cont.) 
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Chemicals Catalogue No. Company 
Opti-MEM I; Reduce Serum Medium 31985-070 Life technologies, Carlsbad, USA 
Palmitic Acid P-0500-10G Sigma Aldrich, Steinheim, Germany 
Parafomaldehyde extra pure K10362105 Merck , Darmstadt, Germany 
PCR Buffer 10x without MgCl2 14109300 
Roche Diagnostics, Mannheim, 
Germany 
Pen/Strep stock, 10K/10K 100 mL DE17-602E Lonza , Verviers, Belgium 
Polyethylene Glycole (PEG) P-2139 Sigma Aldrich, Steinheim, Germany 
Ponceau S, sodium salt P-3504 Sigma Aldrich, Steinheim, Germany 
Potassium Phosphate Monobasic 5104 Merck, Darmstadt, Germany 
Potassium Acetate 4986.1 
Roche Diagnostics, Manheim, 
Germany 
Potassium Chloride 1.04936.0500 Merck, Darmstadt, Germany 
Potassium dihydrogen Phosphate 1.04873.1000 Merck, Darmstadt, Germany 
Potassium Sulfate 1.05153.0500 Merck, Darmstadt, Germany 
Powdered Milk T-145.3 
Carl ROTH GmbH, Karlsruhe, 
Germany 
QIAzol Lysis Reagent 79306 Qiazen Sciences, Maryland, USA 
Random Primers 20 μg c1181 Promega Co. Madison, USA 
Rosiglitazone 50 mg ab120762 
Abacam Biochemicals, Cambridge, 
UK 
Roti®-C/I Phenol for DNA/RNA Isolation A156.1 Carl Roth, Karlscruhe, Germany 
Rubidium chloride R2252 Sigma Aldrich, Steinheim, Germany 
SDS 4360.2 
Carl Roth Gmbh, Karlsruhe, 
Germany 
Sodium Acetate 6268.1 Merck, Darmstadt, Germany 
Sodium Carbonate Anhydrous 106392 Merck, Darmstadt, Germany 
Sodium Chloride 106404 Merck, Darmstadt, Germany 
Sodium Hydroxide 50% 7067 J.T. Baker,Deventer, Holland 
Sodium Pyruvate 100 mL S8636 Sigma Aldrich, Steinheim, Germany 
Standard chow diet N/A SSNIFF GmbH, Soest, Germany 
SYBR Green ER qPCR SuperMix 11760-500 Life technologies, Carlsbad, USA 
Table 10-vii: Material and equipment used in this study (cont.) 
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Chemicals Catalogue No. Company 
Sodium Pyruvate 100 mL S8636 
Sigma- Aldrich, Steinheim, 
Germany 
Standard chow diet N/A SSNIFF GmbH, Soest, Germany 
SYBR Green ER qPCR SuperMix 11760-500 Life technologies, Carlsbad, USA 
Tissue Tek - O.C.T. compound 4583 Sakura Finetek, Tokyo, Japan 
TITRIPLEX III 108418 Merck, Darmstadt, Germany 
Tricine 6977.2 Carl Roth, Karlsruhe, Germany 
Trisodium citrate  106448 Merck, Darmstadt, Germany 
Triton X 100 3051.2 Carl Roth, Karlsruhe, Germany 
Trizma Base T-1503 Sigma Aldrich, Steinheim, Germany 
Tween 20 A 4974.0500 
Applichem GmbH, Dramstadt, 
Germany 
Xylene  P2N09208831 Otto Fischer, Saarbrücken, Germany 
Yeast extract granulated 1.03753 Merck, Darmstadt, Germany 
Enzymes Catalogue No. Company 
Complete Protease Inhibitor Coctail 
Tablets 11849300 
Roche Diagnostics, Mannheim, 
Germany 
Fermentas-EcoRI restriction endonuclease 
10 u/μl ER0271 Thermo Scientific, Rockford, USA 
Fermentas-HindIII restriction 
endonuclease 10 u/μl ER0501 Thermo Scientific, Rockford, USA 
Lysozyme 10837059001 
Roche Diagnostics, Mannheim, 
Germany 
PacI restriction endonuclease R0547S NEB, Ipswich, MA, USA 
Phospahatase Inhibitor Coctail, Aqueous 
solution P-5726 Sigma Aldrich, Steinheim, Germany 
PmeI restriction endonuclease R0560S NEB, Ipswich, MA, USA 
PureLink DNase 12185-010 Life technologies, Carlsbad, USA 
Rnase A 109169 
Roche Diagnostics, Mannheim, 
Germany 
SalI restriction endonuclease 10348783001 
Roche Diagnostics, Mannheim, 
Germany 
SuperScript II Reverse Transcriptase 18064-022 Life technologies, Carlsbad, USA 
Taq DNA Polymerase Recombinant  10342-020 Life technologies, Carlsbad, USA 
Table 10-viii: Material and equipment used in this study (cont.) 
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Molecular size standards Catalogue No. Company 
GeneRuler 100bp 100 to 1000bpDNA 
Ladder 
SM0241 Thermo Scientific, Rockford, USA 
SeeBlue Plus2 prestained Protein 
Standard 
LC5925 Life technologies, Carlsbad, USA 
λ DNA-HindIII Digest N3012L NEB, Ipswich, USA 
Vectors Catalogue No. Company 
GeneRuler 100bp 100 to 1000bpDNA 
Ladder 
SM0241 Thermo Scientific, Rockford USA 
pCMV-SPORT6-mLCN2 vector IMAGp998L208764Q 
ImaGenes GmbH (Source 
BioScience LifeSciences, 
Nottingham, UK 
pCMV-SPORT6-mPLIN5 vector IRAVp968B0772D 
ImaGenes GmbH (Source 
BioScience LifeSciences, 
Nottingham, UK 
Adenoviral shuttle vector pShuttleCMV  N/A Stratagene, Agilent, La Jolla, USA 
pAdEasy-1 vector N/A Stratagene, Agilent, La Jolla, USA 
AdEasy-CMV-Luc vector N/A ? 
Multi-Component systems Catalogue No. Company 
Adeno-X-Maxi purification kit  N/A Clontech, Carlsbad, USA 
DC Protein Assay, Kit 500-0116 Bio Rad, Munich, Germany 
Free Fatty Acid Quantification kit AB65341 
Abcam Biochemicals, Cambridge, 
UK 
Nupage 4-12% Bis-Tris Midi Gel 1.0mm 
12+2 well WG1401BX10 Life technologies, Carlsbad, USA 
Nupage 4-12% Bis-Tris Midi Gel 1.0mm 
20 well WG1402BX10 Life technologies, Carlsbad, USA 
Purelink RNA mini kit 12183018A Life technologies, Carlsbad, USA 
MPO activity Quantification Kit AB105136 
Abcam Biochemicals, Cambridge, 
UK 
SuperSignal West Dura Extended 
Duration Substrate  34076 Thermo Scientific, Rockford USA 
Triglyceride Quantification Kit AB65336 
Abcam Biochemicals, Cambridge, 
UK 
VectaStain ABC Kit PK-4000 
Vector Laboratories, Burlingame, 
USA. 
Table 10-ix: Material and equipment used in this study (cont.) 
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Cell strains Catalogue No. Company 
293A 
From primary human 
embryonal kidney Life Technologies, Carlsbad, USA 
Mouse Hepatocytes 
From C57BL/6 ( WT) and 
C57BL/6 (LCN2-/-) this laboratory 
XL1-Blue Bacteria Escherichia coli strain Stratagene, Agilent, La Jolla, USA 
Table 10-x: Material and equipment used in this study (cont.) 
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Apparatus-Equipment Company 
Avanti® J-20 centrifuge Beckman, Pasadena, CA, USA 
Avanti® J-25 centrifuge Beckman, Pasadena, CA, USA 
Axiovert 25 CFL inverted microscope with HBO 50 and 
fluoresence reflectors Carl Zeiss Microscopy, Jena, Germany 
Blotting chamber, Transphor + 4 cassetes and cooler 
GE Healthcare Bio-sciences Co., 
Piscataway,USA 
Cary 50 Scan UV Visible Spectrophotometer Varian Med. Systems Palo Alto, CA, USA 
Centrifuge 5427 R Eppedorf, Berzdorf, Germany 
Dispersing drive Ultra Turrax T 25 basic IKA, Staufen, Germany 
Electrophoresis system, Sub cell, GT Bio-Rad, Munich, Germany  
Eppendorf Microcentrifuge 5415R (5415D) Eppedorf, Berzdorf, Germany 
Eppendorf Reference Pipette adjustable volume, 100-1000ul Eppedorf, Berzdorf, Germany 
Eppendorf Reference Pipette adjustable volume, 10-100 ul Eppedorf, Berzdorf, Germany 
Eppendorf Reference Pipette adjustable volume, 20-200 ul Eppedorf, Berzdorf, Germany 
Eppendorf Reference Pipette adjustable volume, 2-20 ul Eppedorf, Berzdorf, Germany 
Gel documentation system CN UV/WL MWG-Biotech, Ebersberg, Deutschland 
Genevac- Spinfreezer SF50 Biomentra, Göttingen, Germany 
Genevac-Vacuum pump Vac CVP MK 1V Biomentra, Göttingen, Germany 
Heraeus HeraFreeze HFC 586 basic Thermo Fisher Scientific Waltham, MA, USA 
Herasafe™ KS (NSF) Class II, Type B3 Biological Safety 
Cabinet  Heraus, Hanau, Germany 
Incubator-shaker/ Certomat orbital shaker incubator BS-1 
orbital shaker 
B. Brown Biotech International, Melsungen, 
Germany 
KS 260 control shaker IKA, Staufen, Germany 
Laboratory Air Circulation Oven, ,Model UT 20P Heraus, Hanau, Germany 
Lauda Heating Circulator Water Bath E100  Lauda-Brinkmann, Delran, NJ, USA 
Leica DM IL LED inverted Microscope Leica Microsystems, Wetzlar, Germany 
Lumi imagerTM Serial No. 1300039 Roche Diagnostics, Manheim, Germany 
MELAG Vacuclav 24 Pul Grah GmbH, Düsseldorf, Germany 
Microbiological Incubator type B290 Heraus, Hanau, Germany 
Nikon ECLIPSE 80i microscope Nikon, Dusseldorf, Germany 
PCR®-Workstation CleneCab®/UV Transilluminators Herolab, Wiesloch Germany 
Pharmacia GeneQuant II RNA/DNA Calculator Pharmacia Biotech, Amersham, UK 
Power Pack P25, power supply Biometra, Göttingen, Germany 
Real-Time PCR System 7300 Life Technologies, Carlsbad, USA 
Ultrasonic processor UP100H (100W, 30kHz) Hielscher, Teltow, Germany,  
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10.2 Solutions and buffers  
Ammonium acetate 10 M, 20 mL: Dissolve 15.42 g Ammonium acetate in final volume of 20 mL sterile 
dH2O. Sterilise by filtration with a 0.2 µm syringe filter. 
Ampicilin 50 mg/mL, 10 mL: Dissolve 0.5 g ampicillin in final volume of 10 mL sterile dH2O. Sterilize the 
antibiotic solution by using a 0.2 µm syringe filter. Aliquot (500 µl - 1 mL) and store at -20 °C until use. 
Antigen unmasking solution: Sodium Citrate Buffer 10 mM, 1 L: Add 2.94 g Sodium citrate trisodium 
salt dehydrate (C6H5Na3O7 * 2 H2O), to 1 L H2O. Adjust pH to 6.0. 
Blocking solution: 5% v/v fetal calf serum in 1% (v/v) BSA/PBST, 20 mL: Add 1 mL FCS in 199 mL of 
1% v/v BSA/PBST wash buffer.  
Blocking Solution: 50% (v/v) FCS/0.5% BSA in PBS, 100 mL: Add 50 mL FCS to 50 mL 0.5% BSA in 
PBS solution. 
Bromophenol blue solution 0.5% (w/v), 10 mL: Dissolve 50 mg Bromophenol blue sodium salt in 10 mL 
H2O and keep at 4 
o
C. 
BSA (Bovine serum albumin) for Protein standards 20 mg/mL, 10mL: Dissolve 200 mg of bovine 
albumin in 10 mL Ripa CP. 
BSA (Bovine serum albumin) for cell culture, 200 µg /µl, 5 mL: Dissolve 1 g bovine albumin, for cell 
culture, in 5 mL sterile PBS 1X. Filter to sterilise. Keep at -20 
o
C. 
BSA 0.5% (w/v) in PBS 1X, 100 mL: Dissolve 0.5 g Albumin in 100 mL of PBS 1X. Sterilise by using a 
0.2 µm syringe filter. 
BSA 10% (w/v) in PBS 1X, 100 mL: Dissolve 10 g Albumin in 100 mL of PBS 1X. Sterilise by using a 0.2 
µm syringe filter. 
BSA 2% (w/v) in PBS 1X, 100 mL: Dissolve 2 g Albumin in 100 mL of PBS 1X. Sterilise by using a 0.2 
µm syringe filter. 
CaCl2 1 M, 100 mL: Dissolve 14.70 g CaCl2 in final volume of 100 mL dH2O. Sterilization is not required. 
CaCl2 2.5 M, 100 mL (for transfection): Dissolve 36.76 g CaCl2 * 2 H2O in 100 mL dH2O and autoclave. 
Collagen working solution 0.05 mg/mL, 50 mL, (for coating): Add 1.25 mL of Collagen stock solution 2 
mg/mL, in 50 mL 0.1% Acetic acid solution. Mix well and filter – sterilise.  
DAPI stock solution, 5 mg/mL (14.3 mM for the dihydrochloride or 10.9 mM for the dilactate) (Life 
Technologies): Dissolve the contents of one vial (10 mg) in 2 mL dH2O. The less water-soluble DAPI 
dihydrochloride may take some time to completely dissolve in water and sonication may be necessary. Keep 
in small aliquots in -20 
o
C in the dark. 
DAPI working solution 100 ng/mL or 300nm, 50 mL: Dilute 1 μl DAPI stock solution in 50 mL PBS. 
Keep at 4 
o
C in dark. 
DTT (Dithiothreitol) 1M, 10 mL: Mix 1.54 g of 1.4DTT and 33.3 µl of NaOAC 3M pH 5.5 in sterile 
dH2O. Prepare solution under hood and keep at -20 
o
C. 
EDTA (ethylene diamine tetraacetic acid) 0.5 M pH 8.0, 1 L: Dissolve 181.6 TripleX III/EDTANa22H20 
in 900 mL dH2O. Then fix pH to 8.0 with NaOH pellets (around 10 g) while stirring. Add dH2O to reach 
volume of 1 L. 
EDTA 100 mM pH 8.0, 200 mL (for blood withdrawal): Dissolve 7.264 g TripleX III/EDTANa22H20 in 
150 mL dH2O. Then fix pH to 8.0 with NaOH pellets while stirring. Add dH2O to reach volume of 200 mL. 
Glucose 1M, 100mL: Dissolve 19.8 g Glucose (or 18 g unhydrated glucose) in 100 mL final volume of 
sterile dH2O. Sterilise solution by a 0.2 µm syringe filter. Keep solution in 4 
o
C. 
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Glycerol 50%, 500 mL: Mix 50 mL of Glycerol with 50 mL of dH2O. Autoclave the solution at 121 
o
C for 
15 min. 
Hydrogen peroxide (H2O2) 3%, 500 mL: Add with great protections 50 mL of 30% Hydrogen peroxide 
solution to 450 mL dH2O. 
Kalium/Potasium Acetate (CH3COOK) 5 M, 500 mL: Dissolve 245.38 g CH3COOK in 500 mL final 
volume of dH2O. 
Kanamycin 50 mg/mL, 10 mL: Dissolve 0.5 g Kanamycin sulfate powder in final volume of 10 mL dH2O 
sterile. Sterilize antibiotic solution by a 0.2 µm syringe filter. Aliquot (500 µl - 1 mL aliquots) and store at -
20 °C until use. NOTE: It is best to avoid repeated freeze/thaw cycles of the kanamycin aliquot.  
KCl 1 M, 100 mL: Dissolve 7.45 g KCl in 100 mL dH2O and autoclave. 
KOAc 3M, 100 mL: Mix 29.4 g of potassium acetate, 40 mL of dH2O, add Glacial acetic acid to pH 4.8, 
and dH2O to 100 mL. Sterilize by filtering. Store at 4 
o
C. 
LB (Lysogeny broth) medium, 1L (with or without Antibiotic): Dissolve 10 g Bacto-tryptone, 5 g yeast 
extract, and 10 g NaCl in 950 mL dH2O, adjust the pH of the medium to 7.0 using 1M NaOH and bring 
volume up to 1 L. Autoclave on liquid cycle for 20 min at 15 psi. Allow solution to cool to 55°C, and add 
antibiotic if needed (50 µg/mL of Ampicillin or Kanamycin). Store at room temperature or at 4 °C. 
LB plates (with or without antibiotic): Prepare LB medium and add 15 g/l Agar after autoclaving. After 
autoclaving, let it cool to approximately 55 °C, add antibiotic if needed in final concentration of 50 µg/mL, 
and pour into petri-dishes. Let harden, and then invert plates and store at 4 °C in the dark. 
LiCl 5 M, 100 mL: Dissolve 21.2 g LiCl in final volume of 100 mL sterile dH2O. 
Lysozyme solution 10 mg/mL, 5 mL: Mix 50 mg Lysozyme in 5 mL of 10 mM Tris-HCl (pH 8.0) solution. 
The solution needs to be made fresh. 
MES SDS running buffer 20X, 500 mL: Mix 97.6 g (1 M) MES, 60.6 g (1 M) Tris Base, 10 g (69.3 mM) 
SDS, and 3 g (20.5 mM) EDTA in dH2O to final volume of 500 mL (pH 7.2, no adjustment necessary). 
Methacarn fixative solution: Mix 60% absolut methanol, 30% CHCl3 and 10% glacial acetic acid. 
MgCl2 1 M, 100 mL: Dissolve 20.33 g MgCl2 * 6H2O in 100 mL dH2O and autoclave. 
MgSO4 1 M, 100 mL: Dissolve 24.6 g MgSO4 * 7H2O in 100 mL dH2O and autoclave. 
Milk Solution (no fat) 5%, 100 mL: Dissolve 5 g of Milk powder (no fat) in100 mL TBST 1X. 
MnCl2 1 M, 20 mL: Dissolve 3.96 g MnCl2 in final volume of 20 mL sterile dH2O. Filter-sterilise the 
solution by using a 0.2 µm syringe filter. 
MnCl2 1 M, 20 mL: Dissolve 3.96 g MnCl2 * 4H2O in 20 mL dH2O and sterilize by filter. Keep in -20 
o
C. 
MOPS Buffer (3-(N-morpholino)propanesulfonic acid) 1 M, 100mL: Dissolve 20.93 g MOPS, in sterile 
dH2O. Fix pH to 7.0 with NaOH. Adjust Final volume to 100 mL. Sterilise by a 0.2 µm syringe filter. 
MOPS running buffer: MOPS 1M, Tris Base 1M, SDS 2%, EDTA 20mM, (pH 7.4, no adjustment 
necessary). 
Na-Citrat 0.1%/Triton 0.1%, 100 mL: Add 10 mL of 1% NaCitrat and 100 μl in sterile dH2O to final 
volume 100 mL. 
NaCitrat 1% (for Immunostaining): Dissolve 1 g Trisodium citrate in 100 mL dH2O. 
NaCl 1.6 M/PEG 13% (w/v) solution, 100mL: Dissolve 13 g PEG (Polyethylene glycol) and 9.35 g NaCl 
in final volume of 100mL sterile dH2O. 
NaCl 0.9% (w/v), 100 mL: Dissolve 0.9 g NaCl in 100 mL dH2O. 
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NaCl 5 M, 200 mL: Dissolve for extended time 58.44 g NaCl in dH2O till final volume of 200 mL and 
autoclave. 
NaCl 150 mM, 250 mL: Dissolve 2.19 g NaCl in 250 mL dH2O.  
NaOAC 3 M pH 5.2, 50 mL: Dissolve 20.4 g NaOAC (C2H3NaO2) in 40 mL dH2O. Adjust pH to 5.2 with 
glacial Acetic acid. Adjust final volume with dH2O to 50 mL. 
NaOH 1 M, 100 mL: Dissolve 4 g of NaOH pellets in 100 mL sterile dH2O 
NaOH 2 M, 100 mL: Dissolve 8 g of NaOH pellets in 100 mL sterile dH2O. 
NaOH 5 M, 100 mL: Dissolve 20 g of NaOH pellets in 100 mL sterile dH2O. 
Nile red stock solution 1 mg/mL in DMSO, 5 mL: Dissolve at a dark room 5 mg Nile Red (ENZO - Life 
Sciences) in 5 mL DMSO. Aliquot and keep in -20 
o
C for 1 month. 
Nile red working solution in 150 mM NaCl: Add at a dark room 1 μl from the Nile red stock solution 1 
mg/mL in 10 mL 150 mM NaCl. Make always fresh 
NuPAGE 1% (enhanced with 10% Methanol) blotting buffer 1 L: Mix 50 mL NuPAGE blotting buffer 
20X and 100 mL Methanol in 850 mL dH2O. 
NuPAGE blotting buffer 20X 1 L: Mix 81.6 g Bicine, 104.64 g Bis Tris, 6 g EDTA and 0.2 mL (1 mM) 
Chlorobutanol in dH2O to final volume of 1L (pH 7.2, no adjustment necessary).  
Oil Red O stock solution, 100 mL: Dissolve 0.5 g Oil Red O in 100 mL Isopropanol. Initially vortex 
vigorously and then shake in water bath for 30 min. Then keep in RT in the dark. 
Oil Red O working solution, 10 mL: Mix 6 mL of Oil Red O stock solution and 4 mL dH2O. Then filter 
through two Whatmman paper filters used at that time. Always prepare fresh. 
Oleic acid stock solution 10mM, 20 mL: Dilute 564μl Oleic acid conjugated to Albumin (Sigma Aldrich, 
354 mM) in 19.43 mL HepatoZYME medium or PBS. Keep at -20
 o
C. 
Palmitic acid Stock solution, 5mM, 40mL: Dissolve 0.51 g Palmitic acid powder (Sigma Aldrich) in 10 
mL vehicle-absolute ethanol (conc.= 200Mm). Heat for 20 min at 70 
o
C or at 37 
o
C overnight. Dillute 1 mL 
in 39 mL BSA 10% to prepare 5 mM stock solution. Incubate for 30 min at 45
o
C to enhance conjugation of 
Palmitic acid and BSA. Sterilize through a 0.22μm filter. The solution is stable for a month at 4 oC or longer 
at -20
 o
C.  
PBS 10X, 1 M, 1 L: Dissolve 80 g NaCl, 2 g KCl, 14.4 g Na2PO4, 2.4 g KH2PO4 in dH2O. Adjust pH to 7.4 
with HCl/NaOH. Adjust volume to 1L and sterilize by autoclaving. 
PBST 1X, 1 L: Add 100 mL PBS 10X in 900 mL dH2O. Then add 1 mL Tween-20 and mix well.  
Permeabilize solution 0.1% Na-Citrat/0.1% Triton, 50 mL: Add 0.5 mL Triton in 49.5 mL 0.1% Na-
Citrat solution. 
PFA 3% (Parafolmadehyde) 100 mL: Dissolve 3 g of pure parafolmadehyde respectively in 50 mL warm 
dH2O (around 50
o
C). Add a couple drops of 5 M NaOH till the color of the solution is clear (not cloudy). 
Add 10 mL of PBS 10X and adjust pH to 7.4 with phosphoric acid H3PO4. Adjust volume with sterile dH2O 
to 100 mL. Prepare solution in the hood and keep solution at -20
o
C. 
PFA 4% (Parafolmadehyde) 100 mL: Dissolve 4 g of pure parafolmadehyde respectively in 50 mL warm 
dH2O (around 50
o
C). Add a couple drops of 5 M NaOH till neutral/clear point. Add 10 mL of PBS 10X and 
adjust pH 7.4 with phosphoric acid H3PO4. Adjust volume with sterile dH2O to 100 mL. Prepare solution in 
the hood and keep solution at -20 
o
C. 
Ponceau S, 1L: Dissolve 0.1% (w/v) Ponceau S powder in 5% (v/v) Acetic acid and adjust final volume 
with dH2O to 1 L. Keep in dark. 
RbCl 4 M, 20mL: Dissolve 9.67 g RbCl in sterile dH2O to final volume 20mL. 
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RIPA Buffer 500 mL: Mix 1% (v/v) NP-40, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% 
(w/v) DOC, 1 mM EDTA in dH2O of final volume of 500 mL. 
RipaC with Phosphatase Inhibitor 1% (v/v): In 5 mL RipaC add 50 μl of Phospahatase inhibitor cocktail, 
aqueous solution. Make always fresh. 
RipaC: In 50 mL RIPA buffer add one Complete protease inhibitor cocktail Tablet and mix well. Keep at -
20
 o
C. 
RNAse A solution 10 mg/mL, 5mL: Dissolve 50 mg RNAse A in 5 mL sterile dH2O. Aliquot and keep 
aliquots at -20 
o
C. Before using, cook the required amount for 10 min. 
Rosiglitazone stock solution 10 mM: Dissolve 35.7 mg (Abcam) in 10 mL vehicle-DMSO. For working 
solution dilute stock in HepatoZYME medium. Notice: DMSO in working solution becomes toxic if above 
0.1% in final concentration. 
Rubidium Chloride 4 M, 20 mL: Dissolve 9.67 RbCl in 20 mL dH2O. 
SDS 20% (w/v), 100 mL: Dissolve 20 g of SDS in dH2O in final volume of 100 mL. 
Sodium Chloride-Tris-EDTA Buffer (STE buffer) pH 8.0, 1X, 1L: Dissolve 100mM NaCl (20 mL NaCl 
5 M) , 1 mM EDTA (2 mL 0.5 M EDTA) and 10 mM Tris-HCl (10 mL Tris-HCl, pH 8,0) in final volume of 
1 L sterile dH2O. 
Solution I, 500 mL: Add 50 mM Glucose (25 mL 1 M glucose), 10 mM EDTA (10 mL 0.5 M EDTA, pH 
8,0) and 25 mM Tris-HCl (12.5 mL Tris-HCl, pH 8,0) in final volume of 500 mL sterile dH2O. Keep 
solution 4 
o
C. 
Solution II, 100 mL: Add 1% SDS (5 mL of 20% SDS (w/v), 0.2 M NaOH (4 mL 5 M NaOH) in final 
volume of 100 mL sterile dH2O. Solution needs to be made always fresh. 
Solution III, 500 mL: Mix 300 mL of a 5 M Potassium Acetate (CH3COOK) solution and 57.5 mL Glacial 
acetic acid 142.5 mL sterile dH2O. Keep solution at 4 
o
C. 
Standards for protein Quantification 200 μl each, 0 μg/μl: 200 μl RipaC, 0.6 μg/μl: Mix 6 μl 20 mg/mL 
BSA in 194 μl RipaC, 0.9 μg/μl: Mix 9 μl 20 mg/mL BSA in 191 μl RipaC, 1.2 μg/μl: Mix 12 μl 20 mg/mL 
BSA in 188 μl RipaC, 1.5 μg/μl: Mix 15 μl 20 mg/mL BSA in 185 μl RipaC , 1.8 μg/μl: Mix 18 μl 20 
mg/mL BSA in 182 μl RipaC, 2.1 μg/μl: Mix 21 μl 20 mg/mL BSA in 179 μl RipaC , 2.4 μg/μl: Mix 24 μl 
20 mg/mL BSA in 176 μl RipaC. All standards should be kept at -20 oC. 
STOP Mix 5X, 5 mL: Mix 20mM EDTA (0.2 mL 0.5 M EDTA, pH 8.0), 30% Glycerol (1.7 mL Glycerol), 
0.1% w/v Bromophenol blue (1 mL) and 0.5% SDS (w/v) (0.125 mL 20% SDS solution) with dH2O to final 
volume 5 mL. 
TBE 10X, 1 L: Dissolve 108 g Tris-Base, 55 g Boric acid and 7.44 g EDTA in dH2O to final volume 1 L. 
TBS (Tris-buffered saltine) 10X: Dissolve 10 mM (12.1 g) Tris and 150 mM (87.6 g) NaCl in final volume 
of 1 L dH2O. Adjust pH to 7.6 with HCl. 
TBST (Tris-buffered saltine-Tween20. 0.1%) 1X, 1 L: Add 100 mL TBS 10X in 900 mL dH2O. Then add 1 
mL Tween 20 and mix well. 
TE pH 8.0, 100 mL: 10 mM Tris-HCl (1 mL of 1M Tris-HCl pH 8.0) and 1 mM EDTA (0.2 mL of 0.5 M 
EDTA pH 8.0) in 98.8 mL dH2O. 
TE buffer pH 8.0, 100 mL: Mix 10 mM Tris-Cl (1 mL of 1M Tris-HCl solution, pH 8.0), and 1 mM EDTA 
(0.2 mL of a 0.5 M EDTA solution pH 8.0) in final volume of 100 mL sterile dH2O. 
TFB I buffer: Mix: 30 mM KOAc (0.6 mL of a 3 M KOAc solution), 50 mM MnCl2 (5 mL of a 1M MnCl2 
solution), 100 mM RbCl (2.5 mL of a 4M RbCl solution), 10 mM CaCl2 (1 mL of a 1 M CaCl2 solution) and 
15% Glycerol (v/v) in final volume of 100 mL dH2O. Keep in 4 
o
C degrees. 
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TFB II buffer: Mix: 10 mM MOPS (1 mL of a 1M MOPS buffer, pH 7.0), 75mM CaCl2 (7.5 mL of a 1 M 
CaCl2 solution), 10 mM NaCl (1 mL of a 1 M NaCl solution and 15% Glycerol (v/v) (15 mL glycerol) in 
100mL final volume of sterile dH2O. Keep at 4 
o
C. 
Tris-HCl pH 7.4, 500 mL: Dissolve 60.55 g Tris-HCl in 350 mL dH2O, fix desirable pH with HCl and add 
dH2O to reach 500 mL of total volume. Autoclave the solution. 
YT 2X medium, 1 L: Dissolve 16 g Bacto-tryptone, 10 g yeast extract and 5 g NaCl in dH2O in a final 
volume of 1 L. Autoclave. 
Wash buffer Citrate/PBST: 1 X PBS/0.1% Tween-20, 1L (for immunohistochemistry): Add 100 mL 10 X 
PBS to 900 mL dH2O. Add 1 mL Tween-20 and mix well. 
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